{
    "000004.SZ": {
        "short_name": "SHENZHEN GUOHUA NE",
        "long_name": "Shenzhen GuoHua Network Security Technology Co., Ltd.",
        "summary": "Shenzhen GuoHua Network Security Technology Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products in China. It offers products in the areas of cardiovascular, anti-infective, tumor immunity, nerve/analgesic, API, and gastrointestinal/reproductive. The company also provides clindamycin phosphate, adenosine triphosphate magnesium chloride, diisopropylamine dichloroacetate, cyclophosphamide, cytidine triphosphate disodium, urokinase, and other injection products. In addition, it engages in the development and sale of real estate properties, as well as housing property management activities. The company was formerly known as Shenzhen Cau Technology Co., Ltd and changed its name to Shenzhen GuoHua Network Security Technology Co., Ltd. in November 2020. Shenzhen GuoHua Network Security Technology Co., Ltd., was founded in 1990 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518034",
        "website": "http://www.sz000004.cn",
        "market_cap": 3598155008
    },
    "000028.SZ": {
        "short_name": "CN ACCORD MEDICINE",
        "long_name": "China National Accord Medicines Corporation Ltd.",
        "summary": "China National Accord Medicines Corporation Ltd. engages in the distribution of medicine and pharmaceutical products. The company offers Chinese traditional patent, bio-chemical, biological, and diagnosis medicines, as well as antibiotics; chemical preparations; shaped packing food products; chemical products; and various commodities and techniques. It also engages in the sale of drugs, medical apparatus, and instruments; offers freight transportation, storage, loading and unloading, other business, and professional consultation services; provides glass wares, cosmetics, and daily merchandise, as well as goods agency services; import and export of technology; leasing of house properties; and wholesaling and retailing of health products. As of December 30, 2019, the company operated a network of 5,021 drugstores, including 3,744 direct-operated stores and 1,277 franchised stores covering 20 provinces, autonomous regions, and municipalities in China. The company is based in Shenzhen, China. China National Accord Medicines Corporation Ltd. is a subsidiary of Sinopharm Group Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518029",
        "website": "http://www.szaccord.com.cn",
        "market_cap": 15474434048
    },
    "000078.SZ": {
        "short_name": "SHN NEPTUNUS BIO",
        "long_name": "Shenzhen Neptunus Bioengineering Co., Ltd.",
        "summary": "Shenzhen Neptunus Bioengineering Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anti-tumor, cardiovascular disease, and other disease. The company was founded in 1992 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.neptunus.com",
        "market_cap": 9132755968
    },
    "000150.SZ": {
        "short_name": "YIHUA HEALTHCARE C",
        "long_name": "Yihua Healthcare Co., Ltd.",
        "summary": "Yihua Healthcare Co., Ltd. provides medical and elderly care services in China. The company offers integrated medical and logistic services, including medical facilities maintenance, environmental management, safety management, and medical auxiliary services. It also provides medical professional engineering, hospital management, and online medical services. In addition, the company operates as a membership aging communities; and provides old-age management services. The company was founded in 1993 and is based in Shantou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shantou",
        "zipcode": null,
        "website": "http://www.yihuahealth.com",
        "market_cap": 4046187776
    },
    "000153.SZ": {
        "short_name": "ANHUI FENGYUAN PHA",
        "long_name": "Anhui Fengyuan Pharmaceutical Co., Ltd.",
        "summary": "Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biological pharmacy, chemical pharmacy, and traditional Chinese medicines primarily in China. The company offers antipyretic-analgesic, cardiovascular, antibiotic, nervous system, anti-tumor, antiulcer, and hormone drugs, as well as nutraceuticals. It also provides general medicines for vitamin and mineral deficiency; medicines for resisting parasitic diseases and microorganisms; coenzymes; and antiviral and uterine contractive medicines. In addition, the company offers sedative-hypnotic drugs; drugs for curing mesenteric stress syndrome; drugs for lowering blood pressure; and drugs for curing benign prostatic hyperplasia. It also exports its products to Europe, North America, Africa, Southeast Asia, and Central Asia. The company is based in Hefei, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hefei",
        "zipcode": null,
        "website": "http://www.bbcayy.com",
        "market_cap": 2721869568
    },
    "000403.SZ": {
        "short_name": "PACIFIC SHUANGLIN",
        "long_name": "Pacific Shuanglin Bio-pharmacy Co., LTD",
        "summary": "Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taiyuan",
        "zipcode": "030006",
        "website": null,
        "market_cap": 24449970176
    },
    "000503.SZ": {
        "short_name": "CHINA REFORM HEALT",
        "long_name": "China Reform Health Management and Services Group Co., Ltd.",
        "summary": "China Reform Health Management and Services Group Co., Ltd. offers medical insurance management services in China. It is involved in business that covers 177 medical insurance in 25 provinces. It is also involved in the pharmaceutical and medical business. The company was formerly known as SeaRainbow Holding Corp. and changed its name to China Reform Health Management and Services Group Co., Ltd. in May 2018. China Reform Health Management and Services Group Co., Ltd. was founded in 1986 and is based in Haikou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Healthcare Plans",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570105",
        "website": "http://www.crhms.cn",
        "market_cap": 7199564800
    },
    "000504.SZ": {
        "short_name": "NANHUA BIO-MEDICIN",
        "long_name": "NanHua Bio-medicine Co., Ltd",
        "summary": "NanHua Bio-medicine Co., Ltd. provides stem and immune cell storage, noninvasive genetic testing, and biological research and technical services. The company is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": null,
        "website": "http://www.nhbiogroup.com",
        "market_cap": 6421540864
    },
    "000513.SZ": {
        "short_name": "LIVZON PHARMACEUTI",
        "long_name": "Livzon Pharmaceutical Group Inc.",
        "summary": "Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the People's Republic of China. Its products include Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, vertigo, and for the patients of lung cancer and stomach cancer. The company also offers active pharmaceutical ingredients (APIs) and intermediates, such as diagnostic kit for IgM/IgG antibody to coronavirus; and diagnostic reagents and equipment, including diagnostic kit for human immunodeficiency virus antibody, diagnostic kit for anti-nuclear antibody panel, and diagnostic kit for tuberculosis specific infected T cells. In addition, it provides biologic products, traditional Chinese drug medicine, biochemical drugs, microbiological preparations, antibiotics, and pharmaceutical raw materials. The company also exports its products. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519090",
        "website": "http://www.livzon.com.cn",
        "market_cap": 40930263040
    },
    "000518.SZ": {
        "short_name": "JIANGSU SIHUAN BIO",
        "long_name": "Jiangsu Sihuan Bioengineering Co., Ltd",
        "summary": "Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jiangyin",
        "zipcode": "214400",
        "website": "http://www.000518shsw.com/shsw",
        "market_cap": 3963805952
    },
    "000538.SZ": {
        "short_name": "YUNNAN BAIYAO GRP",
        "long_name": "Yunnan Baiyao Group Co.,Ltd",
        "summary": "Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, Chinese medicine resources, and tea. The company offers its products under the Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong brand names. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": "650500",
        "website": "http://www.yunnanbaiyao.com.cn",
        "market_cap": 130103197696
    },
    "000566.SZ": {
        "short_name": "HAINAN HAIYAO CO",
        "long_name": "Hainan Haiyao Co., Ltd.",
        "summary": "Hainan Haiyao Co., Ltd. manufactures and sells pharmaceutical products in China. The company develops approximately 132 products in various forms, such as general medicines, powder formulations, capsules, granules, tablets, injections, APIs, etc. in various anti-infection, anti-tumor, nervous system, digestive system, and sandan. It also produces vitamin C products, sterile raw materials, and pharmaceutical intermediates and chemicals, as well as REZ-1 digital cochlear products; and provides software platform, software products, and their related information services based on mobile Internet and cloud services for medical, health, and other industries. The company also exports its products to Vietnam, India, Cambodia, Singapore, Malaysia, and other Southeast Asia. Hainan Haiyao Co., Ltd. was founded in 1965 and is based in Haikou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570311",
        "website": "http://www.haiyao.com.cn",
        "market_cap": 7680430592
    },
    "000597.SZ": {
        "short_name": "NORTHEAST PHARMACE",
        "long_name": "Northeast Pharmaceutical Group Co., Ltd.",
        "summary": "Northeast Pharmaceutical Group Co., Ltd. provides chemical synthetic and bio-fermentation APIs, and medicinal and micro-ecological preparation products in China. It offers various nutritional products, such as Vitamin C, L-Carnitine, and other products; API products comprising fosfomycin, anti-aids, and other products; and chemical products, including chemical and pharmaceutical intermediates, chiral separation reagent products, etc. The company also provides digestives, narcotic medicines, cardiovascular, cerebrovascular medicines, etc. In addition, it engages in medical distribution business. Northeast Pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Shenyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenyang",
        "zipcode": null,
        "website": "http://www.nepharm.com",
        "market_cap": 6658951168
    },
    "000623.SZ": {
        "short_name": "JILIN AODONG PHARM",
        "long_name": "Jilin Aodong Pharmaceutical Group Co., Ltd.",
        "summary": "Jilin Aodong Pharmaceutical Group Co., Ltd. produces and sells pharmaceutical products in China. The company offers various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, syrups, spirits, and ointments, as well as enzymes, biochemical medicine, and plant chemical medicine. It also provides healthcare products. In addition, the company engages in highway construction and toll collection businesses. The company was founded in 1957 and is headquartered in Dunhua, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Dunhua",
        "zipcode": "133700",
        "website": "http://www.jlaod.com",
        "market_cap": 18189946880
    },
    "000627.SZ": {
        "short_name": "HUBEI BIOCAUSE PH",
        "long_name": "Hubei Biocause Pharmaceutical Co., Ltd.",
        "summary": "Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. It is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company also exports its products to the United States, the European Union, and internationally. The company is based in Jingmen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jingmen",
        "zipcode": null,
        "website": "http://www.biocause.com",
        "market_cap": 18576769024
    },
    "000638.SZ": {
        "short_name": "VANFUND URBAN INVE",
        "long_name": "Vanfund Urban Investment and Development Co., Ltd.",
        "summary": "Vanfund Urban Investment and Development Co., Ltd. engages in land consolidation and development activities. It is also involved in mining activities, as well as timber import business. The company was formerly known as Vanfund Real Estate Co., Ltd. and changed its name to Vanfund Urban Investment and Development Co., Ltd. in April 2013. Vanfund Urban Investment and Development Co., Ltd. is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100028",
        "website": "http://www.vanfund.cn",
        "market_cap": 1949220096
    },
    "000650.SZ": {
        "short_name": "RENHE PHARMACY CO",
        "long_name": "Renhe Pharmacy Co., Ltd.",
        "summary": "Renhe Pharmacy Co., Ltd. produces and sells pharmaceutical products. It offers Chinese and western medicines; chemical drugs; dietary supplements; and active pharmaceutical ingredients. It also provides health related products, such as oral solid and liquid dosages, large and small volume injections, lotions for external use, liniments, suppositories, and ointments; and eye drops, bulk medicines, hard and soft capsules, and granules tablets. The company was founded in 1996 and is based in Nanchang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanchang",
        "zipcode": "330038",
        "website": "http://www.renheyaoye.com",
        "market_cap": 11549504512
    },
    "000661.SZ": {
        "short_name": "CHANGCHUN HIGH NEW",
        "long_name": "Changchun High & New Technology Industry (Group) Inc.",
        "summary": "Changchun High & New Technology Industry (Group) Inc., together with its subsidiaries, manufactures and sells biopharmaceuticals and proprietary Chinese medicines in China. It also engages in real estate development, property management, and real estate leasing services. The company was founded in 1993 and is based in Changchun, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changchun",
        "zipcode": "130021",
        "website": "http://www.cchn.com.cn",
        "market_cap": 164712955904
    },
    "000705.SZ": {
        "short_name": "Z/ZHENYUAN SHARE C",
        "long_name": "Zhejiang Zhenyuan Share Co., Ltd.",
        "summary": "Zhejiang Zhenyuan Share Co., Ltd. operates as a pharmaceutical company in China and internationally. It offers Chinese patent medicines, Chinese medicinal materials, Chinese herbal medicines, chemical preparations, chemical raw materials, biochemical drugs, anesthetics, psychotropic drugs, medical devices, chemical reagents, etc. The company offers its products under the Zhenyuan and Zhenyuantang brands. It serves pharmaceutical commerce and health service industries. The company was founded in 1752 and is based in Shaoxing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shaoxing",
        "zipcode": "312000",
        "website": "http://www.zjzy.com",
        "market_cap": 2502581248
    },
    "000710.SZ": {
        "short_name": "BERRY GENOMICS CO",
        "long_name": "Berry Genomics Co.,Ltd",
        "summary": "Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for life sciences and clinical applications in China. The company offers sequencing-based genetic tests for genetic disease and cancer from preconception to adulthood. Its products include fetal chromosome aneuploidy detection kits; pre-implantation chromosome copy number anomaly detection kits; chromosome copy number variation detection kits; CSMART tumor gene mutation detection kit 1; BRCA 1/2, PTEN, and TP53 gene mutation detection kits; BRCA1/2 whole exon gene mutation detection sampling boxes; motor neuron survival gene 1 exon deletion detection kits; FMR1 gene regulatory region CGG repeat number detection kits; DNA preparation systems; and NextSeq CN500 sequencing supplies. The company also provides fetal chromosome aneuploidy data analysis and Keyongan data analysis software; and sells reagent equipment. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.berrygenomics.com",
        "market_cap": 11049523200
    },
    "000739.SZ": {
        "short_name": "APELOA PHARMACEUTI",
        "long_name": "Apeloa Pharmaceutical Co.,Ltd",
        "summary": "Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Dongyang",
        "zipcode": "322118",
        "website": "http://www.apeloa.com",
        "market_cap": 33151768576
    },
    "000756.SZ": {
        "short_name": "SHANDONG XINHUA PH",
        "long_name": "Shandong Xinhua Pharmaceutical Company Limited",
        "summary": "Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical Bulk Drugs, Preparations, and Chemical Intermediates and Other products. It offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for central nervous system diseases; and other drugs under the brand of Xinhua. The company also provides prepared Chinese herbal medicine for decoction, traditional Chinese medicines, chemical raw materials, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates, powders for injection and tablets, and bulk pharmaceutical and intermediates; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; develops and sells real estate; and health products research and development activities. Additionally, the company engages in the certification and import and export business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as sales of mechanical, hardware, and electrical equipment. It also provides contract manufacturing services of APIs and pharmaceutical intermediates, as well as OTC and generic products; and internet data services, internet sales, and internet information services for pharmaceuticals and medical devices, etc. The company operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zibo",
        "zipcode": "255086",
        "website": "http://www.xhzy.com",
        "market_cap": 4586890752
    },
    "000766.SZ": {
        "short_name": "TONGHUA GH PHARMAC",
        "long_name": "Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd",
        "summary": "Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products primarily focus on the rheumatism, digestion, cancer, and gynecology fields. The company offers traditional Chinese medicines, such as gynecological, rheumatic and bone pain, urology, detoxification, cardio-cerebral, digestive, respiratory, diabetes, and pediatric medication products, as well as anti-tumor drugs, prescription and OTC drugs, and Western medicines. The company offers its products in the form of capsules, tablets, injections, liquids, etc. Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. was founded in 1990 and is based in Tonghua, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tonghua",
        "zipcode": "134001",
        "website": "http://www.thjm.cn",
        "market_cap": 4648840704
    },
    "000788.SZ": {
        "short_name": "PKU HEALTHCARE COR",
        "long_name": "PKU HealthCare Corp.,Ltd.",
        "summary": "PKU HealthCare Corp.,Ltd. researches, develops, manufactures, and exports pharmaceutical preparations in western China. The company offers various products, including anti-microbials, anti-tumor, cardiovascular, anti-allergy, nonsteroidal anti-inflammatory products, as well as blood sugar products, regulatory immune anti-tumor, digestive system, and blood volume expanders. It also provides treatment of mental disorders and other products. The company was formerly known as PUK International Hospital Group Southwest Synthetic Pharmaceutical Corp., Ltd. and changed its name to PKU HealthCare Corp., Ltd. in November 2013. PKU HealthCare Corp.,Ltd. was founded in 1965 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401121",
        "website": "http://www.pku-hc.com",
        "market_cap": 4171909120
    },
    "000790.SZ": {
        "short_name": "CHENGDU HUASUN TEC",
        "long_name": "Chengdu Huasun Technology Group Inc., Ltd.",
        "summary": "Chengdu Huasun Technology Group Inc., Ltd. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, traditional Chinese medicines, and chemical medicines; and sells drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of cardiovascular and cerebrovascular diseases. In addition, the company designs, produces, installs, and services steel structure buildings. The company was formerly known as Chengdu Taihe Health Technology Group Inc., Ltd. and changed its name to Chengdu Huasun Technology Group Inc., Ltd. in April 2020. Chengdu Huasun Technology Group Inc., Ltd. was founded in 1998 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.thjkjt.com",
        "market_cap": 3661184512
    },
    "000908.SZ": {
        "short_name": "HUNAN JINGFENG PHA",
        "long_name": "Hunan Jingfeng Pharmaceutical Co.,Ltd.",
        "summary": "Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides CMO services covering cell culture, microbial fermentation, biologics, and pre-filled platforms. The company was founded in 2003 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200120",
        "website": "http://www.jfzhiyao.com",
        "market_cap": 4460454400
    },
    "000915.SZ": {
        "short_name": "SHANDONG WIT DYNE",
        "long_name": "Shandong Shanda Wit Science and Technology Co., Ltd.",
        "summary": "Shandong Shanda Wit Science and Technology Co., Ltd. engages in the pharmaceutical and environment protection businesses in China. Its medical products include azithromycin granules, licorice zinc granules, combined calcium carbonate, vitamin AD drops, epalat tablet, valsartan hydrochlorothiazide gel, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets. The company's environmental products comprise deep disc filters, sulfuric acid diluents, industrial wastewater treatment solutions, chlorine dioxide generators, chlorine dioxide preparation devices, and power plant flue gas desulfurization and denitrification total contracting devices, as well as involved in the planning and construction of constructed wetland. Its environmental products also consists of optional equipment and raw materials; chlorine dioxide disinfectants, compounds, and composites; gas exhaust treatment; and solid waste treatment. The company also provides information products comprising DLP splicing display units, LCD splicing display units, image stitching processors, industrial automation control products, and communication products; and modified asphalt products, rubber asphalt non - curing waterproof materials, and asphalt anti \u00c2\u0096 corrosion products. In addition, it is involved in the design and installation of display, communications, and industrial control system; system integration; research, development, and production of high-performance road modified and waterproof asphalt products; property rental and management activities; and provision of education services. Shandong Shanda Wit Science and Technology Co., Ltd. was founded in 1993 and is based in Jinan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jinan",
        "zipcode": "250061",
        "website": "http://www.sd-wit.com",
        "market_cap": 6326937088
    },
    "000919.SZ": {
        "short_name": "JINLING PHARMACEUT",
        "long_name": "Jinling Pharmaceutical Company Limited",
        "summary": "Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210058",
        "website": "http://www.jlyy000919.com",
        "market_cap": 3659040000
    },
    "000950.SZ": {
        "short_name": "C.Q. PHARMACEUTICA",
        "long_name": "C.Q. Pharmaceutical Holding Co., Ltd.",
        "summary": "C.Q. Pharmaceutical Holding Co., Ltd. distributes pharmaceutical products. Chongqing Medicines Co., Ltd. was formerly known as Southwest Branch of China Medicine Company. The company was founded in 1950 and is based in Chongqing, China. C.Q. Pharmaceutical Holding Co., Ltd. develops, manufactures, and distributes pharmaceuticals. The company is based in Chongqing, China. C.Q. Pharmaceutical Holding Co., Ltd. operates as a subsidiary of Chongqing Chemical & Pharmaceutical Holding Group Company",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "400010",
        "website": "http://www.cqphar.com/cqp/",
        "market_cap": 9072945152
    },
    "000952.SZ": {
        "short_name": "HUBEI GUANGJI PHAR",
        "long_name": "Hubei Guangji Pharmaceutical Co., Ltd.",
        "summary": "Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, medicinal feed additives, fine chemicals, and preparations in China. The company also exports its products to approximately 30 countries and regions worldwide. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuxue",
        "zipcode": "435400",
        "website": "http://www.guangjipharm.com",
        "market_cap": 2668391680
    },
    "000963.SZ": {
        "short_name": "HUADONG MEDICINE",
        "long_name": "Huadong Medicine Co., Ltd",
        "summary": "Huadong Medicine Co., Ltd. produces and sells various pharmaceutical products in China. The company offers Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, and antibiotic drugs. Its products include gastrointestinal agents, APIs, and other products. The company also engages in the production and management of traditional Chinese and western raw medicines and preparations, and health care products; sale of biological products as a proxy; wholesale of TCM materials, TCM decoction pieces, chemical preparations, etc.; warehousing and storage business; and research, development, production, and sale of aesthetic medicine products. Huadong Medicine Co., Ltd. was founded in 1993 and is headquartered in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310011",
        "website": "http://www.eastchinapharm.com",
        "market_cap": 83780902912
    },
    "000989.SZ": {
        "short_name": "JIUZHITANG CO.LTD",
        "long_name": "Jiuzhitang Co., Ltd.",
        "summary": "Jiuzhitang Co., Ltd. provides traditional Chinese, chemical, biological, and health medicine products in China. The company offers shuxuetong injections, Angong Niuhuang Wan, Danxi granules, and Gastrodia Uncaria for cardiovascular and cerebrovascular disease; Guizhi Fuling pills, Buxue Shengru granules, and hemostasis and analgesia products for gynecological disease; Schicon for respiratory disease; and Jiaqi Ganzian granules, Jianwei Yuyang tablets, Jienchang Ning, and Chidan yellowing products for digestive disease. It also provides non-prescription drugs for treating nourishing QI and blood, cardiovascular and cerebrovascular, urinary system, pediatric, gynecological, skeletal muscle, respiratory, dermatology, nervous system, ENT, digestive system, and tumor diseases. Jiuzhitang Co., Ltd. was founded in 1999 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100026",
        "website": "http://www.hnjzt.com",
        "market_cap": 7589459968
    },
    "000990.SZ": {
        "short_name": "CHENGZHI CO. LTD.",
        "long_name": "Chengzhi Shareholding Co., Ltd.",
        "summary": "Chengzhi Shareholding Co., Ltd. engages in the clean energy, functional materials, medical healthcare, and life science and technology related businesses in China. The company offers functional materials, such as liquid crystal material and other display chemical materials, display glass processing materials, daily chemicals, construction chemicals, and recycled wet chemicals. It also provides medical and health services. The company was founded in 1998 and is based in Nanchang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanchang",
        "zipcode": "330013",
        "website": "http://www.chengzhi.com.cn",
        "market_cap": 16514672640
    },
    "000999.SZ": {
        "short_name": "CHINA RESOURCES SA",
        "long_name": "China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.",
        "summary": "China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518110",
        "website": "http://www.999.com.cn",
        "market_cap": 25588445184
    },
    "002001.SZ": {
        "short_name": "ZHEJIANG NHU CO",
        "long_name": "Zhejiang NHU Company Ltd.",
        "summary": "Zhejiang NHU Company Ltd. engages in the production and sale of nutritional products, aroma chemicals, and polymer materials in China. The company offers nutrition products, comprising feed and food additives, such as vitamin E, vitamin A, vitamin C, DL-Methionine, vitamin D3, D-Biotin, coenzyme Q10, carotenoids, etc.; and aroma chemicals, including linalool series, citral series, leaf alcohol series, methyl dihydro jasmonate, raspberry ketone, ligustral, etc. for daily chemicals, food, and medicine fields. Zhejiang NHU Company Ltd. was founded in 1999 and is based in Xinchang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xinchang",
        "zipcode": "312500",
        "website": "http://www.cnhu.com",
        "market_cap": 66135756800
    },
    "002004.SZ": {
        "short_name": "HUAPONT-LIFE SCIEN",
        "long_name": "Huapont Life Sciences Co., Ltd.",
        "summary": "Huapont Life Sciences Co., Ltd. engages in the pharmaceutical and agrochemical businesses in China and internationally. It is involved in the research and development, production, sale, and services of pesticide intermediates, original drugs, and preparations. The company also offers medicines for skin and other applications, as well as provides medical services. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co., Ltd. in September 2015. Huapont Life Sciences Co., Ltd. was founded in 2001 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401121",
        "website": "http://www.huapont.com.cn",
        "market_cap": 12869480448
    },
    "002007.SZ": {
        "short_name": "HUALAN BIOLOGICAL",
        "long_name": "Hualan Biological Engineering Inc.",
        "summary": "Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its plasma products comprise surgical lyophilized fibrin sealant, human coagulation factor VIII, human albumin, human fibrinogen, human hepatitis B immunoglobulin, human tetanus immunoglobulin, human prothrombin complex, human immunoglobulin, human thrombin lyophilized for external use, human rabies immunoglobulin, and human immunoglobulin (PH4) for intravenous injection. The company's vaccines consist of meningococcal polysaccharide vaccine, inactivated influenza vaccine, recombinant hepatitis B vaccine, influenza A vaccine, and H7N9 inactivated influenza vaccine. It also offers gene products. Hualan Biological Engineering Inc. has strategic alliance with the Chinese Academy of Sciences. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xinxiang",
        "zipcode": "453003",
        "website": "http://www.hualanbio.com",
        "market_cap": 67501690880
    },
    "002019.SZ": {
        "short_name": "YIFAN PHARMACEUTIC",
        "long_name": "Yifan Pharmaceutical Co., Ltd.",
        "summary": "Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Lin'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lin'an",
        "zipcode": "311300",
        "website": "http://www.xinfupharm.com",
        "market_cap": 21643941888
    },
    "002020.SZ": {
        "short_name": "ZHEJIANG JINGXIN P",
        "long_name": "Zhejiang Jingxin Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China and internationally. The company offers APIs, antihypertensive products, antibiotics, quinolones, gastrointestinal promotions, antidiabetics, antipileptics, antihistamines, H+ pump depressants, antihyper cholesterolemia products, histamine H2 receptor blokades, antihyper cholesterolemirs, antidepressants, cephalosporin products, and biopharma products. It also provides diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1974 and is headquartered in Xinchang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xinchang",
        "zipcode": "312500",
        "website": "http://www.jingxinpharm.com",
        "market_cap": 7520714752
    },
    "002022.SZ": {
        "short_name": "SHANGHAI KEHUA BIO",
        "long_name": "Shanghai Kehua Bio-Engineering Co.,Ltd",
        "summary": "Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.skhb.com",
        "market_cap": 8989292544
    },
    "002044.SZ": {
        "short_name": "MEINIAN ONEHEALTH",
        "long_name": "Meinian Onehealth Healthcare Holdings Co., Ltd.",
        "summary": "Meinian Onehealth Healthcare Holdings Co., Ltd. offers health checkup and medical treatment services. It operates approximately 300 medical treatment and health checkup centers in approximately 200 cities in China. The company was founded in 2001 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.health-100.cn",
        "market_cap": 41295339520
    },
    "002099.SZ": {
        "short_name": "ZHEJIANG HISOAR PH",
        "long_name": "Zhejiang Hisoar Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Hisoar Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells fine chemicals and special raw drugs in China and internationally. It offers antibiotic, anti-virus, cardiovascular, sugar-reducing, and other materials; and medicine intermediates, and other customized and processed products, such as clindamycin, 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, voglibose, eclindamycin, 4-AA iso-carbapenem, thiamphenicol, florfenicol, voglibose, etc. It also exports its products. The company was founded in 1966 and is based in Taizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "318000",
        "website": "http://www.hisoar.com",
        "market_cap": 12674577408
    },
    "002107.SZ": {
        "short_name": "SHANDONG WOHUA PHA",
        "long_name": "Shandong Wohua Pharmaceutical Co., Ltd.",
        "summary": "Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. It offers Xinkeshu tablets, Naoxueshu oral solutions, Tongluo Huayu capsules, oral liquids, and Zhenju Jiangya tablets for cardiovascular and cerebrovascular; respiratory system drugs; medicines for women and children; urinary system drugs; heat purging fire drugs; digestive system drugs; anti-rheumatic drugs; and drugs for soothe the nerves. The company is based in Weifang, China. Shandong Wohua Pharmaceutical Co., Ltd. is a subsidiary of Beijing Zhongzheng Wanrong Investment(Group) Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Weifang",
        "zipcode": "261205",
        "website": "http://www.wohua.cn",
        "market_cap": 4392567808
    },
    "002118.SZ": {
        "short_name": "JILIN ZIXIN PHARMA",
        "long_name": "Jilin Zixin Pharmaceutical Industrial Co.,Ltd.",
        "summary": "Jilin Zixin Pharmaceutical Industrial Co.,Ltd researches, develops, produces, and sells Chinese medicines, gene sequencers, and supporting reagents in China. It provides ginseng products; prescription products; OTC drugs; and other products. Jilin Zixin Pharmaceutical Industrial Co.,Ltd was founded in 1998 and is based in Changchun, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changchun",
        "zipcode": "130041",
        "website": "http://www.jilinzixin.com.cn",
        "market_cap": 3727011840
    },
    "002198.SZ": {
        "short_name": "GUANGDONG JIAYING",
        "long_name": "Guangdong Jiaying Pharmaceutical Co., Ltd",
        "summary": "Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in Mainland China, Taiwan, Hong Kong and Macao, Southeast Asia, Europe, the United States, and internationally. The company provides medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, and gastrointestinal diseases. It offers products in various dosage forms, such as powders, tablets, capsules, granules, and pills. The company sells its products through distribution agencies and sales outlets. Guangdong Jiaying Pharmaceutical Co., Ltd. is based in Meizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Meizhou",
        "zipcode": null,
        "website": "http://www.gdjyzy.com.cn",
        "market_cap": 3846925824
    },
    "002219.SZ": {
        "short_name": "HENGKANG MEDICAL G",
        "long_name": "Hengkang Medical Group Co.,Ltd",
        "summary": "Hengkang Medical Group Co.,Ltd provides medical services, pharmaceuticals, health care, and daily products in China and internationally. It operates hospitals. The company also manufactures pharmaceutical products in the areas of pain, cold, cough, gynecology, cardiovascular, digestive, and urinary systems. In addition, it offers Chinese herbal medicines, infusion, and hemostasis products, as well as daily care products, including toothpaste and toothbrush. The company was formerly known as Gansu Duyiwei Biological Pharmaceutical Co., Ltd. and changed its name to Hengkang Medical Group Co.,Ltd in January 2014. Hengkang Medical Group Co.,Ltd. was founded in 2001 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "610063",
        "website": "http://www.hkmg.com",
        "market_cap": 6528339968
    },
    "002223.SZ": {
        "short_name": "JIANGSU YUYUE MEDI",
        "long_name": "Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.",
        "summary": "Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. researches, develops, manufactures, and markets medical equipment in China and internationally. The company provides respiratory products, such as oxygen concentrators, nebulizers, oxygen regulators, oxygen intake devices, and BreathCare CPAP products; homecare products, including electronic blood pressure monitors, sphygmomanometers, stethoscopes, thermometers, and pulse oximeters; and blood glucose meters. It also offers hospital instruments comprising oxygen generators, medical diagnostic equipment, suction apparatus, and medical disposable products; and rehabilitation products consisting of rehabilitation care series, anti-decubitus mattress, and tracks for neck ache. The company was formerly known as Yuwell medical. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. was founded in 1998 and is based in Danyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Danyang",
        "zipcode": null,
        "website": "http://www.yuyue.com.cn",
        "market_cap": 33633204224
    },
    "002252.SZ": {
        "short_name": "S/H RAAS BLOOD PRO",
        "long_name": "Shanghai RAAS Blood Products Co., Ltd.",
        "summary": "Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. It offers human albumin, human immunoglobulin, coagulation factor, and other products. The company was founded in 1988 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201401",
        "website": "http://www.raas-corp.com",
        "market_cap": 50758148096
    },
    "002262.SZ": {
        "short_name": "JIANGSU NHWA PHARM",
        "long_name": "Jiangsu Nhwa Pharmaceutical Co., LTD",
        "summary": "Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs in China and internationally. It offers drugs in the anesthesia, psychiatry, and neurological categories. The company also provides APIs in the areas of central nervous system, anesthetic and sedative, anti-fungal, and others. In addition, it is developing various cardiovascular products, such as Iptakalim, an anti-hypertension drug. The company has a collaborative research agreement with the Ann Romney Center for Neurologic Diseases at Brigham, and Women's Hospital and Biodextris to develop a novel immuno-stimulatory therapy for neurologic disorders. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is based in Xuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xuzhou",
        "zipcode": "221009",
        "website": "http://www.nhwa-group.com",
        "market_cap": 15064517632
    },
    "002275.SZ": {
        "short_name": "GUILIN SANJIN PHAR",
        "long_name": "Guilin Sanjin Pharmaceutical Co., Ltd.",
        "summary": "Guilin Sanjin Pharmaceutical Co., Ltd. researches, produces, and sells traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand, as well as Naomaitai capsules. It also produces contemporary TCM preparations. The company was founded in 1967 and is based in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. is a subsidiary of Guilin SanJin Group Co.,Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guilin",
        "zipcode": null,
        "website": "http://www.sanjin.com.cn",
        "market_cap": 7867365888
    },
    "002286.SZ": {
        "short_name": "BAOLINGBAO BIOLOGY",
        "long_name": "Baolingbao Biology Co.,Ltd.",
        "summary": "Baolingbao Biology Co.,Ltd. manufactures corn-based health and food ingredients in China and internationally. The company offers isomalto-oligosaccharide, galacto-oligosaccharides, fructose-oligosaccharides, and erythritol products; high fructose corn syrups, crystalline fructose products, sugar alcohols, and resistant dextrin-soluble corn fiber and polydextrose products; starch sugars, such as trehalose, maltodextrin, and glucose syrup products; terminal products; and corn steep liquors, corn husk sprayed products, and corn gluten meal products. It also provides agglomerated powder and organic products. The company's products are used in various food items, such as beverages, dairy, bakery, candy, meat, honey, seafood, canned food, condiment, health food, infant nutrition, fermentation, and animal nutrition, as well as in various fields, including daily chemicals, pharmaceuticals, cosmetics, etc. Baolingbao Biology Co.,Ltd. was founded in 1997 and is based in Yucheng, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yucheng",
        "zipcode": "251200",
        "website": "http://www.blb-cn.com",
        "market_cap": 4061816064
    },
    "002287.SZ": {
        "short_name": "TIBET CHEEZHENG TI",
        "long_name": "Tibet Cheezheng Tibetan Medicine Co., Ltd.",
        "summary": "Tibet Cheezheng Tibetan Medicine Co., Ltd. together with its subsidiaries, engages in the research, development, production, and sale of Tibetan medicine in China. It provides drug products in the areas of cardiovascular, respiratory, digestive, urinary and reproductive system, nervous system, musculoskeletal system, and gynecological disorders. The company was founded in 1995 and is based in Nyingchi, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nyingchi",
        "zipcode": "860000",
        "website": "http://www.cheezheng.com.cn",
        "market_cap": 14080712704
    },
    "002294.SZ": {
        "short_name": "SHENZHEN SALUBRIS",
        "long_name": "Shenzhen Salubris Pharmaceuticals Co., Ltd.",
        "summary": "Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is a subsidiary of Shenzhen Xinlitai Pharmaceutical Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.salubris.com",
        "market_cap": 35376394240
    },
    "002317.SZ": {
        "short_name": "GUANGDONG ZHONGSHE",
        "long_name": "Guangdong Zhongsheng Pharmaceutical Co., Ltd.",
        "summary": "Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Dongguan",
        "zipcode": null,
        "website": "http://www.zspcl.com",
        "market_cap": 7126533632
    },
    "002332.SZ": {
        "short_name": "ZHEJIANG XIANJU PH",
        "long_name": "Zhejiang Xianju Pharmaceutical Co.,Ltd.",
        "summary": "Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. It offers active pharmaceutical ingredients, such as steroid drugs, and male and female hormones; intermediates; and finished formulations in the form of tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-injections. The company was founded in 1972 and is based in Xianju, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xianju",
        "zipcode": "317300",
        "website": "http://en.xjpharma.com/",
        "market_cap": 12938801152
    },
    "002349.SZ": {
        "short_name": "NANTONG JINGHUA PH",
        "long_name": "Nantong Jinghua Pharmaceutical Co., Ltd.",
        "summary": "Nantong Jinghua Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was founded in 1957 and is based in Nantong, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nantong",
        "zipcode": "226407",
        "website": "http://www.jinghuapharm.com",
        "market_cap": 3936260096
    },
    "002365.SZ": {
        "short_name": "QIANJIANG YONGAN P",
        "long_name": "Qianjiang Yongan Pharmaceutical Co., Ltd.",
        "summary": "Qianjiang Yongan Pharmaceutical Co., Ltd. manufactures and sells taurine in China and internationally. The company was founded in 2001 and is based in Qianjiang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qianjiang",
        "zipcode": "433132",
        "website": "http://www.chinataurine.com",
        "market_cap": 3041117952
    },
    "002370.SZ": {
        "short_name": "ZHEJIANG YATAI PHA",
        "long_name": "Zhejiang Yatai Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers tablets, capsules, patches, powder injections, and troches. It also provides chemical agents and raw materials, and diagnostic reagents, as well as pharmaceutical research and development outsourcing services. Zhejiang Yatai Pharmaceutical Co., Ltd. was founded in 1989 and is based in Shaoxing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shaoxing",
        "zipcode": "312030",
        "website": "http://en.ytyaoye.com",
        "market_cap": 2302022400
    },
    "002390.SZ": {
        "short_name": "GUIZHOU XINBANG PH",
        "long_name": "Guizhou Xinbang Pharmaceutical Co., Ltd.",
        "summary": "Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guiyang",
        "zipcode": "550018",
        "website": "http://www.xinbang.com",
        "market_cap": 18022756352
    },
    "002393.SZ": {
        "short_name": "TIANJIN LISHENG PH",
        "long_name": "Tianjin Lisheng Pharmaceutical Co.,Ltd.",
        "summary": "Tianjin Lisheng Pharmaceutical Co.,Ltd. researches and develops medicines. The company offers raw materials, drugs, and medicinal plastic bottles. It also exports its products. The company was founded in 1951 and is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. is a subsidiary of Tianjin Pharmaceutical Holdings Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300385",
        "website": "http://www.lishengpharma.com",
        "market_cap": 3506785024
    },
    "002399.SZ": {
        "short_name": "SHENZHEN HEPALINK",
        "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
        "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.hepalink.com",
        "market_cap": 22630932480
    },
    "002412.SZ": {
        "short_name": "HUNAN HANSEN PHARM",
        "long_name": "Hunan Hansen Pharmaceutical Co., Ltd.",
        "summary": "Hunan Hansen Pharmaceutical Co., Ltd. produces and sells Chinese and western medicines in China and internationally. It provides medicines in injection, oral liquid, tablet, capsule, granule, syrup, ointment, tincture, pill, and other forms. The company is based in Yiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yiyang",
        "zipcode": "413000",
        "website": "http://www.hansenzy.com",
        "market_cap": 3029263872
    },
    "002422.SZ": {
        "short_name": "SICHUAN KELUN PHAR",
        "long_name": "Sichuan Kelun Pharmaceutical Co., Ltd.",
        "summary": "Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China and internationally. It offers infusion and non-infusion products, and new injection package. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "610071",
        "website": "http://www.kelun.com",
        "market_cap": 29219794944
    },
    "002424.SZ": {
        "short_name": "GUIZHOU BAILING GR",
        "long_name": "Guizhou Bailing Group Pharmaceutical Co., Ltd.",
        "summary": "Guizhou Bailing Group Pharmaceutical Co., Ltd. researches, develops, produces, and sells Chinese medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, pills, powders, tinctures, sprays, and ointments for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 2005 and is based in Anshun, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Anshun",
        "zipcode": null,
        "website": "http://www.gzbl.com",
        "market_cap": 10132415488
    },
    "002432.SZ": {
        "short_name": "ANDON HEALTH CO LT",
        "long_name": "Andon Health Co., Ltd.",
        "summary": "Andon Health Co., Ltd. develops, manufactures, and sells health electronics and intelligent hardware products. It offers sphygmomanometers, nebulizers, blood glucose meters, thermometers, fetal heart rate instruments, electrocardiographs, oximeters, smart watches, and body weight scales. The company was founded in 1995 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.jiuan.com",
        "market_cap": 3785749760
    },
    "002433.SZ": {
        "short_name": "GUANGDONG TAIANTAN",
        "long_name": "Guangdong Taiantang Pharmaceutical Co., Ltd.",
        "summary": "Guangdong Taiantang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of traditional Chinese medicines in China. It offers medicines for the areas, including reproductive male, reproductive gynecology, cardiovascular, dermatology, pediatrics, respiratory, replenishment, digestive hepatobiliary, rheumatology, and health and other areas. Goangdong Taiantang Pharmaceutical Co., Ltd. was founded in 1995 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.pibao.cn",
        "market_cap": 2890734080
    },
    "002437.SZ": {
        "short_name": "HARBIN GLORIA PHAR",
        "long_name": "Harbin Gloria Pharmaceuticals Co., Ltd",
        "summary": "Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150025",
        "website": "http://www.gloria.cc",
        "market_cap": 5759073792
    },
    "002462.SZ": {
        "short_name": "CACHET PHARMACEUTI",
        "long_name": "Cachet Pharmaceutical Co., Ltd.",
        "summary": "Cachet Pharmaceutical Co., Ltd. engages in the wholesale and retail sale of pharmaceutical products in China. It is involved in the supply of medicines to hospitals; wholesale of biological products, medical instruments, and traditional Chinese medicines; pharmaceutical logistic operations; and manufacture of medicines. The company owns 150 chain stores in Beijing that sell medicines, health care foods, medical instruments, cosmetics, daily necessities, and traditional Chinese medicines. Cachet Pharmaceutical Co., Ltd. was founded in 1998 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100195",
        "website": "http://www.cachet.com.cn",
        "market_cap": 4133488384
    },
    "002550.SZ": {
        "short_name": "CHANGZHOU QIANHONG",
        "long_name": "Changzhou Qianhong Biopharma CO.,LTD",
        "summary": "Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is based in Changzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changzhou",
        "zipcode": "213022",
        "website": "http://www.qhsh.com.cn",
        "market_cap": 5119200256
    },
    "002551.SZ": {
        "short_name": "SHENZHEN GLORY MED",
        "long_name": "Shenzhen Glory Medical Co., Ltd.",
        "summary": "Shenzhen Glory Medical Co., Ltd. provides hospital building integrated solutions in China. The company is involved in the hospital construction system analysis and planning, and medical engineering activities. It also sells medical equipment and medical consumables. In addition, the company provides hospital management professional medical logistic, smart medical, and park development services. Shenzhen Glory Medical Co., Ltd. was founded in 1998 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.glory-medical.com.cn",
        "market_cap": 4618215936
    },
    "002566.SZ": {
        "short_name": "JILIN JIAN YISHENG",
        "long_name": "Jilin Jian Yisheng Pharmaceutical Co., Ltd.",
        "summary": "Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and food and health products in China. It offers capsules, injections, tablets, granules, and other products; and Ginseng medicinal and bee products. The company was founded in 1997 and is based in Ji'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Ji'an",
        "zipcode": "134200",
        "website": "http://www.yisheng-pharm.com",
        "market_cap": 2535092224
    },
    "002589.SZ": {
        "short_name": "REALCAN PHARMAC.GR",
        "long_name": "Realcan Pharmaceutical Group Co., Ltd.",
        "summary": "Realcan Pharmaceutical Group Co., Ltd. supplies medicines and medical equipment in China. It sells drugs, vaccines, and medical devices. The company also provides direct selling services to medical institutions and pharmacies; medical logistics services; third-party logistics services; and mobile medical information services. In addition, it provides clothing washing, disinfection and sterilization, lease, and hospital logistics services for medical institutions. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. Realcan Pharmaceutical Group Co., Ltd. was founded in 2004 and is based in Yantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yantai",
        "zipcode": "264004",
        "website": "http://www.realcan.cn",
        "market_cap": 6966807552
    },
    "002603.SZ": {
        "short_name": "SHIJIAZHUANG YILIN",
        "long_name": "Shijiazhuang Yiling Pharmaceutical Co., Ltd.",
        "summary": "Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceuticals primarily in China. It operates through three segments: Modern Chinese Medicine, Chemical Pharmaceutical, and Health Industry. The company offers drugs for cardiac and cerebral blood disease, influenza and respiratory disease, tumor, and diabetes mellitus. It sells its products through physical display, online product distribution, and join distribution parallels. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": null,
        "website": "http://www.yiling.cn",
        "market_cap": 34727321600
    },
    "002626.SZ": {
        "short_name": "XIAMEN KINGDOMWAY",
        "long_name": "Xiamen Kingdomway Group Company",
        "summary": "Xiamen Kingdomway Group Company engages in the manufacturing and sale of the nutrition and health resources in China and internationally. It offers a series of raw material products, including coenzyme Q10, VA, VD3, microalgae DHA, and plant ARA, as well as provides dietary supplements and sports nutrition products. The company was formerly known as Xiamen Jindawei Vitamin Co., Ltd. Xiamen Kingdomway Group Company was founded in 1997 and is based in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xiamen",
        "zipcode": null,
        "website": "http://www.kingdomway.com",
        "market_cap": 27254667264
    },
    "002644.SZ": {
        "short_name": "LANZHOU FOCI PHARM",
        "long_name": "LanZhou Foci Pharmaceutical Co.,Ltd.",
        "summary": "LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional Chinese medicines in China. It provides its products in various dosage forms, including pills, tablets, granules, capsules, concentrated decoctions, mixtures, oral liquids, syrups, and medicinal wines under the Min Shan and Foci brands. The company also engages in researching activities for the development of new herbal drugs. It also exports its products to approximately 27 countries, which include the United States, Canada, Japan, Singapore, Indonesia, Thailand, Malaysia, New Zealand, Australia, Russia, Ukraine, Hong Kong, etc. The company was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. is a subsidiary of Lanzhou Foci Pharmaceutical Factory.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lanzhou",
        "zipcode": null,
        "website": "http://www.fczy.com",
        "market_cap": 4218026752
    },
    "002653.SZ": {
        "short_name": "HAISCO PHARMACEUTI",
        "long_name": "Haisco Pharmaceutical Group Co., Ltd.",
        "summary": "Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers capsules, tablets, granules, and bulk drugs in the fields of cardiovascular, anti-infection, digestive system, nervous and mental system, hepatopathy, diabetes mellitus, etc., as well as liver disease, parenteral nutrition, first-aid, antibiotics, anesthesia, and tumor adjuvant. It is also developing nalmefene hydrochloride injection, dolasetron mesylate injection, cefodizime sodium for injection, hydroxyethyl starch and sodium chloride injection, medium and long chain fat emulsion injection, and compound amino acids injection. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.haisco.com",
        "market_cap": 23649304576
    },
    "002688.SZ": {
        "short_name": "JINHE BIOTECHNOLOG",
        "long_name": "Jinhe Biotechnology CO., LTD.",
        "summary": "Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pheumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin America, Europe, etc. The company is based in Dalian, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Dalian",
        "zipcode": "116023",
        "website": "http://www.jinhe.com.cn",
        "market_cap": 4478794752
    },
    "002693.SZ": {
        "short_name": "HAINAN SHUANGCHENG",
        "long_name": "Hainan Shuangcheng Pharmaceuticals Co., Ltd.",
        "summary": "Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570311",
        "website": "http://www.shuangchengmed.com",
        "market_cap": 1725300096
    },
    "002727.SZ": {
        "short_name": "YUNNAN HONGXIANG Y",
        "long_name": "Yixintang Pharmaceutical Group Co., Ltd.",
        "summary": "Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, operates a chain of drugstores in China. It processes and sells medicinal materials; and engages in the wholesale of Chinese and western medicines. As of January 31, 2019, owned 5,872 direct chain stores in Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, Hainan, and Henan provinces. It also sells products online. The company was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Yixintang Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Kunming, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": null,
        "website": "http://www.hx8886.com",
        "market_cap": 21033617408
    },
    "002728.SZ": {
        "short_name": "TEYI PHARMACEUTICA",
        "long_name": "Teyi Pharmaceutical Group Co.,Ltd",
        "summary": "Teyi Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical preparations, raw materials, and products in China. The company offers cough and phlegm, kidney, anti- infection, cardiovascular, and digestive system drugs. Its chemical raw materials and products include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, strontium and tannic acid, and zinc sulfate. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co., Ltd. in November 2016. Teyi Pharmaceutical Group Co., Ltd. is based in Taishan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taishan",
        "zipcode": "529200",
        "website": "http://www.tczy.com.cn",
        "market_cap": 2857392640
    },
    "002737.SZ": {
        "short_name": "SUNFLOWER PHARMACE",
        "long_name": "Sunflower Pharmaceutical Group Co.,Ltd",
        "summary": "Sunflower Pharmaceutical Group Co.,Ltd develops, manufactures, and sells Chinese pharmaceuticals in China. The company produces Chinese patent medicines, chemicals, biological medicines, and health care medicines. Its products include children's medicines, digestive medicines, flu medicines, gynecologic medicines, liver and gallbladder gastrointestinal medicines, cold medicines, rheumatic medicines, heart and brain vascular medicines, geriatrics and chronic disease medicines, cardiovascular medicines, etc. under the Sun Flower and Little Sun Flower brands. The company was founded in 2005 and is based in Harbin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": null,
        "website": "http://www.kuihuayaoye.com",
        "market_cap": 8625680384
    },
    "002750.SZ": {
        "short_name": "KUNMING LONGJIN PH",
        "long_name": "Kunming Longjin Pharmaceutical Co., Ltd.",
        "summary": "Kunming Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. It offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. The company was founded in 1996 and is based in Kunming, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": "650503",
        "website": "http://www.longjin.com.cn",
        "market_cap": 3071835136
    },
    "002758.SZ": {
        "short_name": "ZJAMP GROUP CO LTD",
        "long_name": "ZJAMP Group Co., Ltd.",
        "summary": "Zjamp Group Co., Ltd. engages in the production of pesticides and fertilizers. The company was founded in 1999 and is based in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310000",
        "website": null,
        "market_cap": 5114135040
    },
    "002773.SZ": {
        "short_name": "CHENGDU KANGHONG P",
        "long_name": "Chengdu Kanghong Pharmaceuticals Group Co., Ltd",
        "summary": "Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic system, central nervous system, digestive system, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.cnkh.com",
        "market_cap": 21156866048
    },
    "002788.SZ": {
        "short_name": "LUYAN PHARMA CO LT",
        "long_name": "Luyan Pharma Co.,Ltd.",
        "summary": "Luyan Pharma Co.,Ltd. engages in the research and development, production, and sale of human health products in China. It also operates pharmaceutical distribution and retail direct stores. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and changed its name to Luyan Pharma Co.,Ltd. in June 2016. Luyan Pharma Co.,Ltd. was founded in 1992 and is headquartered in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xiamen",
        "zipcode": "361015",
        "website": "http://www.luyan.com.cn",
        "market_cap": 3073169408
    },
    "002793.SZ": {
        "short_name": "LUOXIN PHARMACEUTI",
        "long_name": "Luoxin Pharmaceuticals Group Stock Co., Ltd.",
        "summary": "Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers medical treatment and health services. The company was formerly known as Zhejiang Doyin Pump Industry Co., Ltd. and changed its name to Luoxin Pharmaceuticals Group Stock Co., Ltd. in April 2020. Luoxin Pharmaceuticals Group Stock Co., Ltd. is based in Linyi, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.luoxin.cn",
        "market_cap": 15215071232
    },
    "002817.SZ": {
        "short_name": "ANHUI HUANGSHAN CA",
        "long_name": "Anhui Huangshan Capsule Co., Ltd.",
        "summary": "Anhui Huangshan Capsule Co., Ltd. manufactures and sells vacant hard capsules. It offers entersoluble vacant gelatin capsules, vegetable entersoluble capsules, vacant gelatin capsules, colon soluble vacant gelatin capsules, vegetable capsules, and pulluan capsules. The company was founded in 1989 and is based in Jingde, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jingde",
        "zipcode": "242605",
        "website": "http://www.hsjn.com",
        "market_cap": 1520538496
    },
    "002821.SZ": {
        "short_name": "ASYMCHEM LABORATOR",
        "long_name": "Asymchem Laboratories (Tianjin) Co., Ltd.",
        "summary": "Asymchem Laboratories (Tianjin) Co., Ltd. researches, develops, and manufactures peptide API and drug products. It also provides analytical services. The company was founded in 1998 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300457",
        "website": "http://www.asymchem.com.cn/en/faci.aspx?CID=44",
        "market_cap": 95595044864
    },
    "002864.SZ": {
        "short_name": "SHAANXI PANLONG PH",
        "long_name": "Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd",
        "summary": "Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells drugs and GAP cultivation of medicinal materials in China. It offers orthopedic, cardio-cerebrovascular, digestive, supplement category, respiratory, Chinese anti-inflammatory, pediatric, gynecology, hepatobiliary, and specialty drugs. The company was founded in 1992 and is headquartered in Xi'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xi'an",
        "zipcode": "710025",
        "website": "http://www.pljt.com",
        "market_cap": 2066212864
    },
    "002868.SZ": {
        "short_name": "LIFECOME BIOCHEMIS",
        "long_name": "Lifecome Biochemistry Co., Ltd.",
        "summary": "Lifecome Biochemistry Co., Ltd. operates as a biopharmaceutical company in China. The company primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. Lifecome Biochemistry Co., Ltd. was founded in 2003 and is based in Pucheng, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Pucheng",
        "zipcode": null,
        "website": "http://www.lifecomepc.com",
        "market_cap": 1720455040
    },
    "002872.SZ": {
        "short_name": "TIANSHENG PHARMACE",
        "long_name": "Tiansheng Pharmaceutical Group Co., Ltd.",
        "summary": "Tiansheng Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and circulation activities. It offers products in various categories, including respiratory, digestive, cardiovascular and cerebrovascular, pediatric, gynecological, orthopedic, tumor, hepatobiliary, blood, surgery, diabetes, and other systems, as well as antipyretic, and analgesic and non-steroidal anti-inflammatory drugs. The company also provides antimicrobials, and vitamins and minerals. Tiansheng Pharmaceutical Group Co., Ltd. was founded in 2001 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401120",
        "website": "http://www.tszy.com.cn",
        "market_cap": 1653600000
    },
    "002873.SZ": {
        "short_name": "GUIYANG XINTIAN PH",
        "long_name": "Guiyang Xintian Pharmaceutical Co.,Ltd.",
        "summary": "Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guiyang",
        "zipcode": null,
        "website": "http://www.gyxtyy.com",
        "market_cap": 2115837312
    },
    "002880.SZ": {
        "short_name": "SHENZHEN WEIGUANG",
        "long_name": "Shenzhen Weiguang Biological Products Co., Ltd.",
        "summary": "Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous immunoglobulin (pH4), freeze-dried intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, histamine human immunoglobulin, and human fibrinogen, as well as a total of 9 varieties and 21 specifications. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518107",
        "website": "http://www.szwg.com",
        "market_cap": 8229599744
    },
    "002898.SZ": {
        "short_name": "ZHUHAI SAILONG PHA",
        "long_name": "Zhuhai Sailong Pharmaceutical Co.,Ltd.",
        "summary": "Zhuhai Sailong Pharmaceutical Co.,Ltd. principally engages in the fields of neuroprotective agents and treatment of diseases of the aged. The company is based in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "5190015",
        "website": "http://www.sailong.cn",
        "market_cap": 1881439872
    },
    "002900.SZ": {
        "short_name": "HARBIN MEDISAN PHA",
        "long_name": "Harbin Medisan Pharmaceutical Co., Ltd.",
        "summary": "Harbin Medisan Pharmaceutical Co., Ltd. researches, develops, produces, and sells chemical formulations in China. It offers Araxetan, alanyl glutamine, brain protein hydrolyzate, ligustrazine hydrochloride, bone peptide, Yanhuning, glucose, and sodium chloride injections, as well as rice nitrogen tablets, valsartan dispersible tablets, and other drugs for use in the various indications comprising nervous system, cardiovascular and cerebrovascular, musculoskeletal, systemic anti-infective, regulating water, electrolyte and acid-base balance, nutritional supplements, and other medical fields. The company was founded in 1996 and is based in Harbin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150025",
        "website": "http://www.medisan.com.cn",
        "market_cap": 9216226304
    },
    "002907.SZ": {
        "short_name": "CHONGQING PHARSCIN",
        "long_name": "Chongqing Pharscin Pharmaceutical Co., Ltd.",
        "summary": "Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, API synthesis, and botanical drug extractions. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. The company is headquartered in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401120",
        "website": "http://www.pharscin.com",
        "market_cap": 5157853696
    },
    "002923.SZ": {
        "short_name": "ZHUHAI RUNDU PHARM",
        "long_name": "Zhuhai Rundu Pharmaceutical Co., Ltd.",
        "summary": "Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceutical ingredients for cardiovascular, gastrointestinal, CNS, and anesthesia. It offers APIs, intermediates, and pellets, as well as formulations in the forms of capsules, tablets, and injections. The company serves in the United States, Germany, Spain, Holland, Slovenia, Argentina, Brazil, Honduras, Japan, Korea, India, Jordan, Syria, Saudi Arabia, Algeria, Tunisia, Egypt, etc. Zhuhai Rundu Pharmaceutical Co., Ltd. was founded in 1997 and is based in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519041",
        "website": "http://www.rdpharma.cn",
        "market_cap": 3979476736
    },
    "002932.SZ": {
        "short_name": "WUHAN EASY DIAGNOS",
        "long_name": "Wuhan Easy Diagnosis Biomedicine Co.,Ltd.",
        "summary": "Wuhan EasyDiagnosis Biomedicine Co.,Ltd. engages in the development, production, and sale of in vitro and POCT rapid diagnostic reagents and related equipment in China and internationally. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics and gynecology, and eugenics diseases, as well as health inspection and other products; and chemiluminescence detection kit and analyzers, blood gas analyzers, mobile electrocardiography, and molecular diagnosis products. The company is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430074",
        "website": "http://www.mdeasydiagnosis.com",
        "market_cap": 6244961792
    },
    "002940.SZ": {
        "short_name": "ZHEJIANG ANGLIKANG",
        "long_name": "Zhejiang AngLiKang Pharmaceutical CO.,LTD.",
        "summary": "Zhejiang Anglikang Pharmaceutical Co., Ltd. produces and sells bulk pharmaceutical materials, pharmaceutic preparations, and medical empty capsules. The company offers pharmaceutical preparations, such as Levamlodipine Besylate, Levofloxacin Hydrochloride, Nifedipine sustain-released, Cefaclor sustained-release, Cefpodoxime Proxetil tablets, as well as Cefaclor capsules and granules. It also provides APLs, including Cefradine, Cefalexin, Cefradine sterile with L-arginine, Cefadroxil, Cefaclor, Cefixime, Doxofylline, Oryzanol, Telmisartan, and 7-Amino-3-methyl-3-cephem-4-carboxylic acid, as well as Ketoleucine, Ketovaine, D, L-Ketoisoleucine, D, L-a-Hydroxymethionine, and Ketone phenylalanine calcium. The company was founded in 2001 and is based in Shengzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shengzhou",
        "zipcode": "312400",
        "website": "http://www.alkpharm.com",
        "market_cap": 2828511744
    },
    "002950.SZ": {
        "short_name": "ALLMED MEDICAL PRO",
        "long_name": "Allmed Medical Products Co., Ltd",
        "summary": "Allmed Medical Products Co., Ltd engages in the research and development, manufacture, and distribution of medical dressings and other disposable medical supplies in the People's Republic of China. The company offers general wound care products, such as elastic and adhesive bandage, oil emulsion, xeroform gauze, woven gauze swabs, fluffy bandages/sponges, abdominal pads, gauze/non-woven drain sponges, post-op sponges, eye pads, cotton filled exodontia sponges, non-stick pads, and petrolatum gauze dressing. It also provides OR/surgery products, including X-ray non-woven swabs, OR towels, laparotomy and neuro sponges, and X-ray detectable gauze balls and nonwoven balls; various kits; and patient care products comprising disposable nursing pads and disposable drapes. In addition, the company exports its products to the United States, Canada, Germany, Japan, the Middle East, and internationally. Allmed Medical Products Co., Ltd was founded in 1997 and is based in Shenzhen, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.allmed-china.com",
        "market_cap": 12620972032
    },
    "003020.SZ": {
        "short_name": "HEFEI LIFEON PHARM",
        "long_name": "Hefei Lifeon Pharmaceutical Co., Ltd.",
        "summary": "Hefei Lifeon Pharmaceutical Co., Ltd. engages research, development, production, and sales of pharmaceutical preparations and an active ingredient (APIs). It offers APIs, such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate; medicinal preparations comprising felodipine sustained release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablet, yiqihewei capsule, kunning granule, armillariella oral solution, paeonol ointment, urea and vitamin e cream, Kecuo Yintong gel, and Compound Golden Larch bark gel; and plant extracts, including clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. The company also operates retail chain of pharmaceuticals. Hefei Lifeon Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Hefei, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hefei",
        "zipcode": "230088",
        "website": "http://www.lifeonapi.com",
        "market_cap": 5290670592
    },
    "04CN.F": {
        "short_name": "CHINA JO-JO D.NEW DL-,001",
        "long_name": "China Jo-Jo Drugstores, Inc.",
        "summary": "China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates dada360.com, an online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms, such as Tmall, JD.com, and Amazon.com. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2020, it had 118 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 10 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310008",
        "website": "http://www.jiuzhou-drugstore.com",
        "market_cap": 32881788
    },
    "0503.HK": {
        "short_name": "LANSEN PHARMA",
        "long_name": "Lansen Pharmaceutical Holdings Limited",
        "summary": "Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People's Republic of China and internationally. It operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. The company offers specialist medicines and Chinese medicine generic drugs; cosmetic products; and plant extracts and healthcare products. It also engages in research, development, and industrialization of industrial enzyme preparations, molecular biology tool enzymes, and bioactive factors for cosmetics and biological skincare products. The company was founded in 2001 and is headquartered in Ningbo, the People's Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Ningbo",
        "zipcode": "315174",
        "website": "http://www.lansen.com.cn",
        "market_cap": 1048534144
    },
    "0570.HK": {
        "short_name": "TRAD CHI MED",
        "long_name": "China Traditional Chinese Medicine Holdings Co. Limited",
        "summary": "China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of Chinese medicine and pharmaceutical products in the People's Republic of China. The company offers granules, finished drugs, decoction pieces, and healthcare products. It is also involved in the cultivation of Chinese medicinal herbs; preparation of traditional Chinese medicines; trading of pharmaceutical products; provision of traditional Chinese medical consultation services; and retail of pharmaceuticals and decoction. The company also provides logistics and warehouse, and property leasing services. The company sells its products to hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in July 2016. China Traditional China Traditional Chinese Medicine Holdings Co. Limited is headquartered in Foshan, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Foshan",
        "zipcode": null,
        "website": "http://www.china-tcm.com.cn",
        "market_cap": 25279715328
    },
    "0708.HK": {
        "short_name": "EVERG VEHICLE",
        "long_name": "China Evergrande New Energy Vehicle Group Limited",
        "summary": "China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510620",
        "website": "http://health.evergrande.com",
        "market_cap": 315537391616
    },
    "0719.HK": {
        "short_name": "SHANDONG XINHUA",
        "long_name": "Shandong Xinhua Pharmaceutical Company Limited",
        "summary": "Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical Bulk Drugs, Preparations, and Chemical Intermediates and Other products. It offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for central nervous system diseases; and other drugs under the brand of Xinhua. The company also provides prepared Chinese herbal medicine for decoction, traditional Chinese medicines, chemical raw materials, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates, powders for injection and tablets, and bulk pharmaceutical and intermediates; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; develops and sells real estate; and health products research and development activities. Additionally, the company engages in the certification and import and export business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as sales of mechanical, hardware, and electrical equipment. It also provides contract manufacturing services of APIs and pharmaceutical intermediates, as well as OTC and generic products; and internet data services, internet sales, and internet information services for pharmaceuticals and medical devices, etc. The company operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Zibo",
        "zipcode": "255086",
        "website": "http://www.xhzy.com",
        "market_cap": 5117285376
    },
    "0853.HK": {
        "short_name": "MICROPORT",
        "long_name": "MicroPort Scientific Corporation",
        "summary": "MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment provides coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment offers reconstructive joints, spine and trauma, and other professional implants and equipment. The company's Cardiac Rhythm Management Business segment develops, manufactures, and markets defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment provides products and services for neurovascular diseases, such as cerebral aneurysms, intracranial atherosclerotic diseases, carotid artery diseases, and other neurovasculature related diseases. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. The company's Heart Valve Business segment engages in the research and development, manufacture, and sale of VitaFlow Transcatheter aortic valve and delivery system for the treatment of valvular heart diseases. Its Surgical Robot Business segment provides research and technology integration in the fields of robot, intelligent control, and information to provide medical products. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.microport.com",
        "market_cap": 121058230272
    },
    "0874.HK": {
        "short_name": "BAIYUNSHAN PH",
        "long_name": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited",
        "summary": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the People's Republic of China and internationally. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, ganoderma spore oil capsules, lozenges, tortoise herb jelly, etc. In addition, it invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2020, the company had 141 retail chain pharmacy outlets, which included 27 Cai Zhi Lin pharmacy outlets, 33 Jian Min pharmacy outlets, 36 GPC Prescription Pharmacy outlets, and 24 Hainan Guangyao Chenfei Pharmaceutical Chain outlets, as well as 21 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510130",
        "website": "http://www.gybys.com.cn",
        "market_cap": 56217513984
    },
    "08HH.SG": {
        "short_name": "Shanghai Fos.Pharm.(Gr.)Co.LtdR",
        "long_name": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "summary": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.fosunpharma.com",
        "market_cap": 20562434048
    },
    "0UC.F": {
        "short_name": "ANPAC BIO-MED SP.ADS/1  A",
        "long_name": "AnPac Bio-Medical Science Co., Ltd.",
        "summary": "Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Lishui",
        "zipcode": "323006",
        "website": "http://www.anpacbio.com",
        "market_cap": 54172852
    },
    "1061.HK": {
        "short_name": "ESSEX BIO-TECH",
        "long_name": "Essex Bio-Technology Limited",
        "summary": "Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, Xalatan eye drops, and Xalacom eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties; and eye health care products, including Beifu shuhui capsules to treat fundus ocular diseases, asthenopia, and visual impairments. Further, the company offers T-Bactum, an anti-microbial oral care product; Carisolv dental caries removal gel; and Yi Xue An Granules. Essex Bio-Technology Limited has license agreements with Mitotech S.A. and Mitotech LLC. Essex Bio-Technology Limited was founded in 1990 and is headquartered in Zhuhai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": null,
        "website": "http://www.essexbio.com",
        "market_cap": 3787480320
    },
    "1066.HK": {
        "short_name": "WEIGAO GROUP",
        "long_name": "Shandong Weigao Group Medical Polymer Company Limited",
        "summary": "Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. The company also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, it engages in the production and sale of orthopedic products; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemo-dialysis equipment; and type I, type II, and type III medical devices. Further, the company is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; and provision of asset management and enterprise consulting services, as well as logistics and storage services. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. The company also export its products. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Weihai",
        "zipcode": "264210",
        "website": "http://www.weigaogroup.com",
        "market_cap": 80497475584
    },
    "1093.HK": {
        "short_name": "CSPC PHARMA",
        "long_name": "CSPC Pharmaceutical Group Limited",
        "summary": "CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": "050035",
        "website": "http://www.cspc.com.hk",
        "market_cap": 146559303680
    },
    "1099.HK": {
        "short_name": "SINOPHARM",
        "long_name": "Sinopharm Group Co., Ltd.",
        "summary": "Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200023",
        "website": "http://www.sinopharmgroup.com.cn",
        "market_cap": 83321626624
    },
    "1110.HK": {
        "short_name": "KINGWORLD",
        "long_name": "Kingworld Medicines Group Limited",
        "summary": "Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products in the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, and internationally. The company also supplies general foodstuffs and medical products. It offers products for various functional categories, such as cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and Mentholatum Product Range brands. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices. In addition, it is involved in the property investment business. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518016",
        "website": "http://www.kingworld.com.cn",
        "market_cap": 497999968
    },
    "1167.HK": {
        "short_name": "JACOBIO-B",
        "long_name": "Jacobio Pharmaceuticals Group Co., Ltd.",
        "summary": "Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "101111",
        "website": "http://www.jacobiopharma.com",
        "market_cap": 16972164096
    },
    "1302.HK": {
        "short_name": "LIFETECH SCI",
        "long_name": "LifeTech Scientific Corporation",
        "summary": "LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; import and export business; development, manufacture, and sale of medical polymer materials and products; manufacturing and trading of materials for hemp; investment in medical projects; staff training and internal personnel management business; information consulting for investors; and import and export, sale, and distribution of medical and paramedical devices, including software and accessories and related services, as well as technical consultation, technology transfer, technical, consulting, and technology services. It has operations in the People's Republic of China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.lifetechmed.com",
        "market_cap": 22764838912
    },
    "1349.HK": {
        "short_name": "FUDANZHANGJIANG",
        "long_name": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",
        "summary": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-MMAE, which is in clinical trial Phase I for tumors; Trop 2 antibody-conjugated drug that is in pre-clinical studies for triple negative breast cancer, bladder and gastric cancer, and other tumors; and HER2 antibody-drug conjugate, which is in pre-clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV; and aminolevulinic acid that is in Phase I clinical trials for acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs comprising Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for Hepatobiliary disease; and JAK1 inhibitor that is in Phase I clinical trial for rheumatoid arthritis. Additionally, it researches and develops pharmaceutical and medical devices; medical diagnostic products; provides related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; and production of freeze-dried powder injections and APIs, as well as invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.fd-zj.com",
        "market_cap": 5215000064
    },
    "1477.HK": {
        "short_name": "OCUMENSION-B",
        "long_name": "Ocumension Therapeutics",
        "summary": "Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. It offers drugs for the treatment of blepharitis, infective conjunctivitis, allergic conjunctivitis, dry eye, cataract, glaucoma, uveitis, age-related macular degeneration, and myopia. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": null,
        "website": "http://www.ocumension.com",
        "market_cap": 18698027008
    },
    "1501.HK": {
        "short_name": "KDL MEDICAL",
        "long_name": "Shanghai Kindly Medical Instruments Co., Ltd.",
        "summary": "Shanghai Kindly Medical Instruments Co., Ltd. engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally. It offers interventions products, which includes guiding catheter used to provide a channel for introducing balloon catheter, guidewire or other treatment devices; micro catheter to support the placement of guide wires; guidewire used in percutaneous transluminal angioplasty (PTA) surgical procedures; angiography catheter used to inject and infuse contrast media and fluid; and Y-connector pack used in PTCA surgery. The company also provides inflation device used to inflate the balloon of dilating the vessel or placing the stent in the vessel; manifold for single use; manifold kit; pressure bandage used to assist compression hemostasis; angiography syringe for single use; stopcocks used for pressure monitoring tubing during surgery; sterile seldinger needle used to puncture into the artery; introducer set; pressure transducer for single use; extension tube for pressure monitoring; and introducer tool kit used in percutaneous vertebroplasty. In addition, the company also provides medical accessories, such as check value, needle free connector, male Luer locks, bi-stopper, Heparian cap, flush device, and flow regulator; other products, including joint intervention kit, disposable respirator masks, vaginal dilator used during a vaginal examination, foley catheter, infusion pumps, disposable automatic umbilical cord clamps, infusion connector and accessory for single use, and burette infusion sets without a needle. It serves medical device manufacturers and other customers. The company was founded in 2006 and is headquartered in Shanghai, China. Shanghai Kindly Medical Instruments Co., Ltd. is a subsidiary of Shanghai Kindly Enterprise Development Group Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201803",
        "website": "http://www.kdl-int.com",
        "market_cap": 7055000064
    },
    "1513.HK": {
        "short_name": "LIVZON PHARMA",
        "long_name": "Livzon Pharmaceutical Group Inc.",
        "summary": "Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the People's Republic of China. Its products include Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, vertigo, and for the patients of lung cancer and stomach cancer. The company also offers active pharmaceutical ingredients (APIs) and intermediates, such as diagnostic kit for IgM/IgG antibody to coronavirus; and diagnostic reagents and equipment, including diagnostic kit for human immunodeficiency virus antibody, diagnostic kit for anti-nuclear antibody panel, and diagnostic kit for tuberculosis specific infected T cells. In addition, it provides biologic products, traditional Chinese drug medicine, biochemical drugs, microbiological preparations, antibiotics, and pharmaceutical raw materials. The company also exports its products. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519090",
        "website": "http://www.livzon.com.cn",
        "market_cap": 49355874304
    },
    "1548.HK": {
        "short_name": "GENSCRIPT BIO",
        "long_name": "Genscript Biotech Corporation",
        "summary": "Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "211122",
        "website": "http://www.genscript.com",
        "market_cap": 63676923904
    },
    "1558.HK": {
        "short_name": "HEC PHARM",
        "long_name": "YiChang HEC ChangJiang Pharmaceutical Co., Ltd.",
        "summary": "YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Yichang",
        "zipcode": null,
        "website": "http://cj.hec.cn",
        "market_cap": 6590960128
    },
    "1643.HK": {
        "short_name": "MODERN CHI MED",
        "long_name": "Modern Chinese Medicine Group Co., Ltd.",
        "summary": "Modern Chinese Medicine Group Co. Ltd. produces and sells Chinese medicines. The company was founded in 1986 and is based in Chengde, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Chengde",
        "zipcode": "067000",
        "website": "http://www.cdysjdyy.com",
        "market_cap": 510000000
    },
    "1652.HK": {
        "short_name": "FUSEN PHARM",
        "long_name": "Fusen Pharmaceutical Company Limited",
        "summary": "Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products under the Fusen brand in the People's Republic of China. It offers over the counter and prescription based proprietary Chinese medicine (PCM) products in various dosage forms. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and other PCM and western medicine products, such as Chaihu injection, as well as flunarizine hydrochloride capsules, compound ferrous sulfate granules, and clarithromycin sustained release tablets. In addition, it researches, develops, produces, and sells various PCMs and chemical medicines for the treatments of cold and fever, cardiovascular and gynecological diseases, and anemia. Further, the company offers business management and consulting services. The company was founded in 2003 and is headquartered in Nanyang, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Nanyang",
        "zipcode": null,
        "website": "http://www.fusenyy.com",
        "market_cap": 2710167808
    },
    "1666.HK": {
        "short_name": "TONG REN TANG",
        "long_name": "Tong Ren Tang Technologies Co. Ltd.",
        "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100079",
        "website": "http://www.tongrentangkj.com",
        "market_cap": 8888613888
    },
    "1672.HK": {
        "short_name": "ASCLETIS-B",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.ascletis.com",
        "market_cap": 4142400768
    },
    "1681.HK": {
        "short_name": "CONSUN PHARMA",
        "long_name": "Consun Pharmaceutical Group Limited",
        "summary": "Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.chinaconsun.com",
        "market_cap": 4581704192
    },
    "1763.HK": {
        "short_name": "CIRC",
        "long_name": "China Isotope & Radiation Corporation",
        "summary": "China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through four segments: Pharmaceuticals, Radioactive Source Products, Irradiation, and Independent Clinical Laboratory Services and Other Businesses. The company's Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. Its Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The company's Irradiation segment offers irradiation service to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities to irradiation service providers. Its Independent Clinical Laboratory Services and Other Businesses segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. As of December 31, 2019, the company's sales network included 11,000 hospitals and other medical institutions, such as 1,800 tertiary hospitals, 5,000 secondary hospitals, and 4,400 primary hospitals in China. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100089",
        "website": "http://www.circ.com.cn",
        "market_cap": 9852149760
    },
    "1801.HK": {
        "short_name": "INNOVENT BIO",
        "long_name": "Innovent Biologics, Inc.",
        "summary": "Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has a strategic collaboration with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.innoventbio.com",
        "market_cap": 130931212288
    },
    "1858.HK": {
        "short_name": "CHUNLI MEDICAL",
        "long_name": "Beijing Chunlizhengda Medical Instruments Co., Ltd.",
        "summary": "Beijing Chunlizhengda Medical Instruments Co., Ltd., an orthopedic medical device company, engages in the research and development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China. The company offers implantable orthopedic medical devices, which consist of joint prosthesis products and spinal products. It primarily sells its products through distributors, or on ODM and OEM bases under the Chunli brand, as well as to hospitals directly. The company also exports its products to 38 countries and regions in Asia, South America, Africa, Oceania, and Europe. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.clzd.com/tc/index.php",
        "market_cap": 9614685184
    },
    "1877.HK": {
        "short_name": "JUNSHI BIO",
        "long_name": "Shanghai Junshi Biosciences Co., Ltd.",
        "summary": "Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients, as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.junshipharma.com",
        "market_cap": 83975315456
    },
    "1951.HK": {
        "short_name": "JXR",
        "long_name": "Jinxin Fertility Group Limited",
        "summary": "Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and property holding and management services. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.jxr-fertility.com",
        "market_cap": 46289924096
    },
    "1952.HK": {
        "short_name": "EVEREST MED-B",
        "long_name": "Everest Medicines Limited",
        "summary": "Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200040",
        "website": "http://www.everestmedicines.com",
        "market_cap": 21155969024
    },
    "1LP.F": {
        "short_name": "LANSEN PHARMAC.HLD.DL-,01",
        "long_name": "Lansen Pharmaceutical Holdings Limited",
        "summary": "Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People's Republic of China and internationally. It operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. The company offers specialist medicines and Chinese medicine generic drugs; cosmetic products; and plant extracts and healthcare products. It also engages in research, development, and industrialization of industrial enzyme preparations, molecular biology tool enzymes, and bioactive factors for cosmetics and biological skincare products. The company was founded in 2001 and is headquartered in Ningbo, the People's Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Ningbo",
        "zipcode": "315174",
        "website": "http://www.lansen.com.cn",
        "market_cap": 106123680
    },
    "1ZL.F": {
        "short_name": "ZAI LAB LTD  ADR/1",
        "long_name": "Zai Lab Limited",
        "summary": "Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00c3\u00afve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.zailaboratory.com",
        "market_cap": 13985496064
    },
    "200028.SZ": {
        "short_name": "CN ACCORD MEDICINE",
        "long_name": "China National Accord Medicines Corporation Ltd.",
        "summary": "China National Accord Medicines Corporation Ltd. engages in the distribution of medicine and pharmaceutical products. The company offers Chinese traditional patent, bio-chemical, biological, and diagnosis medicines, as well as antibiotics; chemical preparations; shaped packing food products; chemical products; and various commodities and techniques. It also engages in the sale of drugs, medical apparatus, and instruments; offers freight transportation, storage, loading and unloading, other business, and professional consultation services; provides glass wares, cosmetics, and daily merchandise, as well as goods agency services; import and export of technology; leasing of house properties; and wholesaling and retailing of health products. As of December 30, 2019, the company operated a network of 5,021 drugstores, including 3,744 direct-operated stores and 1,277 franchised stores covering 20 provinces, autonomous regions, and municipalities in China. The company is based in Shenzhen, China. China National Accord Medicines Corporation Ltd. is a subsidiary of Sinopharm Group Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518029",
        "website": "http://www.szaccord.com.cn",
        "market_cap": 20315363328
    },
    "2096.HK": {
        "short_name": "SIMCERE PHARMA",
        "long_name": "Simcere Pharmaceutical Group Limited",
        "summary": "Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and distribution of pharmaceutical and vaccine products for pharmaceutical distributors and government in China. Its principal branded generic pharmaceuticals include Bicun, a prescription edaravone injection pharmaceutical for the treatment of strokes; Zailin, a line of generic prescription amoxicillin antibiotics; Yingtaiqing, an anti-inflammatory pain reliever and analgesic drug used to treat rheumatoid arthritis and osteoarthritis; Enlength, an oncology injection; and Sinofuan for the treatment of cancer. The company also offers generic anti-diarrhea pharmaceutical products under the Biqi brand; amoxicillin and clavulanate potassium tablets, granules, and injection for the treatment of infections under the Anqi brand name; cefaclor in dry suspension antibiotics for the treatment of infections under the Zaike brand; herbal medicines for the treatment of coughs under the Kechuanning name; Jiebaishu, which is primarily used for the treatment of head and neck cancers, small cell lung carcinoma, non-small-cell lung carcinoma, esophageal cancer, and other solid tumors; and biapenem for the treatment of severe infections under the Anxin brand. In addition, it offers cardiovascular products; autoimmune products; anti-infective drugs; and other pharmaceutical products, such as Biqi-branded diosmectite powder and anti-diarrhea products. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210042",
        "website": "http://www.simcere.com",
        "market_cap": 32608000000
    },
    "2120.HK": {
        "short_name": "KN HOSPITAL",
        "long_name": "Wenzhou Kangning Hospital Co., Ltd.",
        "summary": "Wenzhou Kangning Hospital Co., Ltd. operates and manages a network of healthcare facilities in the People's Republic of China. It primarily focuses on providing psychiatric specialty care. The company also provides property leasing and sale services; and software and information technology services, as well as hospital management, forensic authentication, and medical services. It is also engaged in pharmaceutical retail. The company was formerly known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital and changed its name to Wenzhou Kangning Hospital Co., Ltd. in October 2014. Wenzhou Kangning Hospital Co., Ltd. was founded in 1996 and is headquartered in Wenzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Wenzhou",
        "zipcode": null,
        "website": "http://www.knhosp.cn",
        "market_cap": 2275300096
    },
    "2126.HK": {
        "short_name": "JW THERAP-B",
        "long_name": "JW (Cayman) Therapeutics Co. Ltd",
        "summary": "JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.jwtherapeutics.com",
        "market_cap": 11183547392
    },
    "2135.HK": {
        "short_name": "RAILY AESMED",
        "long_name": "Raily Aesthetic Medicine International Holdings Limited",
        "summary": "Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services in the People's Republic of China. The company's services include aesthetic surgery services, including aesthetic surgical procedures performed on various parts of the face or body; minimally-invasive aesthetic services, primarily comprising aesthetic injection procedures; and aesthetic dermatology services, such as various aesthetic energy-based procedures. Raily Aesthetic Medicine International Holdings Limited was founded in 2008 and is headquartered in Hangzhou City, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.ruilizx.com",
        "market_cap": 1356300160
    },
    "2158.HK": {
        "short_name": "YIDU TECH",
        "long_name": "Yidu Tech Inc.",
        "summary": "Yidu Tech Inc. provides healthcare solutions built on big data and artificial intelligence technologies in China. The company operates through three segments: Big Data Platform and Solutions, Life Sciences Solutions, and Health Management Platform and Solutions. The Big Data Platform and Solutions segment offers the data processing and application platform (DPAP) and its upgraded version Eywa, as well as other solutions to hospitals, regulators, and policy makers. Its DPAP/Eywa platforms aggregate the raw data that reside in the systems and process them into structured and standardized data. These data platforms further empower various applications and solutions for hospitals, such as medical research, clinical diagnosis and treatment, and hospital operations management. The Life Sciences Solutions segment provides analytics-driven clinical development, real-world evidence (RWE)-based research, and digital commercialization solutions to pharmaceutical, biotech and medical device companies. It also offers software and technology platforms to pharmaceutical, biotech and medical device companies, and contract research organizations (CROs) to enhance their clinical trial process. The segment's life sciences solutions serve customers in their drug and medical device development, and commercialization process. The Health Management Platform and Solutions segment offers CausaHealth, a personal health management platform that helps doctors to conduct research and manage their patients. This segment also offers insurance technology and disease management solutions under the CausaCloud brand to insurance companies, and agencies. The company was founded in 2014 and is headquartered in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.yidutechgroup.com",
        "market_cap": 39692369920
    },
    "2159.HK": {
        "short_name": "MEDIWELCOME",
        "long_name": "Mediwelcome Healthcare Management & Technology Inc.",
        "summary": "Mediwelcome Healthcare Management & Technology Inc. provides integrated healthcare marketing solutions in cardio-cerebral-vascular diseases in China. It offers medical conference, patient education and screening, and marketing strategy and consulting services; and patients' recruitment and clinical data collection services. The company also operates WeChat public account and a mobile app to provide internet hospital services, including online follow up consultation to the physicians' existing patients and e-prescription services. It serves physicians, patients, pharmaceutical companies, medical non-governmental organizations, and hospitals. The company was founded in 2000 and is headquartered in Beijing, the Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.mediwelcome.com",
        "market_cap": 454000000
    },
    "2160.HK": {
        "short_name": "CARDIOFLOW-B",
        "long_name": "MicroPort CardioFlow Medtech Corporation",
        "summary": "MicroPort CardioFlow Medtech Corporation, a medical device company, focuses on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases in the People's Republic of China. Its products include Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, which targets aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China. MicroPort CardioFlow Medtech Corporation is a subsidiary of Shanghai MicroPort Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.cardioflowmedtech.com",
        "market_cap": 40030068736
    },
    "2170.HK": {
        "short_name": "BASECARE-B",
        "long_name": "Suzhou Basecare Medical Corporation Limited",
        "summary": "Suzhou Basecare Medical Corporation Limited, an investment holding company, engages in the research, development, manufacture, and provision of genetic testing solutions for assisted reproduction and sale of genetic testing devices and instruments in the People's Republic of China. The company offers genetic test kit products, which include pre-implantation genetic test kits, such as PGT-A, PGT-M, and PGT-SR kits; and prenatal test kit products comprising CNV kits; and postnatal test kit products consist of WES kits. It also distributes noninvasive prenatal testing and DA8600 kits, as well as metagenomic genetic detection kits, such as respiratory virus nucleic acid, respiratory pathogens nucleic acid, and novel coronavirus (2019-nCoV) nucleic acid detection kits. In addition, the company offers marketing and testing services. Its customers primarily include domestic reproductive clinics; women and children hospitals; and hospitals with assisted reproduction capabilities. Suzhou Basecare Medical Corporation Limited was founded in 2010 and is headquartered in Suzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215000",
        "website": "http://www.basecare.cn",
        "market_cap": 7508289536
    },
    "2181.HK": {
        "short_name": "MABPHARM-B",
        "long_name": "Mabpharm Limited",
        "summary": "Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB813 for the treatment of severe lower respiratory tract disease in pediatric patients; CMAB816 for the treatment of periodic fever syndrome and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis, as well as CMAB020, a recombinant bispecific fusion protein, which is in under development stage. The company was founded in 2018 and is headquartered in Taizhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "225300",
        "website": "http://www.mabpharm.cn",
        "market_cap": 4948896256
    },
    "2186.HK": {
        "short_name": "LUYE PHARMA",
        "long_name": "Luye Pharma Group Ltd.",
        "summary": "Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Rykindo, an injection for the treatment of acute and chronic schizophrenia; Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; Fengshiye for patients who have pains in bones, joints, and limbs; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; and glucosamine hydrochloride tablets for osteoarthritis. Additionally, it distributes and sells pharmaceutical drugs; and manufactures and sells of biopharmaceutical products. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Yantai",
        "zipcode": "264003",
        "website": "http://www.luye.cn",
        "market_cap": 16609026048
    },
    "2196.HK": {
        "short_name": "FOSUN PHARMA",
        "long_name": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "summary": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.fosunpharma.com",
        "market_cap": 185086197760
    },
    "2269.HK": {
        "short_name": "WUXI BIO",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Wuxi",
        "zipcode": "214092",
        "website": "http://www.wuxibiologics.com",
        "market_cap": 522058596352
    },
    "2289.HK": {
        "short_name": "CHARMACY PHAR",
        "long_name": "Charmacy Pharmaceutical Co., Ltd.",
        "summary": "Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, and healthcare products to downstream distributors and terminal chemists, as well as related consulting services. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shantou",
        "zipcode": "515041",
        "website": "http://www.chmyy.com",
        "market_cap": 702000000
    },
    "2359.HK": {
        "short_name": "WUXI APPTEC",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200131",
        "website": "http://www.wuxiapptec.com",
        "market_cap": 439852924928
    },
    "2393.HK": {
        "short_name": "YESTAR HEALTH",
        "long_name": "Yestar Healthcare Holdings Company Limited",
        "summary": "Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells Fujifilm color photographic paper, industrial NDT X-ray films, and PWB films; and trades in imaging equipment. Its products are used in professional and minilabs; and industrial imaging applications. This segment provides NDT X-ray films under the Yes!Star brand. The Medical Products and Equipment segment manufactures and sells medical dry and wet films, and dental films; and sells medical equipment and diagnostic reagents. The company also distributes in vitro diagnostic products. In addition, it engages in the biotechnology development activities; management of supply chain; and freight transportation services. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201199",
        "website": "http://www.yestarcorp.com",
        "market_cap": 2681587968
    },
    "2500.HK": {
        "short_name": "VENUS MEDTECH-B",
        "long_name": "Venus Medtech (Hangzhou) Inc.",
        "summary": "Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of cerebral damage during TAVR and other structural heart procedures. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.venusmedtech.com",
        "market_cap": 31796893696
    },
    "2616.HK": {
        "short_name": "CSTONE PHARMA-B",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.cstonepharma.com",
        "market_cap": 16882982912
    },
    "2696.HK": {
        "short_name": "HENLIUS",
        "long_name": "Shanghai Henlius Biotech, Inc.",
        "summary": "Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases worldwide. The company offers HLX01, a rituximab injection for treating non- hodgkin lymphoma and chronic lymphocytic leukemia; Hanquyou, a trastuzumab injection for breast and metastatic gastric cancer; and Han Dayuan, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, and psopiasis and uveitis. It is developing HLX01 for the treatment of rheumatoid arthritis; HLX04 for colorectal and non-squamous non-small cell lung cancer; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX10 for solid tumors and hepatitis B virus; HLX10+Chemotherapy for metastatic esophageal squamous-cell carcinomas, squamous non-small cell lung cancer, small cell lung cancer, neo-/adjuvant treatment of gastric cancer, and cervical cancer; and HLX10+HLX04 for hepatocellular carcinoma, non-squamous, non-small cell lung cancer, and metastatic colorectal cancer. The company is also developing HLX10+HLX07 for squamous cell carcinoma of the head and neck; HLX07, HLX06, HLX56, and HLX20 for solid tumors; HLX05, a cetuximab injection for squamous cell carcinoma of the head and neck and metastatic colorectal cancer; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer; HLX22 for breast and metastatic gastric cancer; HLX55 for metastatic or recurrent solid tumors; HLX11 for breast cancer; HLX14 for osteoporosis; HLX13 for unresectable or metastatic melanoma, adjuvant treatment of melanoma, advanced renal cell carcinoma, and metastatic colorectal cancer; HLX15 for multiple myeloma; HLX26 for solid tumor and lymphoma; and HLX70 and HLX71 for COVID-19. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.henlius.com",
        "market_cap": 21322512384
    },
    "2877.HK": {
        "short_name": "SHINEWAY PHARM",
        "long_name": "China Shineway Pharmaceutical Group Limited",
        "summary": "China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections in various therapeutic areas, including cardio-cerebrovascular, antiviral, orthopedics, pediatrics, gynecology, neurology, gastroenterology, ophthalmology, oncology, and immunology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": "051430",
        "website": "http://www.shineway.com",
        "market_cap": 6764860416
    },
    "2UO1.F": {
        "short_name": "HAPPINESS BIOT.GRP -,0005",
        "long_name": "Happiness Biotech Group Limited",
        "summary": "Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powder, cordyceps mycelia, ejiao solution, American ginseng, and other products. It also offers a range of ganoderma lucidum products, such as essence oil, cleansing milk, shampoo, shower gel, and nourishing cream products under the Cai Zhi Ning brand, as well as edible fungi. In addition, the company provides disinfectants, non-medical face masks, and COVID-19 anti-body testing kits. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Nanping",
        "zipcode": "353200",
        "website": "http://www.happ.org.cn",
        "market_cap": 36525160
    },
    "2VJ.F": {
        "short_name": "ASCLETIS PHARMA  DL-,0001",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.ascletis.com",
        "market_cap": 454719712
    },
    "300003.SZ": {
        "short_name": "LEPU MEDICAL TECHN",
        "long_name": "Lepu Medical Technology (Beijing) Co., Ltd.",
        "summary": "Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; \u00c3\u009f-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102200",
        "website": "http://en.lepumedical.com",
        "market_cap": 55815659520
    },
    "300006.SZ": {
        "short_name": "CHONGQING LUMMY PH",
        "long_name": "Chongqing Lummy Pharmaceutical Co., Ltd.",
        "summary": "Chongqing Lummy Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products in China. The company provides tumor, antibacterial, antiviral, and antifungal, as well as liver disease auxiliary, endocrinology system, and Chinese patent drugs; digestive system, immune system, blood system, cardiovascular system, and nervous system drugs; acid-base balance and nutritional products; and base large infusion products, American ginseng systems, and active pharmaceutical ingredients. Chongqing Lummy Pharmaceutical Co., Ltd. was founded in 1999 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401336",
        "website": "http://www.cqlummy.com",
        "market_cap": 7623670272
    },
    "300009.SZ": {
        "short_name": "ANHUI ANKE BIOTECH",
        "long_name": "Anhui Anke Biotechnology (Group) Co., Ltd.",
        "summary": "Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hefei",
        "zipcode": "230088",
        "website": "http://www.ankebio.com",
        "market_cap": 21013352448
    },
    "300015.SZ": {
        "short_name": "AIER EYE HOSPITAL",
        "long_name": "Aier Eye Hospital Group Co., Ltd.",
        "summary": "Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. It operates approximately 200 ophthalmic hospitals in mainland China, 76 ophthalmic hospitals in Europe, 1 ophthalmic hospital in the United States, and 7 ophthalmic hospitals in Hong Kong. The company was founded in 2007 and is headquartered in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": "410015",
        "website": "http://www.aierchina.com",
        "market_cap": 353873723392
    },
    "300016.SZ": {
        "short_name": "BEIJING BEILU PHAR",
        "long_name": "Beijing Beilu Pharmaceutical Co., Ltd.",
        "summary": "Beijing Beilu Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd. also produces precision medicine. The company was founded in 1992 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100082",
        "website": "http://www.beilu.com.cn",
        "market_cap": 4485060608
    },
    "300026.SZ": {
        "short_name": "TIANJIN CHASE SUN",
        "long_name": "Tianjin Chase Sun Pharmaceutical Co.,Ltd",
        "summary": "Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "10200536",
        "website": "http://www.chasesun.cn",
        "market_cap": 12407140352
    },
    "300030.SZ": {
        "short_name": "GUANGZHOU IMPROVE",
        "long_name": "Guangzhou Improve Medical Instruments Co., Ltd.",
        "summary": "Guangzhou Improve Medical Instruments Co., Ltd. provides technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. Its principal products include IMPROVACUTER evacuated blood collection systems, IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, etc. The company also provides blood collection needles, pulsewave blood pressure monitors, thrombosis viscoelastic analysis systems, feces analysis systems, blood collection tube preparation systems, graphic user interface devices, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels. Guangzhou Improve Medical Instruments Co., Ltd. was founded in 1996 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.improve-medical.com",
        "market_cap": 3504834816
    },
    "300039.SZ": {
        "short_name": "SHANGHAI KAIBAO PH",
        "long_name": "Shanghai Kaibao Pharmaceutical CO.,Ltd",
        "summary": "Shanghai Kaibao Pharmaceutical CO.,Ltd researches, develops, produces, and sells modern Chinese medicines primarily in China. The company's primary product is Tanreqing injection that clears heat and detoxifies; relieves cough and removes phlegm; and for treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection. It also provides Kaibao Chuanxiong capsules; Kaibao Weiyuan tablets; And Kaibao pressure-release sustained release tablets. In addition, the company offers western medicines in various dosage forms, such as lyophilized powder injection, small volume injection, tablet, capsule, granule, pill, cream, and other dosage forms. Its western medicines comprise Kaixilai freeze-dried powder, tiopronin sodium, ginseng capsule, and Shanhaidan, alopecia areata, as well as Yuanman brand health win. The company is also developing Youxinding Capsule for treatment of depressions, which is in phase II clinical study; classic Fangding Guiyou soft capsule that is in phase III clinical study; Shufeng analgesic capsule for the treatment of migraine, which is in phase III clinical study; Huadan Anshen mixture for anti-insomnia that is in phase III clinical study; and Tanzheqing series of products, which is in phase III clinical study. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201401",
        "website": "http://www.xykb.com",
        "market_cap": 5146319872
    },
    "300049.SZ": {
        "short_name": "INNER MONGOLIA FUR",
        "long_name": "Inner Mongolia Furui Medical Science Co., Ltd.",
        "summary": "Inner Mongolia Furui Medical Science Co., Ltd. operates as a professional medical service platform company worldwide. The company provides disease diagnosis, drug treatment, and chronic disease management products in the liver disease field. It also offers health management center and medical care services. The company was formerly known as Inner Mongolia FuRui Pharmaceutical Limited Liability Company. Inner Mongolia Furui Medical Science Co., Ltd. was founded in 1998 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100027",
        "website": "http://www.fu-rui.com",
        "market_cap": 3038262016
    },
    "300061.SZ": {
        "short_name": "SHANGHAI CONANT MA",
        "long_name": "QITIAN Technology Group Co., Ltd.",
        "summary": "QITIAN Technology Group Co., Ltd. manufactures and supplies optical lenses in China. Its products include hard resin, stock, Rx free form, UV++, single vision, bi-focal, trifocal, high index, polarized, photochromic, sunfilter, infra-red, and custom hybrid monomer lenses. The company was founded in 1996 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.qt300061.com",
        "market_cap": 5545320448
    },
    "300086.SZ": {
        "short_name": "HONZ PHARMACEUTICA",
        "long_name": "Honz Pharmaceutical Co., Ltd.",
        "summary": "Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pediatric medicines in China. It offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine. The company markets its products through a network of agents and sales terminals. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.honz.com.cn",
        "market_cap": 2636999936
    },
    "300108.SZ": {
        "short_name": "JI YAO HOLDING GRO",
        "long_name": "Ji Yao Holding Group Co., Ltd.",
        "summary": "Ji Yao Holding Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, and wholesale of pharmaceutical products. It offers Chinese and western medicines in the areas of pediatrics, phlegm and cough, gynecology, cardiovascular and cerebrovascular, antiviral, urinary, anti-inflammatory, gastrointestinal, tonic class, and rheumatoid immunity. The company also engages in the marketing of pharmaceutical products; investment and management of hospital projects; housing leasing activities; development and sale of computer software systems and auxiliary equipment; provision of business management and investment consulting; and design, production, agency, and release of various domestic and international advertising. Ji Yao Holding Group Co., Ltd. is headquartered in Meihekou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Meihekou",
        "zipcode": null,
        "website": "http://www.jiyaogroup.com",
        "market_cap": 2237810176
    },
    "300109.SZ": {
        "short_name": "NKY MEDICAL HOLDIN",
        "long_name": "Boai NKY Medical Holdings Ltd.",
        "summary": "Boai NKY Medical Holdings Ltd. develops, manufactures, and sells polyvinylpyrrolidone (PVP) series products worldwide. The company offers KoVidone and PolyKoVidone line of products representing Povidone, Crospovidone, and Copovidone pharmaceutical excipients; OraRez line of PVM/MA copolymer and derivatives representing functional polymers for bioadhesive/mucoadhesive applications; KoVidone-1 broad spectrum biocidal, antifungal, and antiviral agents; and pharmaceutical solvents and intermediates. It also offers polymers, vinyl and vinyl ether compounds, PolyViscol, KoVidone I, WhiVidone, and PVPP. Its products are used in pharma, industrial, oral care, cosmetics, and food and beverage. The company was formerly known as Boai NKY Pharmaceuticals Ltd. and changed its name to NKY medical holding Ltd. in March 2016. Boai NKY Medical Holdings Ltd. is based in Heping, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Heping",
        "zipcode": "300200",
        "website": "http://www.boai-nky.com",
        "market_cap": 4697423360
    },
    "300110.SZ": {
        "short_name": "HUAREN PHARMACEUTI",
        "long_name": "Huaren Pharmaceutical Co., Ltd.",
        "summary": "Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. The company offers non-PVC double tube double valves, single tube single valves, and single tube double valve soft bags, as well as plastic and glass bottles. It also provides sodium lactate ringer injection, compound sodium chloride injection, glucose injection, sodium chloride injection, sterilized injection water, physiological sodium chloride solution, and mannitol injection products. In addition, the company offers various medical devices, such as incision pull-open fixators, disposable casing puncture device, disposable specimen pickup device, and devices for endoscopy; disposable slip pads, disposable backflow drainage bags, and sterile drainage bags; and abdominal dialysis external short tubes, iodine liquid protection cap, disposable abdominal drainage bags, and various types of rubber plugs, as well as pre-sealing pistons, conveyor plugs for infusion bags, dosing plugs for infusion bags, and polycarbonate for injections to fold plugs. Further, it provides injections for various diseases categories, which include the circulatory system, nervous system, blood volume extender, blood purification, anti-hepatitis and hepatitis assisted drugs, and hemostatic and anti-infective class; and retention needle and accessory products. Huaren Pharmaceutical Co., Ltd. was founded in 1998 and is based in Qingdao, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qingdao",
        "zipcode": "266100",
        "website": "http://www.qdhuaren.com",
        "market_cap": 5071681024
    },
    "300119.SZ": {
        "short_name": "TIANJIN RINGPU BIO",
        "long_name": "Tianjin Ringpu Bio-Technology Co., Ltd.",
        "summary": "Tianjin Ringpu Bio-Technology Co., Ltd. develops, manufactures, and sells animal health products in China. It provides approximately 280 varieties of animal health products, including chemical drugs, biological products, feed additives, and plant extracts for poultry, livestock, pets, and aquatic animals. The company was founded in 1998 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300308",
        "website": "http://www.ringpu.com",
        "market_cap": 15389904896
    },
    "300122.SZ": {
        "short_name": "CHONGQING ZHIFEI B",
        "long_name": "Chongqing Zhifei Biological Products Co., Ltd.",
        "summary": "Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, and marketing of vaccines in China. It offers Meningococcal Group A&C Conjugate Vaccine and Meningococcal Polysaccharide Vaccine for the prevention of infectious and invasive meningococcal disease, including meningitis and pneumonia caused by Neisseria meningitidis serogroups A, C; Mycobacterium Vaccae for Injection, a bidirectional immune-modulator for disease like tuberculosis; Haemophilus Influenzae Type b Conjugate Vaccine for the prevention of invasive disease caused by Haemophilus influenzae type b, such as meningitis, pneumonia, sepsis, etc.; and Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine for the prevention of invasive disease caused by meningococcal groups A,C, as well as Haemophilus influenza type b comprising cerebrospinal meningitis, pneumonia, septicemia, epiglottitis, etc. The company also acts as agent for Hepatitis A vaccine; Pneumococcal vaccine; Human Papillomavirus Quadrivalent vaccine and Human Papillomavirus 9-valent vaccine for the prevention of cervical cancer, grade 1/2/3 cervical intraepithelial neoplasia, and cervical adenocarcinoma in situ caused by human papillomavirus; and Pentavalent Rotavirus vaccine for the prevention of rotavirus gastroenteritis in infants caused by the serotypes. In addition, it offers biologics for the prevention and treatment of TB and viral vaccines for the prevention of rabies, influenza, etc.; and sells generic drugs. Further, the company is involved in the marketing, import, export, and sale of biotechnologies; and provision of foreign investment and financing activities. Chongqing Zhifei Biological Products Co., Ltd. was founded in 2001 and is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": null,
        "website": "http://www.zhifeishengwu.com",
        "market_cap": 309280014336
    },
    "300142.SZ": {
        "short_name": "WALVAX BIOTECHNOLO",
        "long_name": "Walvax Biotechnology Co., Ltd.",
        "summary": "Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": "650106",
        "website": "http://www.walvax.com",
        "market_cap": 99763421184
    },
    "300147.SZ": {
        "short_name": "XIANGXUE PHARMACEU",
        "long_name": "Xiangxue Pharmaceutical Co.,Ltd.",
        "summary": "Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. The company was founded in 1997 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510663",
        "website": "http://www.xphcn.com",
        "market_cap": 5132161536
    },
    "300149.SZ": {
        "short_name": "CHEMPARTNER PHARMA",
        "long_name": "Chempartner Pharmatech Co., Ltd.",
        "summary": "Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company provides medical contract research organization, and contract development and manufacturing organization services for pre-clinical stages. It is also involved in the research, production, and sales of prebiotic fibers as a microecological fortification ingredient, ODM product, and food for special medical purposes product. The company was formerly known as Quantum Hi-Tech (China) Biological Co., Ltd. and changed its name to Quantum Hi-Tech (China) Biological Co., Ltd. in September 2020. Quantum Hi-Tech (China) Biological Co., Ltd. was founded in 2000 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.quantumbio.net.cn",
        "market_cap": 8266311680
    },
    "300158.SZ": {
        "short_name": "SHANXI ZHENDONG PH",
        "long_name": "Shanxi Zhendong Pharmaceutical Co.,Ltd",
        "summary": "Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, researches, develops, manufactures, and markets pharmaceutical products and Chinese medicines in China. It offers cancer drugs, cardiovascular drugs, infectious disease drugs, and respiratory drugs; antibiotics, antitumor drugs, vitamins, etc.; Chinese medicines; calcium preparations; and active pharmaceutical ingredients, as well as sells gastrointestinal drugs. The company offers its products in various dosage forms, such as large volume injections, small volume injections, powder injections, lyophilized powders, tablets, hard capsules, granules, dry suspensions, ointments, psychotropic substances, and other formulations Shanxi Zhendong Pharmaceutical Co.,Ltd is based in Changzhi, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changzhi",
        "zipcode": "047100",
        "website": "http://www.zdjt.com",
        "market_cap": 6421812224
    },
    "300171.SZ": {
        "short_name": "SHANGHAI TOFFLON S",
        "long_name": "Shanghai Tofflon Science and Technology Co., Ltd.",
        "summary": "Shanghai Tofflon Science and Technology Co., Ltd. operates as a pharmaceutical equipment supplier for the pharma and biotech industries worldwide. It offers injectables, such as auto solution preparation systems, aseptic filling lines for ampoule, vials, syringes and powders, freeze dryer and auto loading systems, barrier systems, and plastic packaging machines. The company also provides active pharmaceutical ingredients; and visual inspection, leak detection, and combination systems, as well as focuses on providing bio-process equipment and integrated systems, including medium preparation, cell/microbial cultivation, harvesting, DF/UF, purification, buffer preparation, and finished filling systems. In addition, it offers lyophilization injectable lab services. The company was founded in 1993 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201108",
        "website": "http://www.tofflon.com",
        "market_cap": 22884032512
    },
    "300181.SZ": {
        "short_name": "ZHEJIANG JOLLY PHA",
        "long_name": "Zhejiang Jolly Pharmaceutical Co.,LTD",
        "summary": "Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporin, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Huzhou",
        "zipcode": "313200",
        "website": "http://www.zuoli.com",
        "market_cap": 4856827904
    },
    "300194.SZ": {
        "short_name": "FUAN PHARMACEUTICA",
        "long_name": "Fuan Pharmaceutical (Group) Co., Ltd.",
        "summary": "Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells pharmaceutical intermediates, bulk drugs, and formulations in the People's Republic of China. It offers APIs and intermediates, as well as formulations, such as anti-infective, cardiovascular, digestive, leaflet, and other products. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd. in August 2013. Fuan Pharmaceutical (Group) Co., Ltd. was founded in 2004 and is based in Chongqing, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "401254",
        "website": "http://www.fapharm.com",
        "market_cap": 5258518016
    },
    "300199.SZ": {
        "short_name": "HYBIO PHARMACEUTIC",
        "long_name": "Hybio Pharmaceutical Co., Ltd.",
        "summary": "Hybio Pharmaceutical Co., Ltd., a peptide pharmaceutical company, engages in the research and development, manufacture, and sale of polypeptide drugs in the People's Republic of China and internationally. Its peptide finished dosage products include digestive system agents, immune modulators, PTH and Ca metabolic modulators, hormone and endocrine modulators, FD for circulatory and blood systems, antiviral agents, and hemostatic products. The company also provides custom and GMP peptides; and a range of peptide APIs. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.hybio.com.cn",
        "market_cap": 5739962880
    },
    "300204.SZ": {
        "short_name": "STAIDSON (BEIJING)",
        "long_name": "Staidson (Beijing) BioPharmaceuticals Co., Ltd.",
        "summary": "Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.staidson.com",
        "market_cap": 5093574656
    },
    "300206.SZ": {
        "short_name": "EDAN INSTRUMENTS I",
        "long_name": "Edan Instruments, Inc.",
        "summary": "Edan Instruments, Inc. engages in the research, development, manufacture, and sale of medical equipment worldwide. The company offers diagnostic electrocardiograph (ECG) products, including resting ECG, stress test, holter, wireless solution, and ECG workstation products; patient monitoring systems, such as vital signs, transport, and central monitoring systems, as well as high acuity cares, acute and sub-acute cares, telemetry, and pulse oximetry products; and obstetrics and gynecology products comprising fetal and maternal monitoring systems, fetal telemetry systems, ultrasonic doppler systems, and video colposcopes. It also provides ultrasound imaging systems that include color doppler ultrasound and B/W digital ultrasound systems; and in-vitro diagnostics, which comprise hematology analyzers. In addition, the company offers point-of-care testing systems, including blood gas and chemistry, magnetic immunoassay, and colloidal gold-labeled immunoassay analyzers; and veterinary ultrasound, ECG, ABG, and monitoring products. Edan Instruments, Inc. is headquartered in Shenzhen, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518122",
        "website": "http://www.edan.com.cn",
        "market_cap": 9644950528
    },
    "300238.SZ": {
        "short_name": "GUANHAO BIOTECH CO",
        "long_name": "Guanhao Biotech Co.,Ltd.",
        "summary": "Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicine in China. It offers NormalGEN, a type of biological dura repair patch manufactured from animal tissue; GrandNeuro, an artificial dura patch for dura repairing; ThormalGEN, a biological surgical patch manufactured from animal tissue for surgical repairs; DermalGEN, a wound dressing product manufactured from animal tissue for use on burns, scalds, and wounds due to skin loss or trauma; and IREAL breast patch. The company was founded in 1999 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510530",
        "website": "http://www.guanhaobio.com",
        "market_cap": 5586836992
    },
    "300239.SZ": {
        "short_name": "BAOTOU DONGBAO BIO",
        "long_name": "Baotou Dongbao Bio-Tech Co.,Ltd",
        "summary": "Baotou Dongbao Bio-Tech Co., Ltd. engages in the research and development, production, and sale of gelatin and collagen products in the People's Republic of China and internationally. It offers food additive and pharmaceutical gelatin, as well as collagen peptide. The company was founded in 1997 and is based in Baotou, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Baotou",
        "zipcode": "014030",
        "website": "http://www.dongbaoshengwu.com",
        "market_cap": 3271748608
    },
    "300246.SZ": {
        "short_name": "GUANGDONG BIOLIGHT",
        "long_name": "Guangdong Biolight Meditech Co., Ltd.",
        "summary": "Guangdong Biolight Meditech Co., Ltd. engages in the research and development, marketing, sale, and service of medical devices, medical consumables, and healthcare solutions. It offers patient monitors, ECG machines, fetal monitors, hemodialysis products, homecare medical products, medical pumps, veterinary monitors, and accessories. The company operates in Asia, Africa, Europe, North America, and Latin America. Guangdong Biolight Meditech Co., Ltd. was founded in 1993 and is headquartered in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": null,
        "website": "http://www.blt.com.cn",
        "market_cap": 2813673984
    },
    "300253.SZ": {
        "short_name": "WINNING HEALTH TEC",
        "long_name": "Winning Health Technology Group Co., Ltd.",
        "summary": "Winning Health Technology Group Co., Ltd. provides IT solutions for hospitals and medical service organizations in China. The company offers IT solution designing, planning and consulting, development, system building, maintenance, and operation services. Its solutions are used in building smart hospitals, regional healthcare regulation platforms, community healthcare regulation platforms, public health-care regulation platforms, medical insurance, and other health services. The company was formerly known as Shanghai Kingstar Winning Software Co., Ltd. and changed its name to Winning Health Technology Group Co., Ltd. in January 2016. The company was founded in 1994 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.winning.com.cn",
        "market_cap": 33685952512
    },
    "300255.SZ": {
        "short_name": "HEBEI CHANGSHAN BI",
        "long_name": "Hebei Changshan Biochemical Pharmaceutical Co., Ltd.",
        "summary": "Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of heparin and related products in China. Its API products include heparin sodium injections, heparin calcium and lithium injections, heparinoid, LMW heparins, and sodium hyaluronate. The company also provides dalteparin and enoxaparin sodium injections, and nadroparin calcium injections, as well as sildenafil citrate tablets. It markets and sells its products to approximately 30 countries worldwide. Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000 and is based in Shijiazhuang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": null,
        "website": "http://www.heparin.cn",
        "market_cap": 6217530368
    },
    "300267.SZ": {
        "short_name": "HUNAN ER-KANG PHAR",
        "long_name": "Hunan Er-Kang Pharmaceutical Co., Ltd",
        "summary": "Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate and its series products. The company was founded in 2003 and is based in Liuyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Liuyang",
        "zipcode": null,
        "website": "http://www.hnerkang.com",
        "market_cap": 8085391872
    },
    "300273.SZ": {
        "short_name": "ZHUHAI HOKAI MEDIC",
        "long_name": "Zhuhai Hokai Medical Instruments Co., Ltd.",
        "summary": "Zhuhai Hokai Medical Instruments Co., Ltd. provides medical equipment in China. The company offers minimally invasive tumor, medical imaging, and rehabilitation and conventional equipment; tumor and interventional discipline, and rehabilitation discipline construction services; artificial intelligence system solutions; and medical gas, clean, and auxiliary engineering services. It also provides in-hospital and regional medical information, and telemedicine services, as well as hospital construction; medical supply chain and logistics management; and financial leasing services. Zhuhai Hokai Medical Instruments Co., Ltd. was founded in 1996 and is headquartered in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519030",
        "website": "http://www.hokai.com",
        "market_cap": 4991830016
    },
    "300288.SZ": {
        "short_name": "GUIYANG LONGMASTER",
        "long_name": "Longmaster Information & Technology Co., Ltd.",
        "summary": "Longmaster Information & Technology Co., Ltd. operates as an Internet medical company in China. The company offers telemedicine, medical information, video consultation, physical hospital, smart hardware, and medical e-commerce services. It also provides telephony voice community phone services; health equipment; online consultancy services, such as medication instructions, referral, free consultation, and other services; and drug search services. In addition, the company maintains health records that enable doctors to monitor the background, early warning, prompting of diseases, and eliminate health risks; provides health care, diet, exercise guidance, health knowledge, and early prevention of health risk services. Longmaster Information & Technology Co., Ltd. was founded in 1998 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guiyang",
        "zipcode": null,
        "website": "http://www.longmaster.com.cn",
        "market_cap": 3521345280
    },
    "300289.SZ": {
        "short_name": "BEIJING LEADMAN BI",
        "long_name": "Beijing Leadman Biochemistry Co.,Ltd.",
        "summary": "Beijing Leadman Biochemistry Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products in the People's Republic of China. The company offers biochemical raw materials, such as enzymes, coenzymes, antibodies, buffers, enzyme substrates, culture media, stain reagents, amino acids, and other products primarily for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemistry diagnostic and companion reagents. In addition, the company offers medical instruments, such as EnigmaML, an automated molecular test platform for use in clinical laboratory and at the point-of-care, including clinics, doctor's surgeries, and pharmacies; DiaSys InnovaStar, an automatic compact POCT analyzer to deliver result quality comparable to measurements on laboratory analyzers; DiaSys Respons, a random access bench top analyzer; CI1000 automatic chemiluminescence immunoassay analyzers; and IDS-isys, an instrument to enhance performance and productivity. The company was founded in 1997 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.leadmanbio.com",
        "market_cap": 2627364352
    },
    "300294.SZ": {
        "short_name": "BOYA BIO-PHARMACEU",
        "long_name": "Boya Bio-pharmaceutical Group Co.,Ltd",
        "summary": "Boya Bio-pharmaceutical Group Co., Ltd. develops, produces, and sells blood products and other related health products in China. Its products include human fibrinogen, intravenous human immunoglobulin, rabies patient immunoglobulin, and human albumin. The company also provides orthopedic medications, obstetrics and gynecology, gastrointestinal medication, enhanced immunological preparations, hepatic medication, cardiovascular and cerebral medicine, diabetes medication, anticoagulation hemostatic, API, and others products. In addition, it offers chemical raw materials, such as calcium hydroxybenzenesulfonate, glimepiride, azinamide, simvastatin, and repaglinide; biochemical drugs and chemical medicines; and other products in various categories, such as orthopedics, diabetes, hepatitis, gynecology, and gut and immunomodulatory agents. Further, the company focuses on the development of release preparations and compound preparations; and offers anti-diabetic products, such as metformin hydrochloride enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and glipizide tablets, as well as provides tablets and capsules for the treatment of diabetic retinopathy and glomerular lesions. The company was formerly known as Jiangxi Boya Bio-Pharmaceutical Co.,Ltd and changed its name to Boya Bio-pharmaceutical Group Co., Ltd. in August 2017. Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is headquartered in Fuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Fuzhou",
        "zipcode": null,
        "website": "http://www.china-boya.com",
        "market_cap": 16414351360
    },
    "300298.SZ": {
        "short_name": "SINOCARE INC",
        "long_name": "Sinocare Inc.",
        "summary": "Sinocare Inc. engages in the development, manufacture, and marketing of diagnosis rapid testing products primarily in the People's Republic of China. It offers Safe-Accu blood glucose monitoring systems; Safe-AQ blood glucose monitoring systems; Gold-Accu blood glucose monitoring systems; Safe-Accu UG blood, glucose, and uric acid monitoring systems; Safe-Accu KG blood, glucose, and ketone monitoring systems; and D Nurse mobile glucose meters. The company provides its products for the patients with chronic diseases and diabetes, as well as for healthcare professionals. It also exports its products to 135 countries. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": "410205",
        "website": "http://www.sinocare.com",
        "market_cap": 17315598336
    },
    "300314.SZ": {
        "short_name": "NINGBO DAVID MEDIC",
        "long_name": "Ningbo David Medical Device Co., Ltd.",
        "summary": "Ningbo David Medical Device Co., Ltd. engages in the research and development, production, and distribution of medical equipment in China and internationally. The company primarily provides infant incubators, transport incubators, infant radiant warmers, neonate bilirubin phototherapy equipment, infant resuscitators, etc. It also offers other products, such as infusion pumps, ultrasonic doppler fetal heartbeat detectors, transcutaneous jaundice detectors, infant t-piece resuscitators, air/oxygen blenders, low pressure aspirators, breath resuscitation bags, infant oxygen hoods, far infrared heaters, mother-infant beds, and infant head fixing units. The company offers its products under David brand name. Ningbo David Medical Device Co., Ltd. was founded in 1992 and is headquartered in Ningbo, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Ningbo",
        "zipcode": "315712",
        "website": "http://www.nbdavid.com",
        "market_cap": 4645440000
    },
    "300318.SZ": {
        "short_name": "BEIJING BOHUI INNO",
        "long_name": "Beijing Bohui Innovation Biotechnology Co., Ltd.",
        "summary": "Beijing Bohui Innovation Biotechnology Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. It offers GenPlex, a microfluidic automated nucleic acid detection system, fluorescence immunochromatography analyzer, and human body element detection system; and chemical analysis products, such as atomic fluorescence spectrometer, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, life sciences related consumables, and ICP spectrum. The company was formerly known as Beijing Bohui Innovation Technology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Co., Ltd. in July 2018. Beijing Bohui Innovation Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.bohui-tech.com",
        "market_cap": 6437171712
    },
    "300347.SZ": {
        "short_name": "HANGZHOU TIGERMED",
        "long_name": "Hangzhou Tigermed Consulting Co., Ltd",
        "summary": "Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in China and internationally. It operates through Clinical Trial Solutions; and Clinical-Related and Laboratory Services. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting; clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system; and biometrics services covering data management, biostatistics, and statistical programming. It also provides integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital; medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value added services; and post-marketing study, real world evidence, and vaccine clinical trial services. The company was incorporated in 2004 and is headquartered in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310051",
        "website": "http://www.tigermed.net",
        "market_cap": 156298985472
    },
    "300357.SZ": {
        "short_name": "ZHEJIANG WOLWO BIO",
        "long_name": "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches and develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company is based in Huzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Huzhou",
        "zipcode": null,
        "website": "http://www.wolwobiotech.com",
        "market_cap": 37357719552
    },
    "300358.SZ": {
        "short_name": "TRUKING TECHNOLOGY",
        "long_name": "Truking Technology Limited",
        "summary": "Truking Technology Limited researches and develops pharmaceutical and medical equipment in China. The company offers solutions for sterile products lyophilization, ampoule injectable products, vial injectable products, vial(powder) products, pre-filling and sealing products, plastic bottle blow-fill-seal, cartridge, non-PVC soft bag, and glass infusion bottle production, as well as fluid processing systems. It also offers isolating systems and lyophilization laboratory. In addition, the company exports its products to approximately 30 countries and areas in Asia, Europe, South America, the former Soviet Union, and internationally. Truking Technology Limited was founded in 2000 and is headquartered in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": null,
        "website": "http://www.truking.cn",
        "market_cap": 9914775552
    },
    "300363.SZ": {
        "short_name": "PORTON PHARMA SOLU",
        "long_name": "Porton Pharma Solutions Ltd.",
        "summary": "Porton Pharma Solutions Ltd. manufactures and supplies drug intermediates and active pharmaceutical ingredients to the pharmaceutical companies. It also provides process development, as well as pilot and commercial scale manufacturing services. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. has a strategic collaboration with XtalPi Inc. to offer prediction-guided crystallization and drug solid-state research services; and a strategic cooperation agreement with Jilin Huisheng Biopharmaceutical Co. Ltd. for the development and supply of active pharmaceutical ingredients and related preparations in the therapeutic areas of diabetes and related complications. The company was founded in 2005 and is headquartered in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": null,
        "website": "http://www.porton.cn",
        "market_cap": 41206898688
    },
    "300396.SZ": {
        "short_name": "DIRUI INDUSTRIAL C",
        "long_name": "Dirui Industrial Co.,Ltd.",
        "summary": "Dirui Industrial Co.,Ltd. engages in the research and development, production, and sale of medical inspection products in the People's Republic of China. The company provides medical instruments, diagnostic reagents, test strips, etc. It offers biochemical blood cell, urine, coagulation, chemiluminescence immunoassay, and gynecological secretion analyzers. The company was founded in 1992 and is headquartered in Changchun, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changchun",
        "zipcode": "130103",
        "website": "http://www.dirui.com.cn",
        "market_cap": 6312806912
    },
    "300404.SZ": {
        "short_name": "GUANGZHOU BOJI MED",
        "long_name": "Guangzhou Boji Medical & Biotechnological Co., Ltd.",
        "summary": "Guangzhou Boji Medical & Biotechnological Co., Ltd. provides professional services in various medical study phases in China. It offers services on regulatory affairs, pre-clinical research, clinical trial phases, post marketing study, clinical trial for medical devices, data management and biostatistics, and SMO. Guangzhou Boji Medical & Biotechnological Co., Ltd. was founded in 1998 is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.bojicro.com",
        "market_cap": 2837270016
    },
    "300436.SZ": {
        "short_name": "FUJIAN COSUNTER PH",
        "long_name": "Fujian Cosunter Pharmaceutical Co., Ltd.",
        "summary": "Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers crude drugs and solid preparations in the form of tablets, capsules, granules, medicinal teas, etc. for use in the treatment of hepatitis B virus. Its products include Adefovir Dipivoxil and Lamivudine tablets, as well as Entecavir and Tenofovir Disoproxil Fumarate capsules. The company was founded in 2001 and is based in Fuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Fuzhou",
        "zipcode": "350003",
        "website": "http://www.cosunter.com",
        "market_cap": 4779599872
    },
    "300439.SZ": {
        "short_name": "MEDICALSYSTEM BIOT",
        "long_name": "Medicalsystem Biotechnology Co.,Ltd",
        "summary": "Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, sale, and service of medical diagnostic products in China. The company offers vitro diagnostic, biochemical, blood cell related reagents; in vitro diagnosis; quality control calibration; POCT products; and blood line series, as well as chronic disease management solutions. The company was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Medicalsystem Biotechnology Co., Ltd. in January 2017. Medicalsystem Biotechnology Co., Ltd. was founded in 2003 and is based in Ningbo, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Ningbo",
        "zipcode": null,
        "website": "http://www.nb-medicalsystem.com",
        "market_cap": 7924270080
    },
    "300452.SZ": {
        "short_name": "ANHUI SUNHERE PHAR",
        "long_name": "Anhui Sunhere Pharmaceutical Excipients Co.,Ltd.",
        "summary": "Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. manufactures and sells pharmaceutical excipients and professional medicines in China. The company provides cellulose, starch, povidone, stearic acid, coating powder, resin, food additive, and other products. It also exports its products to Europe, the United States, Southeast Asia, and internationally. The company is based in Huainan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Huainan",
        "zipcode": "232007",
        "website": "http://www.shanhe01.com",
        "market_cap": 2878448640
    },
    "300453.SZ": {
        "short_name": "JIANG XI SANXIN ME",
        "long_name": "Jiangxi Sanxin Medtec Co.,Ltd.",
        "summary": "Jiangxi Sanxin Medtec Co., Ltd. engages in the research and development, manufacture, and marketing of medical devices in China and internationally. It offers blood purification products, such as hollow fiber dialyzers, hemodialysis pipelines, blood dialysis concentrates, powder for haemodialysis solution, disposable A.V.fistula needle, blood purification fluid infusion line, central venous catheter sets, disposable sterile nursing kits for dialysis, and disposable drainage bags. The company also provides infusion and transfusion products, including disposable sterile TPE infusion set with ultrafilter, automatic infusion check and precision filter infusion sets, disposable sterile precision filter infusion sets, disposable sterile light-resistant infusion sets, pediatric type none steel needle infusion sets, burette type infusion sets, infusion bags, disposable sterile anti puncture infusion sets, disposable sterile blood transfusion sets, disposable sterile infusion sets, and disposable intravenous infusion needles. In addition, it offers catheter tubing products comprising positive pressure intravenous catheters, intravenous catheters, central venous drainage bags, extension tubes with three-way stopcock, IV catheter pasters, and heparin caps; syringes consisting of syringes with the needle; and hypodermic needles, dissolving syringes, insulin syringes, safety syringes, and AD syringes. Further, the company offers other medical equipment, including ultrasound coupling gels, vaginal dilators, anesthesia puncture bags, suction catheters, vaginal douches, Vaccum blood collection tubes, invasive pressure transduction products, air compressed atomizers, venous blood collection needles, and connecting tubing products. Jiangxi Sanxin Medtec Co., Ltd. was founded in 1997 and is based in Nanchang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanchang",
        "zipcode": "330200",
        "website": "http://www.sanxin-med.com",
        "market_cap": 5571542016
    },
    "300463.SZ": {
        "short_name": "MACCURA BIOTECHNOL",
        "long_name": "Maccura Biotechnology Co.Ltd",
        "summary": "Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR and NGS; and pathology products. The company was founded in 1994 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.maccura.com",
        "market_cap": 23487047680
    },
    "300482.SZ": {
        "short_name": "GUANGZHOU WONDFO B",
        "long_name": "Guangzhou Wondfo Biotech Co.,Ltd",
        "summary": "Guangzhou Wondfo Biotech Co.,Ltd, a biological company, engages in the research and development, manufacture, and sale of rapid diagnostic reagents and related equipment in China and internationally. The company offers rapid test kits for fertility, DOA, tumor, and sexually transmitted diseases, as well as immunofluorescence system for use in diagnose conditions, such as infection, inflammation, diabetes, cardiovascular diseases, renal injury and cancers, etc. It also provides blood gas, optical coagulation, and dry chemistry analyzer test strips for healthcare professionals. The company was founded in 1992 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.wondfo.com.cn",
        "market_cap": 31831697408
    },
    "300497.SZ": {
        "short_name": "JIANGXI FUSHINE PH",
        "long_name": "Jiangxi Fushine Pharmaceutical Co., Ltd.",
        "summary": "Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products. It also provides contract research, development, and manufacturing services. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. The company was founded in 2002 and is based in Jingdezhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jingdezhen",
        "zipcode": "333000",
        "website": "http://www.fushine.cn",
        "market_cap": 7177565184
    },
    "300519.SZ": {
        "short_name": "ZHEJIANG XINGUANG",
        "long_name": "Zhejiang Xinguang Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Xinguang Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in China. The company offers pharmaceutical products in the areas of cardiovascular, orthopedics, health food, respiratory system, digestive system, and urinary system; and products for the removal of heat and toxic substances, as well as tonic and other products. It offers its products in the form of oral solution, troche, capsule, granule, syrup, and bulks. Zhejiang Xinguang Pharmaceutical Co., Ltd. was founded in 1970 and is based in Shengzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shengzhou",
        "zipcode": null,
        "website": "http://www.xgpharma.com",
        "market_cap": 2723200000
    },
    "300529.SZ": {
        "short_name": "JAFRON BIOMEDICAL",
        "long_name": "Jafron Biomedical Co.,Ltd.",
        "summary": "Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biomaterials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatoid immune diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as disinfectants, online hemodialysis B powder bags/buckets, hemodialysis concentrates, PGA absorbable sutures with needles, and resin bandages. The company offers its products in Germany, Austria, Greece, Turkey, Vietnam, India, Thailand, Iran, Malaysia, Bangladesh, Bulgaria, the Philippines, Sweden, Uganda, Ethiopia, and internationally. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519085",
        "website": "http://www.jafron.com",
        "market_cap": 72770306048
    },
    "300534.SZ": {
        "short_name": "GANSU LONGSHENRONG",
        "long_name": "Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd",
        "summary": "Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd researches, develops, produces, and sells traditional Chinese medicines. It offers Yuan Hu Zhitong dropping pills for abdominal pain, stomach pain, hypochondriac pain, and headache, as well as to regulate qi and promote blood; Ma Xing Zhi cough capsules for acute and chronic bronchitis and wheezing; Qiwei Wenyang capsules; Xiaoshuan Tongluo and Compound Danshen tablets to promote blood circulation; Astragalus Angelica capsules for radiation hazards; and Citrate bismuth bacteriostatic gels. The company also provides Berberine citrate films for the treatment of cervical erosion; Shu Xinning tablets to improve coronary blood circulation, as well as treat hypertension, coronary heart disease, and angina pectoris; Sanqi injury pills for bruises, rheumatism, joint pain, acute and chronic contusion, and neuralgia; and anti-inflammatory and gallbladder tablets for heat, dampness, and daring treatment. In addition, it offers Pediatric Qingfei Zhike tablets for the treatment of heat, cough, and phlegm; pediatric clearing spirit tablets; and Suanzaoren oil drop pills to regulate blood lipids. The company was founded in 2002 and is based in Lanzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lanzhou",
        "zipcode": null,
        "website": "http://www.lsrfzy.com",
        "market_cap": 1871638656
    },
    "300550.SZ": {
        "short_name": "HEREN HEALTH CO LT",
        "long_name": "Heren Health Co., Ltd.",
        "summary": "Heren Health Co., Ltd. provides solutions and services for medical information, hospital scenario applications, and regional health information to hospitals, governments, and individuals in China. The company was founded in 2010 and is headquartered in Hangzhou, China. Heren Health Co., Ltd. operates as a subsidiary of Hangzhou Panyuan Investment Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310051",
        "website": "http://www.herenit.com",
        "market_cap": 3369219328
    },
    "300558.SZ": {
        "short_name": "BETTA PHARMACEUTIC",
        "long_name": "Betta Pharmaceuticals Co., Ltd.",
        "summary": "Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of malignant tumors, diabetes, and cardio-cerebrovascular diseases in China. The company offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer. It is also developing CM082 for treating malignant tumor and eye-ground maculopathy. The company has agreement with Amgen Inc. for marketing Vectibix, an anti-tumor drug in China. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.bettapharma.com",
        "market_cap": 44187783168
    },
    "300562.SZ": {
        "short_name": "GUANGDONG TRANSTEK",
        "long_name": "Guangdong Transtek Medical Electronics Co., Ltd",
        "summary": "Guangdong Transtek Medical Electronics Co., Ltd designs, manufactures, and sells medically approved products, connected healthcare devices, and smart wearables in China. The company offers wearable devices, such as mambo 2, ziva, bonbon, mambo HR, and mambo watches; blood pressure monitors; and electronic scales. Guangdong Transtek Medical Electronics Co., Ltd was founded in 2002 and is based in Zhongshan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhongshan",
        "zipcode": null,
        "website": "http://www.transtek.cn",
        "market_cap": 3494550784
    },
    "300573.SZ": {
        "short_name": "SHENYANG XINGQI PH",
        "long_name": "Shenyang Xingqi Pharmaceutical Co., Ltd.",
        "summary": "Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenyang",
        "zipcode": null,
        "website": "http://www.sinqi.com",
        "market_cap": 13460153344
    },
    "300583.SZ": {
        "short_name": "SHANDONG SITO BIO",
        "long_name": "Shandong Sito Bio-technology Co., Ltd.",
        "summary": "Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include cortisone acetate, ethylene deltenone, norandrostenedione, lactone, anecortave acetate, tetraene acetate, hydroxyprogesterone, and androstenedione. The company was founded in 2002 and is based in Heze, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Heze",
        "zipcode": null,
        "website": "http://www.sitobiotech.com",
        "market_cap": 2342405632
    },
    "300584.SZ": {
        "short_name": "NANJING HICIN PHAR",
        "long_name": "Nanjing Hicin Pharmaceutical Co., Ltd.",
        "summary": "Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210009",
        "website": "http://www.hicin.cn",
        "market_cap": 2334000128
    },
    "300595.SZ": {
        "short_name": "AUTEK CHINA INC",
        "long_name": "Autek China Inc.",
        "summary": "Autek China Inc., an eye-vision technology company, engages in the research, development, production, and sale of various eye-optic products. It also offers mirror squirting solution, cleansing liquid, and contact lens lubricant products. The company was founded in 2001 and is headquartered in Hefei, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hefei",
        "zipcode": null,
        "website": "http://www.orthok.cn",
        "market_cap": 64973123584
    },
    "300601.SZ": {
        "short_name": "SHENZHEN KANGTAI B",
        "long_name": "Shenzhen Kangtai Biological Products Co., Ltd.",
        "summary": "Shenzhen Kangtai Biological Products Co., Ltd. develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait type b haemophilus combined vaccine, measles rubella combined with live attenuated vaccine, haemophilus influenzae type b conjugate vaccine, recombinant hepatitis B vaccine, hepatitis B vaccine, and other products. Shenzhen Kangtai Biological Products Co., Ltd. has an agreement between YTB and Yong Tai Berhad in relation to the development and commercialization of Covid-19 inactivated vaccine in Malaysia. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.biokangtai.com",
        "market_cap": 112427581440
    },
    "300630.SZ": {
        "short_name": "HAINAN POLY PHARM",
        "long_name": "Hainan Poly Pharm. Co., Ltd.",
        "summary": "Hainan Poly Pharm. Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers APIs. The company offers formulations in various therapeutic areas, which include anti-allergy, non-steroid anti-inflammatory, antibiotic, and digestive drugs. Its products include desloratadine preparations in anti-allergy drugs, diclofenac preparations in non-steroidal anti-inflammatory drugs, azithromycin for injection and clarithromycin preparations in antibiotic drugs, and trimebutine maleate preparations in digestive drugs. Hainan Poly Pharm. Co., Ltd. was founded in 1992 and is based in Haikou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": null,
        "website": "http://english.hnpoly.com",
        "market_cap": 22423957504
    },
    "300633.SZ": {
        "short_name": "SONOSCAPE MEDICAL",
        "long_name": "SonoScape Medical Corp.",
        "summary": "SonoScape Medical Corp. develops and manufactures medical equipment in China and internationally. The company offers ultrasound diagnostic systems, such as trolley color Doppler, portable color Doppler, B/W ultrasound, and veterinary ultrasound equipment; and endoscopy equipment, such as image processors, light sources, and gastroenterology products. It also provides technical and spare parts support, training, upgradation, and field services. SonoScape Medical Corp. was founded in 2002 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.sonoscape.com",
        "market_cap": 10895468544
    },
    "300636.SZ": {
        "short_name": "JIANGXI SYNERGY PH",
        "long_name": "Jiangxi Synergy Pharmaceutical Co., Ltd.",
        "summary": "Jiangxi Synergy Pharmaceutical Co., Ltd. manufactures and sells APIs worldwide. It offers APIs, liquid crystal compounds, and intermediates. The company was founded in 2004 and is headquartered in Yichun, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yichun",
        "zipcode": "330700",
        "website": "http://www.jxsynergy.com",
        "market_cap": 2159529984
    },
    "300642.SZ": {
        "short_name": "TELLGEN CORPORATIO",
        "long_name": "Tellgen Corporation",
        "summary": "Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. It offers tumor markers, human papilloma virus test kits, ToRCH products, Y chromosome microdeletions test kits, and multiplex immunoassay systems. The company was founded in 2003 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.tellgen.com",
        "market_cap": 6548177408
    },
    "300653.SZ": {
        "short_name": "YANTAI ZHENGHAI BI",
        "long_name": "Yantai Zhenghai Biotechnology Co., Ltd.",
        "summary": "Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. It offers bone repair material, a partially deproteinised bone prepared from cancellous bones of calves after a series of treatment, such as decellularization and degreasing; oral cavity repair membrane line of products, which are used to treat defects of shallow oral cavity's soft tissue; and bio-membrane line of products that are used in neurosurgery to repair cerebral dura mater defect under the Heal-All brand name. The company also provides skin repair membrane line of products to repair wounds in dermal layer under the Heal-Full brand name. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is based in Yantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yantai",
        "zipcode": "264006",
        "website": "http://www.zhbio.com",
        "market_cap": 7791600128
    },
    "300677.SZ": {
        "short_name": "INTCO MEDICAL TECH",
        "long_name": "Intco Medical Technology Co., Ltd.",
        "summary": "Intco Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical disposable products and durable medical equipment in China and internationally. The company offers disposable gloves; durable medical equipment, such as canes and walkers, shower chairs, commode chairs, buggies, rollators, power and manual wheel chairs, and over bed tables; and nonwoven disposables, including face masks, isolation gowns, shoe covers, and caps. It also provides hot/cold therapy products comprising pet, beauty, cold chain, daily warmer, household, medical care, and home care products; ECG accessories consisting of disposable electrodes, tab electrodes, electrosurgical pencils, ECG papers, electrosurgical disposable grounding pads, and other accessories; and patient lifts. The company was formerly known as Intco Medical Technology Co., Ltd. and changed its name to Intco Medical Technology Co., Ltd. in January 2020. Intco Medical Technology Co., Ltd. was founded in 2009 and is based in Zibo, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zibo",
        "zipcode": null,
        "website": "http://www.intcomedical.com.cn",
        "market_cap": 35516727296
    },
    "300683.SZ": {
        "short_name": "WUHAN HITECK BIOLO",
        "long_name": "Wuhan Hiteck Biological Pharma Co., Ltd.",
        "summary": "Wuhan Hiteck Biological Pharma Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of biological engineering products and freeze-dried powder injection primarily in China. Its products include Jinlujie 20ug, a mouse nerve growth factor for injection; and recombinant allosteric human tumor necrosis factor, which is in phase III clinical trial used for the treatment of apoptosis. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co., Ltd. is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430056",
        "website": "http://www.hiteck.com.cn",
        "market_cap": 4199313664
    },
    "300685.SZ": {
        "short_name": "AMOY DIAGNOSTICS C",
        "long_name": "Amoy Diagnostics Co., Ltd.",
        "summary": "Amoy Diagnostics Co., Ltd., a biotech company, develops and commercializes cancer diagnostics in China and internationally. The company offers molecular diagnostic kits, including EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits for oncology precision medicine; and NGS, real-time PCR, FISH, and extraction assays. The company has a strategic partnership agreement with Loxo Oncology, Inc. Amoy Diagnostics Co., Ltd. Was founded in 2008 and is based in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xiamen",
        "zipcode": "361027",
        "website": "http://www.amoydx.com",
        "market_cap": 19598954496
    },
    "300702.SZ": {
        "short_name": "ZHEJIANG TIANYU PH",
        "long_name": "Zhejiang Tianyu Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It also provides fine chemicals and CMO services. The company was founded in 1993 and is based in Taizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "318020",
        "website": "http://www.tianyupharm.com",
        "market_cap": 13724069888
    },
    "300705.SZ": {
        "short_name": "HUNAN JIUDIAN PHAR",
        "long_name": "Hunan Jiudian Pharmaceutical Co., Ltd.",
        "summary": "Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": "410329",
        "website": "http://www.hnjiudian.com",
        "market_cap": 7737399808
    },
    "300723.SZ": {
        "short_name": "YIPINHONG PHARMACE",
        "long_name": "Yipinhong Pharmaceutical Co.,Ltd",
        "summary": "Yipinhong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers anti-infection, pediatric, cardiovascular, genitourinary, respiratory, liver and digestion, and dermatological products, as well as anti-inflammatory and analgesic products. The company was founded in 2002 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510623",
        "website": "http://www.gdyph.com",
        "market_cap": 7672338944
    },
    "300725.SZ": {
        "short_name": "PHARMABLOCK SCIENC",
        "long_name": "PharmaBlock Sciences (Nanjing), Inc.",
        "summary": "PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services to pharmaceutical research and development, and commercial production. It offers scaffolds and building blocks; custom synthesis services; and process research and development, as well as manufactures key intermediates and RSMs. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210032",
        "website": "http://www.pharmablock.com",
        "market_cap": 31239069696
    },
    "300753.SZ": {
        "short_name": "JIANGSU APON MEDIC",
        "long_name": "Jiangsu Apon Medical Technology Co., Ltd.",
        "summary": "Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices in China. Its principal products include microcomputer injection pumps, disposable injection pumps, wireless analgesia management systems, and pulse oximeters, as well as medical devices, such as sensors in the field of pain management and nasal care sprayers in the field of nasal care. The company was founded in 2001 and is based in Nantong, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nantong",
        "zipcode": null,
        "website": "http://www.apon.com.cn",
        "market_cap": 2394912000
    },
    "300759.SZ": {
        "short_name": "PHARMARON BEIJING",
        "long_name": "Pharmaron Beijing Co., Ltd.",
        "summary": "Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through four segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; and Others. It offers laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, and in vitro biology and in vivo pharmacology services, as well as safety assessment and discovery biologics services; process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and clinical research, site management, regulatory bioanalysis, and radiolabelled science services. The company also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.pharmaron.com",
        "market_cap": 153022005248
    },
    "300760.SZ": {
        "short_name": "SHENZHEN MINDRAY B",
        "long_name": "Shenzhen Mindray Bio-Medical Electronics Co., Ltd.",
        "summary": "Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in the People's Republic of China. The company offers patient monitoring and life support products, such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, endoscopes, and accessories, as well as emergency care, peri-operative care, critical care, and IT solutions. It also provides in-vitro diagnostics products, including hematology and chemistry analyzers and reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry products, and micro plate readers and washers; medical imaging systems comprising ultrasound and radiology products; and veterinary products. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a subsidiary of Mindray Medical International Limited.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.mindray.com",
        "market_cap": 582303350784
    },
    "300813.SZ": {
        "short_name": "ZHEJIANG TAILIN BI",
        "long_name": "Zhejiang Tailin BioEngineering Co.,Ltd",
        "summary": "Zhejiang Tailin BioEngineering Co.,Ltd manufactures microbial test and control equipment, mainly for pharmaceutical and medical sector. The company offers sterility testing equipment, microbiological testing equipment, TOC analyzers, sterile isolation systems, hydrogen peroxide sterilization systems, sterile delivery system, and filters, as well as technical services. Its products are primarily used in bio-pharmaceutical, medical, disease control, food, environmental protection, electronics, and other fields, as well as in bio-security equipment manufacturing industries. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. Zhejiang Tailin BioEngineering Co.,Ltd was founded in 1993 and is based in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310052",
        "website": "http://www.tailingood.com",
        "market_cap": 2376588032
    },
    "300841.SZ": {
        "short_name": "CHENGDU KANGHUA BI",
        "long_name": "Chengdu Kanghua Biological Products Co., Ltd.",
        "summary": "Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "610100",
        "website": "http://www.kangh.com",
        "market_cap": 18291599360
    },
    "300858.SZ": {
        "short_name": "BEIJING SCITOP BIO",
        "long_name": "Beijing Scitop Bio-tech Co., Ltd.",
        "summary": "Beijing Scitop Bio-tech Co., Ltd. develops, produces, and sells doctors' lactic acid bacteria and related products. Its products have applications in the food industry, health care, animal husbandry, and agricultural planting. The company was founded in 2003 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "101407",
        "website": "http://www.scitop.cn",
        "market_cap": 5825748992
    },
    "300869.SZ": {
        "short_name": "CONTEC MEDICAL SYS",
        "long_name": "Contec Medical Systems Co.,Ltd",
        "summary": "Contec Medical Systems Co.,Ltd engages in the research, manufacture, and distribution of medical instruments. The company's products include electronic sphygmomanometers, ambulatory blood pressure monitors, pulse oximeters, monitors, stethoscopes, simulators, analyzers, nebulizers, ultrasound equipment, oxygen concentrators, predictive thermometers, syringe and infusion pumps, and EMG/EP systems; ECG monitors and workstations; and EEG, pulmonary function, home, telemedicine, veterinary, electronic colposcopy, and Capnography related products. It sells its products through distributors in China and internationally. The company was founded in 1992 and is based in Qinhuangdao, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qinhuangdao",
        "zipcode": "066004",
        "website": "http://www.contecmed.com",
        "market_cap": 30239242240
    },
    "300871.SZ": {
        "short_name": "HVSEN BIOTECHNOLOG",
        "long_name": "Hvsen Biotechnology Co., Ltd.",
        "summary": "Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin raw materials, various tylvalosin preparations, florfenicol preparations, and other macrolides products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430042",
        "website": "http://www.whhsyy.com",
        "market_cap": 5232506368
    },
    "300878.SZ": {
        "short_name": "ZHEJIANG WECOME PH",
        "long_name": "Zhejiang Wecome Pharmaceutical Company Limited",
        "summary": "Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of pharmaceutical products. The company also offers healthcare products, OTC products, and Chinese medicines. It offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is based in Lishui, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lishui",
        "zipcode": "323000",
        "website": "http://www.zjwk.com",
        "market_cap": 3707438336
    },
    "300888.SZ": {
        "short_name": "WINNER MEDICAL CO",
        "long_name": "Winner Medical Co., Ltd.",
        "summary": "Winner Medical Co., Ltd. engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China. The company offers wound care, infection prevention, and fabric application products. It provides its products under the winner, Purcotton, and PureH2B brands through sales commerce, pharmacy chain store, hospital, e-commerce, and chain store distribution channels. The company also sells its products to approximately 70 countries worldwide. Winner Medical Co., Ltd. was founded in 1991 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518109",
        "website": "http://www.winnermedical.com",
        "market_cap": 52590727168
    },
    "300896.SZ": {
        "short_name": "IMEIK TECHNOLOGY D",
        "long_name": "Imeik Technology Development Co.,Ltd.",
        "summary": "Imeik Technology Development Co.,Ltd focuses on the research and development, manufacture, and sale of biomedical materials. It offers EME and Bonita that are indicated for injection into the deep dermis to the subcutaneous shallow for the correction of moderate to severe wrinkles of forehead and nasolabial area; IFRESH, which is indicated for injection into mid to deep dermis for the correction of moderate to severe nasolabial folds; Hearty that is indicated for injection into dermis for the correction of moderate to severe neck wrinkles; masks for various skin types; and syringe gun for intradermal injection indication. The company was founded in 2004 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100022",
        "website": "http://www.imeik.net",
        "market_cap": 141499432960
    },
    "300937.SZ": {
        "short_name": "SICHUAN HEZONG MED",
        "long_name": "Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.",
        "summary": "Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. distributes generic drugs and Chinese medicines in China. The company offers medications in the areas of respiratory, anti-inflammatory, five senses, skin and external, digestive, hepatobiliary system, rehabilitation and tranquility, women, pediatrics, cardiovascular and neurological, endocrine system, rheumatoid bone injury, and others. It also provides special compound preparations, biological products, Chinese herbal medicines, and non-medicine products. The company was founded in 2007 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "610081",
        "website": "http://www.hezongyy.com",
        "market_cap": 5215748608
    },
    "300942.SZ": {
        "short_name": "SHENZHEN BIOEASY B",
        "long_name": "Shenzhen Bioeasy Biotechnology Co., Ltd.",
        "summary": "Shenzhen Bioeasy Biotechnology Co., Ltd. develops and sells rapid testing instruments and reagents in China. The company offers detection equipment for use in the fields of food, agricultural, dairy, meat, aquatic, honey, drug, and public safety, as well as clinical diagnosis. The company was founded in 2007 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518101",
        "website": "http://www.bioeasy.com",
        "market_cap": 12021791744
    },
    "300957.SZ": {
        "short_name": "YUNNAN BOTANEE BIO",
        "long_name": "Yunnan Botanee Bio-Technology Group Co.LTD",
        "summary": "Yunnan Botanee Bio-Technology Group Co.LTD manufactures and sells skincare products in China. Its products type cover cleansers and makeup removers, face masks, toners, serums, moisturizers and creams, eye cream, sprays, sun care, foundations, and body cares. The company was founded in 2010 and is based in Kunming, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHZ",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": "650106",
        "website": "http://www.botanee.com.cn",
        "market_cap": 98741166080
    },
    "3347.HK": {
        "short_name": "TIGERMED",
        "long_name": "Hangzhou Tigermed Consulting Co., Ltd",
        "summary": "Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in China and internationally. It operates through Clinical Trial Solutions; and Clinical-Related and Laboratory Services. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting; clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system; and biometrics services covering data management, biostatistics, and statistical programming. It also provides integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital; medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value added services; and post-marketing study, real world evidence, and vaccine clinical trial services. The company was incorporated in 2004 and is headquartered in Hangzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310051",
        "website": "http://www.tigermed.net",
        "market_cap": 172027346944
    },
    "3689.HK": {
        "short_name": "KANGHUA HEALTH",
        "long_name": "Guangdong Kanghua Healthcare Co., Ltd.",
        "summary": "Guangdong Kanghua Healthcare Co., Ltd., an investment holding company, primarily operates private hospitals in the People's Republic of China. The company operates through Hospital Services, Rehabilitation and Other Healthcare Services, Hospital Management Services, Sale of Pharmaceutical Products, and Others segments. It offers inpatient and outpatient healthcare, and physical examination services. The company provides a range of preventive care, diagnostic, minimally invasive treatment, interventional therapy, open heart surgery, pacemaker implantation, and transplant services for infants, children, and adults, as well as cardiac rehabilitation services. It also offers VIP obstetrics, gynecology, and outpatient services; assisted reproductive services for couples with infertility disorders; surgical and non-surgical cosmetic treatment options for various areas of the face and body; and laser treatment and skin care services, including acne, acne scarring, stretch marks, and pigmentation treatment, as well as laser hair removal services. In addition, the company provides hospital management services; sells pharmaceutical products and medical consumables; and offers rehabilitation services and other healthcare services, as well as elderly care services to patients. It operates Kanghua Hospital, Renkang Hospital, and Kangxin Hospital. The company was formerly known as Dongguan Kanghua Enterprise Co., Ltd. and changed its name to Guangdong Kanghua Healthcare Co., Ltd. in December 2015. The company was incorporated in 2002 and is headquartered in Dongguan, the People's Republic of China. Guangdong Kanghua Healthcare Co., Ltd. is a subsidiary of Dongguan Kanghua Investment Group Co., Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Dongguan",
        "zipcode": null,
        "website": "http://www.kanghuagp.com/tc/index.php",
        "market_cap": 1120219776
    },
    "3692.HK": {
        "short_name": "HANSOH PHARMA",
        "long_name": "Hansoh Pharmaceutical Group Company Limited",
        "summary": "Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, diabetes, and cardiovascular, as well as gastrointestinal area. Its principal products include Mailingda, a category 1.1 drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Afatinib Dimaleate, Sunitinib Malate, Oulanning, Ameining, Ailanning, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, Fulairui, Ruibote, Zexin, Ruiyisheng, Empagliflozin, and Saxagliptin, which are generic drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Viela Bio, Inc. to develop and commercialize inebilizumab for the treatment of autoimmune diseases and hematologic cancers; and strategic collaboration and license agreement with EQRx, INC. to research, develop, manufacture, and commercialize Almonertinib. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Lianyungang",
        "zipcode": "222069",
        "website": "http://www.hspharm.com",
        "market_cap": 196325916672
    },
    "36X.F": {
        "short_name": "ASCENTAGE PHARM. DL-,0001",
        "long_name": "Ascentage Pharma Group International",
        "summary": "Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product under development include HQP1351, a BCR-ABL/KIT inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for the treatment of patients with tyrosine kinase inhibitors resistant/refractory GIST. The company also engages in developing APG-2575, an orally administered Bcl-2 selective inhibitor for the treatment of hematologic malignancies with Bcl-2 overexpression, including leukemia, lymphoma, and multiple myeloma; APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of SCLC, lymphoma, and other solid tumors; and APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for the treatment of solid tumors or lymphoma. In addition, it is involved in the development of APG-1387, a small molecule inhibitor of apoptosis proteins for the treatment of advanced solid tumors and chronic HBV infection; AT-101 for the treatment of chronic lymphocytic leukemia; APG-2449 for non-small-cell lung carcinoma; and HQP8361 for the treatment of cancer. Ascentage Pharma Group International has a clinical collaboration with Acerta Pharma to evaluate the combination of Bcl-2 and BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; and MSD to evaluate APG-115. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215000",
        "website": "http://www.ascentagepharma.com",
        "market_cap": 1137405952
    },
    "3737.HK": {
        "short_name": "ZHONGZHIPHARM",
        "long_name": "Zhongzhi Pharmaceutical Holdings Limited",
        "summary": "Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. It provides Chinese patent medicines and decoction pieces under the Zeus, Liumian, and Caojinghua brands. The company is also involved in the operation of chain and online pharmacies; manufacture and sale of food and Chinese herbs; and property management. As of December 31, 2020, it operated 366 self-operated chain pharmacies, including 325 medical insurance designated pharmacies located in Zhongshan in the Guangdong Province under the Zeus brand. The company was founded in 1993 and is headquartered in Zhongshan, the People's Republic of China. Zhongzhi Pharmaceutical Holdings Limited is a subsidiary of Crystal Talent Investment Group Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Zhongshan",
        "zipcode": null,
        "website": "http://www.zeus.cn",
        "market_cap": 1209600000
    },
    "3759.HK": {
        "short_name": "PHARMARON",
        "long_name": "Pharmaron Beijing Co., Ltd.",
        "summary": "Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through four segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; and Others. It offers laboratory chemistry, drug metabolism and pharmacokinetics/absorption, distribution, metabolism and excretion, and in vitro biology and in vivo pharmacology services, as well as safety assessment and discovery biologics services; process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and clinical research, site management, regulatory bioanalysis, and radiolabelled science services. The company also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.pharmaron.com",
        "market_cap": 154048299008
    },
    "3FMA.F": {
        "short_name": "AEST.MED.INT.HLD.SP.ADR/3",
        "long_name": "Aesthetic Medical International Holdings Group Limited",
        "summary": "Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 25 treatment centers in China, Hong Kong, and Singapore. The company was founded in 1997 and is headquartered in Shenzhen, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518052",
        "website": "http://ir.aihgroup.net",
        "market_cap": 141220816
    },
    "3KY.F": {
        "short_name": "HANSOH PHARMAC. HD-,00001",
        "long_name": "Hansoh Pharmaceutical Group Company Limited",
        "summary": "Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, diabetes, and cardiovascular, as well as gastrointestinal area. Its principal products include Mailingda, a category 1.1 drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Afatinib Dimaleate, Sunitinib Malate, Oulanning, Ameining, Ailanning, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, Fulairui, Ruibote, Zexin, Ruiyisheng, Empagliflozin, and Saxagliptin, which are generic drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Viela Bio, Inc. to develop and commercialize inebilizumab for the treatment of autoimmune diseases and hematologic cancers; and strategic collaboration and license agreement with EQRx, INC. to research, develop, manufacture, and commercialize Almonertinib. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Lianyungang",
        "zipcode": "222069",
        "website": "http://www.hspharm.com",
        "market_cap": 20943460352
    },
    "3NX.F": {
        "short_name": "JINXIN FERT.GRP HD-,00001",
        "long_name": "Jinxin Fertility Group Limited",
        "summary": "Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and property holding and management services. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.jxr-fertility.com",
        "market_cap": 4882574336
    },
    "4745.TWO": {
        "short_name": "COWEALTH MEDICAL HOLDING CO LTD",
        "long_name": "Cowealth Medical Holding Co., Ltd.",
        "summary": "Cowealth Medical Holding Co., Ltd. operates as a medical distribution company primarily in the diagnostic clinical laboratory field in Greater China market. It also specializes in reagent, cross-strait hospital department cooperation, and radiotherapy fields. In addition, the company undertakes the Summit project, which consolidates outside procurement of diagnostic reagents at prices as before; and provides related with related logistics management services. The company was founded in 1997 and is based in Shanghai, China.",
        "currency": "TWD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "TWO",
        "market": "tw_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.cowealthholding.com",
        "market_cap": 2098894976
    },
    "49B.F": {
        "short_name": "BEIGENE LTD",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.beigene.com",
        "market_cap": 24456751104
    },
    "49BA.F": {
        "short_name": "BEIGENE LTD SP.ADR",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.beigene.com",
        "market_cap": 27815559168
    },
    "4NM1.F": {
        "short_name": "CHINA EVERGR.NEW EN.VEH.G",
        "long_name": "China Evergrande New Energy Vehicle Group Limited",
        "summary": "China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510620",
        "website": "http://health.evergrande.com",
        "market_cap": 33701502976
    },
    "4RY.F": {
        "short_name": "AKESO INC.  O.N.",
        "long_name": "Akeso, Inc.",
        "summary": "Akeso, Inc., a clinical-stage biopharmaceutical company, engages in discovery, development and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for tumor infiltrating lymphocytes, which is in Phase Ia/Ib trial in Australia, and five Phase Ib/II and Phase II trials in China; Penpulimab AK105, a monoclonal antibody that is in Phase III clinical trials for squamous and non-squamous NSCLC, as well as Phase II clinical trial for relapsed/refractory classical hodgkin's lymphoma; and AK112, a PD-1/VEGF bi-specific antibody that is in a Phase I clinical study for the treatment of solid tumors. It is also developing AK101, a monoclonal antibody, which is in Phase IIb clinical trial to treat severe psoriasis patients; AK111, a monoclonal antibody for autoimmune disease target IL-17; and Ebronucimab (AK102) for the treatment of cardiovascular diseases. The company has collaboration agreements with Merck; Sino Biopharm; Dawnrays Pharma; and Zhongshan Health Technology Industrial Base Development Co., Ltd. and Torch Development Zone Linhai Industry Park Development Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Zhongshan",
        "zipcode": "528437",
        "website": "http://www.akesobio.com",
        "market_cap": 5603302400
    },
    "4WK.F": {
        "short_name": "WENZHOU KANG.HOSP.H YC 1",
        "long_name": "Wenzhou Kangning Hospital Co., Ltd.",
        "summary": "Wenzhou Kangning Hospital Co., Ltd. operates and manages a network of healthcare facilities in the People's Republic of China. It primarily focuses on providing psychiatric specialty care. The company also provides property leasing and sale services; and software and information technology services, as well as hospital management, forensic authentication, and medical services. It is also engaged in pharmaceutical retail. The company was formerly known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital and changed its name to Wenzhou Kangning Hospital Co., Ltd. in October 2014. Wenzhou Kangning Hospital Co., Ltd. was founded in 1996 and is headquartered in Wenzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Wenzhou",
        "zipcode": null,
        "website": "http://www.knhosp.cn",
        "market_cap": 242886992
    },
    "4WO.F": {
        "short_name": "PEIJIA MEDICAL  HD -,01",
        "long_name": "Peijia Medical Limited",
        "summary": "Peijia Medical Limited engages in the research, development, production, and sales of interventional procedural medical devices for the treatment of structural heart and neurovascular diseases. Its product candidates include transcatheter aortic valve replacement (TAVR) products, such as TaurusOne, a transcatheter aortic valve replacement system, including prosthetic aortic valve, delivery catheter system, and LS; TaurusElite, a second-generation TAVR device; and TaurusNXT, a third-generation TAVR device. The company is also developing transcatheter mitral valve replacement devices for the treatment of mitral regurgitation; and transcatheter tricuspid valve replacement devices for the treatment of tricuspid regurgitation. In addition, it is developing lithotripsy and balloon aortic valvuloplasty catheters, introducer sheaths, guidewires, and mitral repair devices. Further, the company is developing neurointerventional procedural products, such as stent retrievers; balloon guide and dilatation, distal access, intermediate, and aspiration catheters; and balloon microcatheter, heat-fusion detachable coils, intracranial stents, and detachable coils. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215028",
        "website": "http://www.peijiamedical.com",
        "market_cap": 2268320768
    },
    "5DG.F": {
        "short_name": "OCUMENSION THER.DL-,00001",
        "long_name": "Ocumension Therapeutics",
        "summary": "Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company researches and develops, manufactures, and commercializes ophthalmic drugs. It offers drugs for the treatment of blepharitis, infective conjunctivitis, allergic conjunctivitis, dry eye, cataract, glaucoma, uveitis, age-related macular degeneration, and myopia. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": null,
        "website": "http://www.ocumension.com",
        "market_cap": 2049182464
    },
    "5HB.F": {
        "short_name": "SHAGHAI HAOH.BI.TE.H YC 1",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and recombinant human epidermal growth factor (rhEGF), as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.3healthcare.com",
        "market_cap": 3043216128
    },
    "600055.SS": {
        "short_name": "BEIJING WANDONG MEDICAL TECHNOL",
        "long_name": "Beijing Wandong Medical Technology Co., Ltd.",
        "summary": "Beijing Wandong Medical Technology Co., Ltd. engages in the research and development, manufacturing, and sale of medical diagnostic equipment. The company offers MRI solutions; radiological imaging solutions, including CT system, CGO series, DR system, DRF system, digital mammography, general and mobile X-ray, and C-arm equipment; and veterinary imaging solutions. It operates in approximately 70 countries worldwide. The company was formerly known as China Resources Wandong Medical Equipment Co., Ltd. The company was founded in 1955 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100015",
        "website": "http://www.wandong.com.cn",
        "market_cap": 8501627904
    },
    "600056.SS": {
        "short_name": "CHINA MEHECO CO LTD",
        "long_name": "China Meheco Group Co., Ltd.",
        "summary": "China Meheco Group Co., Ltd. engages in pharmaceutical business in China and internationally. The company imports and exports China national medicines and health products; produces and distributes pharmaceutical and health care products; and operates retail chain pharmacies. Its products include bulk pharmaceutical chemicals antibiotic fermentation and chemical synthesis tablets, injections, capsules, etc.; antibiotics; medicines for the treatment of cardio-cerebrovascular diseases, chronic diseases, and diabetes; antiviral drugs; anti-infectious agents; gastrointestinal drugs; non-steroidal anti-inflammatory drugs; anti-allergic agents; specialty botanicals; western medicine preparations; Chinese patent medicines and herbal pieces; medical equipment and supplies; biological products and raw materials; chemical raw materials; and nutritional and other healthcare products. The company also plants, processes, warehouses, and transports ginseng, licorice, ephedra, rhubarb, fennel, and other herbs. China Meheco Group Co., Ltd. was founded in 1984 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100061",
        "website": "http://www.meheco.com",
        "market_cap": 13698040832
    },
    "600079.SS": {
        "short_name": "HUMANWELL HEALTHCARE (GROUP) CO",
        "long_name": "Humanwell Healthcare (Group) Co.,Ltd.",
        "summary": "Humanwell Healthcare (Group) Co.,Ltd. provides healthcare solutions in the Asia Pacific, North America, Africa, and internationally. The company offers anesthetic/analgesic products; women's health products for unplanned pregnancy, emergency contraception, and birth control; consumer healthcare products for women; and CNS drugs for bronchitis, migraine, dysmenorrhea, neuralgia, epilepsy, acute and chronic cerebrovascular diseases, and brain injury and peripheral vascular diseases. It also provides herbal medicines for cold and flu, rheumatoid arthritis, skin care, hepatitis, urinary tract infection, and hypomnesis; anti-infection drugs; OTC medicines for digestive disorders, cold and flu, anti-inflammation, anti-infection, and nutritional supplements; and other products targeting cardiovascular, gastrointestinal, and reproductive diseases. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1993 and is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430075",
        "website": "http://www.humanwell.com.cn",
        "market_cap": 44239863808
    },
    "600080.SS": {
        "short_name": "GINWA ENTERPRISE GROUP",
        "long_name": "Ginwa Enterprise (Group) Inc.",
        "summary": "Ginwa Enterprise (Group) Inc. researches, develops, produces, and sells proprietary Chinese, biological, and chemical medicines in China. It offers orthopedic, immune, pediatric, antibiotic, digestive system, gynecological, cardiovascular, antipyretic, analgesic, antiviral, and other products. The company provides its products in the form of capsules, powders, and tablets. Ginwa Enterprise (Group) Inc. is based in Xi'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xi'an",
        "zipcode": null,
        "website": "http://www.ginwa.com.cn",
        "market_cap": 2702474752
    },
    "600085.SS": {
        "short_name": "BEIJING TONGRENTANG CO",
        "long_name": "Beijing Tongrentang Co., Ltd",
        "summary": "Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers 28 product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang Wan, Tongren Dahuo Wan Pills, Tongren Niuhuang Qingxin Pills, Zi Xuesan, National wine, Tongren Wuji Baifeng Pills, Zhuanggu medicinal liquor, Bureau Fang Zhibao, Reconstituted pill, and Yufeng Ningxin Dropping Pills. The company was founded in 1669 and is based in Beijing, China. Beijing Tongrentang Co., Ltd is a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100062",
        "website": "http://www.tongrentanggf.com",
        "market_cap": 51238117376
    },
    "600129.SS": {
        "short_name": "CHONGQING TAIJI IND",
        "long_name": "Chongqing Taiji Industry(Group) Co.,Ltd",
        "summary": "Chongqing Taiji Industry(Group) Co.,Ltd operates in the pharmaceutical industry in China and internationally. It researches, develops, produces, and sells Chinese medicine and health products. The company offers its products in various dosage forms, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, powders, etc. It offers its products in various areas, such as digestive system, respiratory system, cardiovascular and cerebrovascular, pediatrics and gynecology, systemic anti-infective drugs, analgesia and antibiotics, orthopedics, cold clearing and cough relief, and endocrine and nervous system drugs. The company is based in Chongqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chongqing",
        "zipcode": "408000",
        "website": "http://www.taiji.com",
        "market_cap": 11366145024
    },
    "600161.SS": {
        "short_name": "BEIJING TIANTAN BIOLOGICAL PROD",
        "long_name": "Beijing Tiantan Biological Products Co., Ltd.",
        "summary": "Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, and sale and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood injection immunoglobulin; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; and human immunoglobulin. The company was founded in 1998 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100024",
        "website": "http://www.tiantanbio.com",
        "market_cap": 44216078336
    },
    "600195.SS": {
        "short_name": "CHINA ANIMAL HUSBANDRY INDUSTRY",
        "long_name": "China Animal Husbandry Industry Co., Ltd.",
        "summary": "China Animal Husbandry Industry Co., Ltd. manufactures and sells animal health and nutrition products in China. The company offers veterinary drugs and vaccines, veterinary biological products, and feed and feed additives. It also trades in raw materials. The company was founded in 1998 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100070",
        "website": "http://www.cahic.com",
        "market_cap": 11750606848
    },
    "600196.SS": {
        "short_name": "SHANGHAI FOSUN PHARMACEUTICAL G",
        "long_name": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "summary": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.fosunpharma.com",
        "market_cap": 156649521152
    },
    "600200.SS": {
        "short_name": "JIANGSU WUZHONG PHARMACEUTICAL ",
        "long_name": "JiangSu WuZhong Pharmaceutical Development Co., Ltd.",
        "summary": "JiangSu WuZhong Pharmaceutical Development Co., Ltd., together with its subsidiaries, engages in pharmaceutical, real estate, and chemical businesses in China. It develops, produces, and sells anti-infective, digestive system, cardiovascular, cerebrovascular, antiviral, vitamin, and hemostatic drugs; and immunomodulations, including biopharmaceuticals, chemical drugs, and modern Chinese medicines. The company offers its products in various forms, such as infusion solutions, water and powder injections, capsules, granules, tablets, emulsions, and oral liquids. It also engages in the research, development, production, and sale of dyes and dye intermediates; and the fields of commercial housing and affordable housing development. The company was founded in 1994 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215128",
        "website": "http://www.600200.com",
        "market_cap": 5399908352
    },
    "600201.SS": {
        "short_name": "JINYU BIO-TECHNOLOGY CO LTD",
        "long_name": "Jinyu Bio-technology Co., Ltd.",
        "summary": "Jinyu Bio-technology Co., Ltd. engages in the development, production, and sale of veterinary vaccines in China. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hohhot",
        "zipcode": "010030",
        "website": "http://www.jinyu.com.cn",
        "market_cap": 20508829696
    },
    "600211.SS": {
        "short_name": "TIBET RHODIOLA PHARMACEUTICAL H",
        "long_name": "Tibet Rhodiola Pharmaceutical Holding Co.",
        "summary": "Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China. The company offers Tibetan medicines, botanical medicine products, chemical medicine products, and biological products. Tibet Rhodiola Pharmaceutical Holding Co. was founded in 1999 and is based in Lhasa, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lhasa",
        "zipcode": "850000",
        "website": "http://www.xzyy.cn",
        "market_cap": 16115970048
    },
    "600216.SS": {
        "short_name": "ZHEJIANG MEDICINE",
        "long_name": "Zhejiang Medicine Co., Ltd.",
        "summary": "Zhejiang Medicine Co., Ltd. produces and sells fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products. The company offers anti-infective drugs, glucosidase inhibitors, and immune suppressants; and human and animal nutrition products. It also provides glycopeptides medicines, natural drugs, and feed additives; and vitamin D3 oil, various vitamin products, and vitamin APIs, as well as biological medicines, pharmaceutical intermediates, and biological pesticides. In addition, the company offers nutriceuticals, such as high-purity synthetic and natural vitamin E, biotin, vitamin A and its derivatives, vitamin d3, and \u00c3\u009f-carotene; anti-drug-resistant antibiotics, cardiovascular products, and antiviral products, including oncology and anti-infective drugs; nutriceutical soft capsules; and drug products, such as oral solid dosage forms and large volume injections. Further, it engages in the wholesale and retail of medical drugs and apparatus, medical instruments, healthcare products, and food. The company was founded in 1954 and is based in Shaoxing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shaoxing",
        "zipcode": "312366",
        "website": "http://www.china-zmc.com",
        "market_cap": 14554130432
    },
    "600222.SS": {
        "short_name": "HENAN TALOPH PHARMACEUTICAL STO",
        "long_name": "Henan Taloph Pharmaceutical Stock Co.,Ltd",
        "summary": "Henan Taloph Pharmaceutical Stock Co., Ltd. researches, produces, and sells Chinese and western medicines in China. It primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and other forms. The company's principal products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, pazufloxacin mesylate sodium chloride injections, and various infusion products. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhengzhou",
        "zipcode": "450001",
        "website": "http://www.taloph.com",
        "market_cap": 4200845824
    },
    "600252.SS": {
        "short_name": "GUANGXI WUZHOU ZHONGHENG GROUP ",
        "long_name": "Guangxi Wuzhou Zhongheng Group Co.,Ltd",
        "summary": "Guangxi Wuzhou Zhongheng Group Co., Ltd. researches, develops, manufactures, and sells pharmaceuticals in China. The company offers pills, capsules, and injections and tablets for cardiovascular and cerebrovascular diseases, bruises, gynecological diseases, and respiratory diseases. It also produces health food products under the DOUBLE MONEY brand, as well as health-care functional beverages, smokable turtle pastes, jelly-type turtle paste, etc. The company is based in Wuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuzhou",
        "zipcode": "543000",
        "website": "http://www.wz-zhongheng.com",
        "market_cap": 9904062464
    },
    "600267.SS": {
        "short_name": "ZHEJIANG HISUN PHARMACEUTICAL C",
        "long_name": "Zhejiang Hisun Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "318000",
        "website": "http://www.hisunpharm.com",
        "market_cap": 16281940992
    },
    "600276.SS": {
        "short_name": "JIANGSU HENGRUI MEDICAL CO LTD",
        "long_name": "Jiangsu Hengrui Medicine Co., Ltd.",
        "summary": "Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lianyungang",
        "zipcode": "222000",
        "website": "http://www.hrs.com.cn",
        "market_cap": 448664272896
    },
    "600277.SS": {
        "short_name": "ELION CLEAN ENERGY CO LTD",
        "long_name": "Elion Energy Company Limited",
        "summary": "Elion Energy Company Limited manufactures and distributes chemical products in China. It produces and markets polyvinyl chloride, synthetic new materials, caustic soda, liquid chlorine, and other products. The company also focuses on clean energy and environmental protection businesses. Elion Energy Company Limited was founded in 1999 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100026",
        "website": "http://www.elion.cn",
        "market_cap": 9120669696
    },
    "600285.SS": {
        "short_name": "HENAN LINGRUI PHARMACEUTICAL",
        "long_name": "Henan Lingrui Pharmaceutical Co., Ltd.",
        "summary": "Henan Lingrui Pharmaceutical Co., Ltd. produces and sells medicines in China. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is based in Xinyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xinyang",
        "zipcode": "465550",
        "website": "http://www.lingrui.com",
        "market_cap": 5763261440
    },
    "600332.SS": {
        "short_name": "GUANGZHOU BAIYUNSHAN PHARMACEUT",
        "long_name": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited",
        "summary": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the People's Republic of China and internationally. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, ganoderma spore oil capsules, lozenges, tortoise herb jelly, etc. In addition, it invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2020, the company had 141 retail chain pharmacy outlets, which included 27 Cai Zhi Lin pharmacy outlets, 33 Jian Min pharmacy outlets, 36 GPC Prescription Pharmacy outlets, and 24 Hainan Guangyao Chenfei Pharmaceutical Chain outlets, as well as 21 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510130",
        "website": "http://www.gybys.com.cn",
        "market_cap": 45784375296
    },
    "600351.SS": {
        "short_name": "YABAO PHARMACEUTICAL GROUP CO L",
        "long_name": "Yabao Pharmaceutical Group Co., Ltd",
        "summary": "Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, raw materials, pharmaceutical packaging materials, and health care products in China and internationally. The company offers products for children's medication, gynecological, cardiovascular, cerebrovascular, pediatric, and elderly chronic diseases. It provides children's medication drugs under the Ding Gui brand name; gynecological drugs under the 100 Yu brand name; and cardiovascular and cerebrovascular drugs under the Ya Bao brand name. The company offers plastic bottles, cartons, and other pharmaceutical packaging materials. The company offers its products in the form of injections, tablets, capsules, granules, pills, patches, freeze-dried powders, mixtures, suppositories, and solutions. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.yabao.com.cn",
        "market_cap": 4265799936
    },
    "600380.SS": {
        "short_name": "JOINCARE PHARMACEUTICAL GROUP I",
        "long_name": "Joincare Pharmaceutical Group Industry Co.,Ltd.",
        "summary": "Joincare Pharmaceutical Group Industry Co., Ltd. researches, develops, produces, sells, and services medicine and health products primarily in China. It also offers proprietary Chinese medicines, testing reagents, monoclonal antibodies, APIs, and chemical preparations. In addition, the company offers traditional Chinese medicine and health food, such as Taitai Oral Liquid, Jingxin Oral Liquid, Dysmenorrhea Oral Liquid, Zhengyuan Dan, Hanlin Qingzhi Capsule, Yike Post, Kungfu V Effervescent Tablets, etc.; Chinese medicine decoction pieces; pharmaceutical products; and Eagle brand health products, which includes American Ginseng series, deer essence, Ganoderma lucidum series, vitamin series, etc. Further, it supplies the intermediates F9 and 4AA; and provides genetic diagnostic reagents for food safety, human major infectious disease prevention and control, animal disease prevention and control, entry and exit inspection, and quarantine. Additionally, the company offers various evaluation devices for the effectiveness of inhalation preparations, respiratory simulators for different populations, dynamic laser diffraction particle size analyzers for inhalation preparations, and other professional analytical instruments, such as HPLC; and food additives, as well as engages in business investment and other businesses. Joincare Pharmaceutical Group Industry Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": null,
        "website": "http://www.joincare.com",
        "market_cap": 27216723968
    },
    "600385.SS": {
        "short_name": "SHANDONG JINTAI GROUP",
        "long_name": "Shandong Jintai Group Co., Ltd.",
        "summary": "Shandong Jintai Group Co., Ltd. produces and distributes chemical reagent medicines in China. The company provides tablets, capsules, ointments, membranes, and others. It is also involved in the enterprise investment business, as well as in the provision of leasing services. The company is based in Jinan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jinan",
        "zipcode": "250100",
        "website": "http://www.sdjintai.com.cn",
        "market_cap": 833842496
    },
    "600420.SS": {
        "short_name": "SHANGHAI SHYNDEC PHARMACEUTICAL",
        "long_name": "Shanghai Shyndec Pharmaceutical Co., Ltd.",
        "summary": "Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, leptin drugs, metabolism, and endocrine areas. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200040",
        "website": "http://www.shyndec.com",
        "market_cap": 10331217920
    },
    "600422.SS": {
        "short_name": "KPC PHARMACEUTICALS INC",
        "long_name": "KPC Pharmaceuticals, Inc.",
        "summary": "KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunming",
        "zipcode": "650106",
        "website": "http://www.kpc.com.cn",
        "market_cap": 6945625088
    },
    "600436.SS": {
        "short_name": "ZHANGZHOU PIENTZEHUANG PHARMACE",
        "long_name": "Zhangzhou Pientzehuang Pharmaceutical., Ltd",
        "summary": "Zhangzhou Pientzehuang Pharmaceutical., Ltd produces and sells Chinese medicines. The company's product categories include medicines and health products, healthy foods, cosmetics, daily chemicals, and medical apparatus and instruments. The company is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Construction Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhangzhou",
        "zipcode": "363000",
        "website": "http://www.zzpzh.com.cn",
        "market_cap": 235975376896
    },
    "600479.SS": {
        "short_name": "ZHUZHOU QIANJIN PHARMACEUTICAL ",
        "long_name": "ZhuZhou QianJin Pharmaceutical Co.,Ltd",
        "summary": "ZhuZhou QianJin Pharmaceutical Co.,Ltd produces and sells pharmaceutical products in China. The company offers gynecology, pediatrics, beauty, antimicrobial, circulatory, endocrine, specialty, digestive, nervous, and cardiovascular products. It also provides health pillows and ginger tea; hygiene products; and wine. The company is based in Zhuzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhuzhou",
        "zipcode": "412000",
        "website": "http://www.qjyy.com",
        "market_cap": 4046962688
    },
    "600488.SS": {
        "short_name": "TIANJIN TIANYAO PHARMACEUTICAL ",
        "long_name": "Tianjin Tianyao Pharmaceuticals Co., Ltd.",
        "summary": "Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300462",
        "website": "http://www.kingyork.biz/tianyaoyaoyeen",
        "market_cap": 5118673920
    },
    "600511.SS": {
        "short_name": "CHINA NATIONAL MEDICINES CORP",
        "long_name": "China National Medicines Corporation Ltd.",
        "summary": "China National Medicines Corporation Ltd., together with its subsidiaries, distributes pharmaceutical and healthcare products in China. The company also provides logistics and warehousing services; and operates a B2B e-commerce platform. It serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100077",
        "website": "http://www.cncm.com.cn",
        "market_cap": 26566049792
    },
    "600513.SS": {
        "short_name": "JIANGSU LIANHUAN PHARMACEUTICAL",
        "long_name": "Jiangsu Lianhuan Pharmaceutical Co., Ltd.",
        "summary": "Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells chemical raw materials, preparations, and organic intermediates in China. The company offers urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, and other products. Its products portfolio comprises eplet, terfenadine, ebastine tablets, felodipine tablets, felodipine sustained-release capsules, simvastatin tablets, danazol capsules and suppositories, metformin gliclazide tablets, lumbrokinase capsules, balofloxacin tablets, and sertraline hydrochloride; and APIs. It exports its products to approximately 20 countries, such as Europe, the United States, Southeast Asia, and Australia. The company was founded in 2000 and is based in Yangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yangzhou",
        "zipcode": "225009",
        "website": "http://www.lhpharma.com",
        "market_cap": 2600549888
    },
    "600518.SS": {
        "short_name": "KANGMEI PHARMACEUTICAL CO LTD",
        "long_name": "Kangmei Pharmaceutical Co., Ltd.",
        "summary": "Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical medicines and food products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Puning",
        "zipcode": "515300",
        "website": "http://www.kangmei.com.cn",
        "market_cap": 15418964992
    },
    "600521.SS": {
        "short_name": "ZHEJIANG HUAHAI PHARMACEUTICAL ",
        "long_name": "Zhejiang Huahai Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products. It also engages in packaging components business, such as high-density polyethylene bottles and polypropylene caps. In addition, the company provides contract manufacturing and other services. Further, it is involved in import and export trade services. Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Linhai",
        "zipcode": "317024",
        "website": "http://www.huahaipharm.com",
        "market_cap": 30474082304
    },
    "600530.SS": {
        "short_name": "SHANGHAI JIAODA ONLLY CO. LTD.",
        "long_name": "Shanghai Jiaoda Onlly Co.,Ltd",
        "summary": "Shanghai Jiaoda Onlly Co., Ltd., together with its subsidiaries, engages in the health-care food business in China. Its health-care food products are used for gastrointestinal function, heart and brain condition improvement, fatigue, and blood lipid and blood sugar, and other health needs. The company also develops commercial residential building projects; offers finance services to small and micro enterprises, and individual clients; and provides natural organic products and technical services for industries involved in natural medicine, functional food, food additives, natural cosmetics, essence, and flavors. Shanghai Jiaoda Onlly Co., Ltd. was founded in 1990 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200030",
        "website": "http://www.onlly.com.cn",
        "market_cap": 2691000064
    },
    "600535.SS": {
        "short_name": "TASLY PHARMACEUTICAL GROUP CO L",
        "long_name": "Tasly Pharmaceutical Group Co., Ltd",
        "summary": "Tasly Pharmaceutical Group Co., Ltd. engages in biological medicine, health, and medical service businesses in China. It offers herbal and chemical medicines, health products, pharmaceutical substances and APIs, herbal extracts, concentrated herbal granules, and tea series products. The company also provides cosmetic series products, including moisture lotions, moisture creams, eye creams, and face washing foams; daily hygiene products, such as sanitary and carefree pads, honey-propolis soaps, and pollen soaps; and medical equipment, which include massage tappers, massage cushions, and circulation machines. It also exports its products to the United States, Russia, and countries in Europe, Africa, and rest of Asia. Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300410",
        "website": "http://www.tasly.com",
        "market_cap": 20526929920
    },
    "600557.SS": {
        "short_name": "JIANGSU KANION PHARMACEUTICAL C",
        "long_name": "Jiangsu Kanion Pharmaceutical Co.,Ltd.",
        "summary": "Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. The company was founded in 1975 and is based in Lianyungang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lianyungang",
        "zipcode": null,
        "website": "http://www.kanion.com",
        "market_cap": 6409043968
    },
    "600566.SS": {
        "short_name": "HUBEI JUMPCAN PHARMACEUTICAL CO",
        "long_name": "Hubei Jumpcan Pharmaceutical Co., Ltd.",
        "summary": "Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taixing",
        "zipcode": "225441",
        "website": "http://www.jumpcan.com",
        "market_cap": 16157413376
    },
    "600568.SS": {
        "short_name": "ZHONG ZHU HEALTHCARE HOLDING CO",
        "long_name": "Zhongzhu Healthcare Holding Co.,Ltd",
        "summary": "Zhongzhu Healthcare Holding Co.,Ltd constructs and develops real estate properties in China. It also produces ophthalmic drugs; researches and develops natural botanical drugs. In addition, it researches and develops drugs, such as recombinant human endostatin adenovirus injection, which is an anticancer gene therapy; Genistein capsule for the treatment of postmenopausal osteoporosis; and motherwort that is primarily a gynecological drug. Further, the company offers medical instruments, including radiation therapy, hyperthermia, phototherapy, and ultrasound diagnosis, as well as develops imaging breast tumor detection systems. Additionally, it offers medical services. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co.,Ltd in June 2016. Zhongzhu Healthcare Holding Co.,Ltd was founded in 1970 and is headquartered in Qianjiang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qianjiang",
        "zipcode": null,
        "website": "http://www.zz600568.com",
        "market_cap": 3826310400
    },
    "600572.SS": {
        "short_name": "ZHEJIANG CONBA PHARMACEUTICAL C",
        "long_name": "Zhejiang CONBA Pharmaceutical Co.,Ltd.",
        "summary": "Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of traditional Chinese medicines and botanical products in China. It offers chemical medicines, Chinese patent medicines, eye health products, nutritional supplements, health supplies, healthy daily necessities and food products, and other personal care products. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.conbagroup.com",
        "market_cap": 11896247296
    },
    "600587.SS": {
        "short_name": "SHINVA MEDICAL INSTRUMENT CO LT",
        "long_name": "Shinva Medical Instrument Co., Ltd.",
        "summary": "Shinva Medical Instrument Co., Ltd. provides medical instruments and equipment in the People's Republic of China. It offers dental devices, diagnostic equipment, environmental protection equipment, laboratory instruments, OR equipment, and air disinfectors; and radiation oncology products, such as linear accelerators, simulators, brachytherapy systems, Cobalt 60 therapy units, 3D treatment planning systems, radiotherapy networking information systems, and radiotherapy accessories. The company also provides infection control equipment and consumables; pharmaceutical equipment, including washing, sterilization, IV solution, packing, lyophilization, solid, extraction, package material, automatic ampoule impurity detecting, vials sterile filling, biological reaction tank equipment, as well as process information system; and integrated solutions and medical medicine services. Shinva Medical Instrument Co., Ltd. was founded in 1943 and is based in Zibo, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zibo",
        "zipcode": "255086",
        "website": "http://www.shinva.com",
        "market_cap": 7636782592
    },
    "600594.SS": {
        "short_name": "GUIZHOU YIBAI PHARMACEUTICAL CO",
        "long_name": "Guizhou Yibai Pharmaceutical Co., Ltd.",
        "summary": "Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guiyang",
        "zipcode": "550008",
        "website": "http://www.gzcci.com",
        "market_cap": 4355598336
    },
    "600613.SS": {
        "short_name": "SHANGHAI SHENQI PHARM INVEST MA",
        "long_name": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd.",
        "summary": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceutical products primarily in China. It specializes in offering anti-tumor, cardio-cerebral vascular, and antifungal drugs, as well as cold and cough drugs under the miraculous brand, and medications for children under the Magic Doll name. The company also provides cantharidin sodium vitamin B6 injection under the Ai Yishu name for the treatment of cancer; Chinese medicines and chemical medicines; respiratory and digestive system medications; ginseng polysaccharide and cantharidin injections; and pediatric phlegm cough particles. In addition, it offers ethnic medicines; raw material medicines; drugs for rheumatic orthopedics, kidney, diarrhea, and gynecological menstruation; drugs under the Anshen Bunao name; sodium candida sulfate injections; Jie Yin Ling lotions; compound coral ginger solutions; and coral decoctions. Further, the company provides urea miconazole ointment complex products; cephalosporins; Yinqi Xinmai dripping pills; Yindan Xintai and Danxin Taidi pills; Metronidazole B6 tablets; Yuan Ye Zhike syrups; anti-particles; compound Shangfuning cream; and pediatric pharyngeal flat particles and clear toxic syrups. Additionally, it offers Keping, Paidui Jiangzhi, Zhizhike, Jinwugutong, Jingwu, and Tianma capsules; and Zhifan Zhike, Phenol yellow, Ganfu, and pediatric aminophenol alkylamine granules, as well as medications for injury, etc. The company also provides products in various other forms, such as sprays, films, tinctures, etc. It also operates under the magic, Guizhou, God, Speed Stop, and Qiang Lulu brand names. The company is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200003",
        "website": "http://www.gzsq.com",
        "market_cap": 2632611840
    },
    "600645.SS": {
        "short_name": "ZHONGYUAN UNION CELL & GENE ENG",
        "long_name": "Vcanbio Cell & Gene Engineering Corp., Ltd",
        "summary": "Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the detection and storage of stem cell sources in the People's Republic of China. The company is involved in the storage of newborns and adults cells; and preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, and adipose-derived stem cells and immune cells. It also provides genetic testing services related to children's genes, non-invasive prenatal genes, oncology and cardiovascular genes, and adult susceptibility genes. In addition, the company produces and sells biochemical diagnostic reagents; and beauty and make-up products. Vcanbio Cell & Gene Engineering Corp., Ltd is based in Tianjin, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300384",
        "website": "http://www.vcanbio.com",
        "market_cap": 11230775296
    },
    "600664.SS": {
        "short_name": "HARBIN PHARMACEUTICAL GROUP CO ",
        "long_name": "Harbin Pharmaceutical Group Co., Ltd.",
        "summary": "Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injection; Shuang Huanglian powder for injection; roxithromycin dispersible tablets; belladonna, sulfamethoxazole, and trimerhoprim tablets; pediatric paracetamol, atificial cow-bezoar, and chlorphenamine maleate granules; Shuanghuanglian oral liquid; and ceftriaxone sodium for injection. Its lead products also comprise amoxicillin capsules, cefotiam hydrochloride for injection, panax ginseng extract, cefepime hydrochloride for injection, cefoperazone sodium for injection, and amoxicillin sodium and clavulanate potassium for injection; cefuroxime, ceftazidime, cefotaxime sodium, and ceftriaxone sodium for injection; and ampicillin capsules. The company is based in Harbin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150070",
        "website": "http://www.hayao.com",
        "market_cap": 7370462208
    },
    "600671.SS": {
        "short_name": "HANGZHOU TIAN-MU-SHAN PHARMACEU",
        "long_name": "Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd",
        "summary": "Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd engages in the Chinese medicine, Western medicine, biological medicine, raw material medicine, health food, Chinese herbal medicine, and pharmaceutical businesses in China. It offers pearl eyesight eye drops, river car made of capsules, Xiangdan injections, Fu Le granules, Eucommia granules, compound fresh bamboo leachate, heart worry films, Liuwei Dihuang oral liquids/pills, menthols, metal Dendrobium soft capsules, metal maple bucket particles, iron maple dust particles, pinellia lotions, Jinkui Shenqi pills, nourishing and concentrating syrups, compound wild chrysanthemum cold particles, and Lily solid gold oral solutions. The company was founded in 1958 and is based in Lin'an City, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lin'an City",
        "zipcode": "311300",
        "website": "http://www.hztmyy.com",
        "market_cap": 1002241088
    },
    "600713.SS": {
        "short_name": "NANJING PHARMACEUTICAL CO LTD",
        "long_name": "NanJing Pharmaceutical Company Limited",
        "summary": "NanJing Pharmaceutical Company Limited engages pharmaceutical wholesale and retail businesses in China. It also operates approximately 510 pharmacy retail stores and an e-commerce platform. The company was founded in 1951 and is based in Nanjing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": null,
        "website": "http://www.njyy.com",
        "market_cap": 5426787840
    },
    "600739.SS": {
        "short_name": "LIAONING CHENGDA",
        "long_name": "Liaoning Cheng Da Co., Ltd.",
        "summary": "Liaoning Cheng Da Co., Ltd. engages in trading, pharmaceutical and medical treatment, financial investment, and energy development businesses in China and internationally. The company trades in textile and apparel, chemical products, coal, aquatic products, timber and board materials, flooring, and furniture and components, and steel; and offers medical insurance. It is also involved in research, development, production, and marketing human and veterinary vaccines; pharmaceutical retail, and wholesale and logistics distribution activities; and the provision of medical enterprise management consulting; and medical industry investment and medical equipment sales businesses. In addition, the company offers medical technology, computer hardware and software technology development, technology consulting and transfer, and technical services; and operates gastroenterology and thoracic specialist hospital, as well as medical examination and pathology imaging center. Further, it engages in securities, insurance, and fund activities; and the development of oil shale projects. Liaoning Cheng Da Co., Ltd. was founded in 1991 and is headquartered in Dalian, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Dalian",
        "zipcode": null,
        "website": "http://www.chengda.com.cn",
        "market_cap": 34219612160
    },
    "600763.SS": {
        "short_name": "TOPCHOICE MEDICAL CORPORATION",
        "long_name": "Topchoice Medical Corporation",
        "summary": "Topchoice Medical Corporation provides medical services in China. It provides various specialty medical services in oral, reproductive, and ophthalmology areas; and operates dental medical institutions and assisted reproductive medical institutions. It operates approximately 32 dental hospitals; and Tongze Dental College, a non-profit educational training organization. The company was formerly known as Topchoice Medical Investment Co., Inc. and changed its name to Topchoice Medical Corporation in November 2019. Topchoice Medical Corporation was founded in 1995 and is based in Hangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310023",
        "website": "http://www.tcmedical.com.cn",
        "market_cap": 122708934656
    },
    "600767.SS": {
        "short_name": "WINSAN(CHENGDU)MEDICAL SCIE & T",
        "long_name": "Winsan (Chengdu) Medical Science and Technology Co., Ltd.",
        "summary": "Winsan (Chengdu) Medical Science and Technology Co., Ltd. engages in the medical informatization, telemedicine, Internet health management, medical equipment, and medical services in China. It offers health information system that provides regional population health, Chinese medicine, and hospital performance management informationization, as well as home pension, chronic disease management, remote diagnosis and treatment, medical insurance, and pharmacy services. The company also operates Jingde County Chinese Medicine Hospital, a non-profit second-class Chinese medicine hospital. It provides medical testing reagents, instruments, consumables, and other products to medical institutions and clinical medical examination services. The company was formerly known as Winsan (Shanghai) Medical Science and Technology Co., Ltd. and changed its name to Winsan (Chengdu) Medical Science and Technology Co., Ltd. in April 2020. The company was founded in 1993 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.winsan.cn",
        "market_cap": 1687999360
    },
    "600771.SS": {
        "short_name": "GUANGYUYUAN CHINESE HERBAL MEDI",
        "long_name": "GuangYuYuan Chinese Herbal Medicine Co., Ltd.",
        "summary": "GuangYuYuan Chinese Herbal Medicine Co., Ltd. manufactures and sells Chinese medicinal products. The company offers traditional Chinese medicines and health wines. It offers its products in the form of pills, capsules, and wine. The company was formerly known as Topsun Science And Technology Co Ltd. and changed its name to GuangYuYuan Chinese Herbal Medicine Co., Ltd. in July 2013. GuangYuYuan Chinese Herbal Medicine Co., Ltd. was founded in 1996 and is based in Xi'an, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xi'an",
        "zipcode": "710065",
        "website": "http://www.guangyuyuan.com",
        "market_cap": 10582920192
    },
    "600781.SS": {
        "short_name": "FUREN GROUP PHARMACEUTICAL CO L",
        "long_name": "FUREN Group Pharmaceutical Co., Ltd.",
        "summary": "FUREN Group Pharmaceutical Co., Ltd. primarily engages in the manufacture and distribution of pharmaceuticals in Henan Province and Shanghai, China. The company produces traditional Chinese medicines, such as capsules, tablets, granules, gels, injections, oral liquids, and others. It provides granules for heart attacks; capsules for diabetes and hyperlipidemia; and others. It is also involved in warehousing and trading businesses. The company was founded in 1996 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200031",
        "website": "http://www.shfuren.cn",
        "market_cap": 2000634112
    },
    "600789.SS": {
        "short_name": "SHANDONG LUKANG PHARMACEUTICAL ",
        "long_name": "Shandong Lukang Pharmaceutical Co.,Ltd.",
        "summary": "Shandong Lukang Pharmaceutical Co.,Ltd. manufactures and sells bio-pharmaceuticals and antibiotics in China. The company offers human and animal active pharmaceutical ingredients; human and animal preparations; bio-pesticides; herbal medicines; and amino acid. It is also involved in the sewage treatment, odor control, sewage facilities management, environmental protection material production and sale, and management of water disposal. The company exports its products to approximately 40 countries in Asia, Europe, Africa, and the United States. The company was formerly known as Jining Antibiotic Factory and changed its name to Shandong Lukang Pharmaceutical Co.,Ltd. in October 1993. Shandong Lukang Pharmaceutical Co.,Ltd. was founded in 1966 and is based in Jining, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jining",
        "zipcode": "272021",
        "website": "http://www.lkpc.com",
        "market_cap": 6557713408
    },
    "600829.SS": {
        "short_name": "HPGC RENMINTONGTAI PHARMACEUTIC",
        "long_name": "HPGC Renmintongtai Pharmaceutical Corporation",
        "summary": "HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese medicines, Chinese herbal medicine, chemical preparations, antibiotics, biological products, and biochemical drugs, as well as medical equipment and health products. It also provides logistics services, including warehousing and distribution; and hospital services comprising medical treatment, scientific research, prevention, health care, rehabilitation, blood purification, and renal disease treatment. In addition, the company offers Chinese and Western medicines, Chinese herbal medicines, nourishing health care products, medical equipment, cosmetics, and daily necessities through an e-commerce platform. It operates 319 chain stores in Heilongjiang Province. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150071",
        "website": "http://www.hyrmtt.com.cn",
        "market_cap": 3647501824
    },
    "600833.SS": {
        "short_name": "SHANGHAI NO.1 PHARMACY CO",
        "long_name": "Shanghai No.1 Pharmacy Co., Ltd.",
        "summary": "Shanghai No.1 Pharmacy Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company offers products in the categories of Chinese and Western medicines, nutrition and health products, medical equipment, Chinese herbal medicines, etc. In addition, it provides consulting and guidance on safe medication, rational medication, and chronic disease medication. Shanghai No. 1 Pharmacy Co., Ltd. is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.shdyyy.com.cn",
        "market_cap": 2039006080
    },
    "600866.SS": {
        "short_name": "STAR LAKE BIOSCIENCE CO INC Z",
        "long_name": "Star Lake Bioscience Co., Inc.Zhaoqing Guangdong",
        "summary": "Star Lake Bioscience Co., Inc. manufactures and sells pharmaceutical raw materials, and food and feed additives in China and internationally. The company offers guanosine that is used as an intermediate for food and pharmaceutical raw material; L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; adefovir dipivoxil tablets used to reduce the activity of HBV DNA polymerase and anti-virus by destroying Hepatitis B virus DNA; and L-threonine that is used in premixtures, and pig and poultry feed. It also provides disodium 5'-ribonucleotide to cure chronic hepatitis, muscular atrophy, and eye diseases; disodium 5-inosinate to cure leukopenia, thrombocytopenia, and chronic and acute hepatitis; and inosine, which is used for the treatment of chronic hepatitis, heart disease, leukopenia or thrombocytopenia, central choroidoretinitis, etc. In addition, the company offers disodium 5'-guanylate for canned meat, ham, salted meat, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc. The company offers its products under the Star Lake and Yue Bao brands. Star Lake Bioscience Co., Inc. was founded in 1964 and is based in Zhaoqing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhaoqing",
        "zipcode": "526040",
        "website": "http://www.starlake.com.cn",
        "market_cap": 2963466496
    },
    "600867.SS": {
        "short_name": "TONGHUA DONGBAO MEDICINES CO LT",
        "long_name": "Tonghua Dongbao Pharmaceutical Co., Ltd.",
        "summary": "Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. It lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, insulin detemir, and insulin lispro; antidiabetic drug agonist products; oral hypoglycemic agents; and Zhen Nao Ning and Nao Xue Kang capsules, as well as Gan Shulin pens, blood glucose meters, and other medical devices. The company is also involved in developing Y-PEG of recombinant human interferon a 2b injection, which has been completed Phase III clinical stage to treat chronic hepatitis C (2,3 gene type) and chronic hepatitis B III; Y-PEG a recombinant human granulocyte colony-stimulating factor injection that is in Phase II clinical stage for the treatment of chemotherapy-induced neutropenia; Y-PEG injection of recombinant human growth hormone, which is in Phase II clinical stage to treat short stature and growth hormone deficiency; and Y-PEG of recombinant human interferon a 2a injection that is in Phase II clinical stage to treat chronic hepatitis B and hepatitis C. It offers building materials comprising plastic windows and sections; and other products. The company has a strategic alliance with Adocia. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is based in Tonghua, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tonghua",
        "zipcode": "134123",
        "website": "http://www.thdb.com",
        "market_cap": 24855359488
    },
    "600896.SS": {
        "short_name": "LANHAI MEDICAL INVESTMENT CO LT",
        "long_name": "Lanhai Medical Investment Co., Ltd.",
        "summary": "Lanhai Medical Investment Co., Ltd. provides medical and health services. The company operates rehabilitation hospitals. It also offers financial insurance services; and industrial investment services. The company was formerly known as China Shipping Haisheng Co., Ltd. and changed its name to Lanhai Medical Investment Co., Ltd. in November 2016. Lanhai Medical Investment Co., Ltd. was founded in 1989 and is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200120",
        "website": "http://www.lanhaimedical.com",
        "market_cap": 4273457664
    },
    "600976.SS": {
        "short_name": "JIANMIN PHARMACEUTICAL GROUP CO",
        "long_name": "Jianmin Pharmaceutical Group Co., Ltd.",
        "summary": "Jianmin Pharmaceutical Group Co., Ltd. manufactures and sells Chinese medicines in China. It offers pediatric drugs under the Jianmin, Longmu, and Yekaitai brands. The company is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": null,
        "website": "http://www.whjm.com",
        "market_cap": 5361295360
    },
    "600993.SS": {
        "short_name": "MAYINGLONG PHARMACEUTICAL GP CO",
        "long_name": "Mayinglong Pharmaceutical Group Co., LTD.",
        "summary": "Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. It offers hemorrhoid, gynecological, cough, skin, cosmeceutical, and other products, as well as drugstore and merchants varieties. The company provides its products in various dosage forms comprising ointments, suppositories, tablets, lotions and granules, and creams. It also operates hospitals. Mayinglong Pharmaceutical Group Co., Ltd. was founded in 1582 and is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430064",
        "website": "http://www.mayinglong.cn",
        "market_cap": 9543535616
    },
    "600998.SS": {
        "short_name": "JOINTOWN PHARMACEUTICAL GROUP C",
        "long_name": "Jointown Pharmaceutical Group Co., Ltd.",
        "summary": "Jointown Pharmaceutical Group Co., Ltd. engages in the wholesale, logistics, and pharmaceutical e-commerce activities specializing in Chinese herbal medicines, Chinese patent medicines, chemical raw materials, chemical preparations, antibiotics, biochemicals, biological products, and second class psychoactive drugs. It serves drug manufacturers, drug distributors, retailers, medical institutions, and government procurement groups. Jointown Pharmaceutical Group Co., Ltd. was founded in 1999 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.jzteyao.com",
        "market_cap": 31124152320
    },
    "603079.SS": {
        "short_name": "ZHEJIANG SHENGDA BIO-PHARM CO L",
        "long_name": "Zhejiang Shengda Bio-Pharm Co., Ltd.",
        "summary": "Zhejiang Shengda Bio-Pharm Co., Ltd. engages in the research, development, production, and sale of food and feed additives worldwide. The company offers vitamins, such as biotin and folic acid, etc.; biological fresh-keeping agents, including nisin and natamycin; and intermediate APIs. It also produces natural food preservatives. The company is based in Tiantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tiantai",
        "zipcode": "317200",
        "website": "http://www.sd-pharm.com",
        "market_cap": 2958145792
    },
    "603108.SS": {
        "short_name": "SHANGHAI RUNDA MEDICAL TECHNOLO",
        "long_name": "Shanghai Runda Medical Technology Co., Ltd.",
        "summary": "Shanghai Runda Medical Technology Co., Ltd. provides integrated medical laboratory services in China. It offers platform supply, laboratory design/renovation, laboratory standardization, and information management system services; medical solutions to help healthcare professionals in the areas of biochemistry, diabetes, POCT, immunoassay analyzer, and molecular biology diagnosis; professional technical services; and logistic services. The company was founded in 1999 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200085",
        "website": "http://www.rundamedical.com",
        "market_cap": 6467633152
    },
    "603127.SS": {
        "short_name": "JOINN LABORATORIES (CHINA) CO L",
        "long_name": "Joinn Laboratories (China) Co.,Ltd.",
        "summary": "Joinn Laboratories (China) Co., Ltd. provides preclinical and non-clinical services. It evaluates various drugs, including biologics, pharmaceutical chemicals, and plant medicines for indications, such as renal, metabolic, cardiology, hematology, COPD, ophthalmic, oncology, and immune-related diseases. The company's services include screening services, such as efficiency screening, bioavailability, ADME screening, and non-GLP toxicology studies; pre-clinical safety assessment comprising general toxicology, safety pharmacology, developmental and reproductive toxicology, genetic and ocular toxicology, clinical pathology, analytical and bioanalytical analysis, immunology, and biomarker assays; pharmacodynamics services; and services to evaluate and optimize the absorption, distribution, metabolism, and elimination (ADME), as well as pharmacokinetic properties of potential drugs from early discovery projects. Its services also comprise clinical trials; a range of safety assessment services for medical devices, chemicals, and agrochemicals; regulatory consulting services in the areas of pharmaceuticals, biologics, Chinese medicine, medical devices, veterinary medicines, and agrochemicals; and food animal evaluation services comprising candidate selection, efficacy, safety evaluation studies on animals' health products, animal remedies, and fodders. In addition, the company offers traditional animals, such as outbred rats, inbred strain mice, outbred mice, and immunodeficient mice. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies, as well as regulatory and other government agencies. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies. The company operates in China, Europe, North America, Southeast Asia, and Australia. The company was founded in 1995 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.joinn-lab.com",
        "market_cap": 46776520704
    },
    "603139.SS": {
        "short_name": "SHAANXI KANGHUI PHARMACEUTICAL ",
        "long_name": "Shaanxi Kanghui Pharmaceutical Co., Ltd.",
        "summary": "Shaanxi Kanghui Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory, urinary system, gastrointestinal liver and gallbladder, and other drugs in the form of tablets, capsules, granules, and oral liquids. The company is based in Xianyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xianyang",
        "zipcode": "712000",
        "website": "http://www.sxkh.com",
        "market_cap": 1698958848
    },
    "603168.SS": {
        "short_name": "ZHEJIANG SHAPUAISI PHARM CO LTD",
        "long_name": "Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.",
        "summary": "Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antipyretic and analgesic, antibacterial anti-inflammatory, endocrine, liver disease adjuvant, cardiovascular, detoxification, diuretic row stone, gynecology, infusion, and jianweixiaosh categories. It offers its products in injections, oral solutions, eye drops, tablets, capsules, suppositories, granules, medicine raw materials, rinsing agents, mixtures, and other dosage forms. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 1978 and is based in Pinghu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Pinghu",
        "zipcode": null,
        "website": "http://www.zjspas.com",
        "market_cap": 2696877312
    },
    "603222.SS": {
        "short_name": "CHIMIN HEALTH MANAGEMENT CO LTD",
        "long_name": "Chimin Health Management Co., Ltd.",
        "summary": "Chimin Health Management Co., Ltd. develops, produces, and sells human drugs and medical devices in China. The company offers non-PVC soft bag double tube double valves, single valves, and single-tube double valves; plastic bottles; and other packaging forms. It also provides safe self-destruct syringes, disposable sterile infusion equipment, disposable and precision infusion sets, multi-layer PP co-extruded hoses, and other syringes; peritoneal dialysis solutions; and hemodialysis supplies, as well as medical services. The company was formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd. Chimin Health Management Co., Ltd. was founded in 1996 and is based in Huangyan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Huangyan",
        "zipcode": "318020",
        "website": "http://www.chimin.cn",
        "market_cap": 5530258944
    },
    "603229.SS": {
        "short_name": "ZHEJIANG AUSUN PHARMACEUTICAL C",
        "long_name": "Zhejiang Ausun Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. The company offers prostaglandins and its intermediates; APIs; fluorine and antibacterial products; and intermediates. It also provides products for liver disease, respiratory system, and cardiovascular and cerebrovascular, as well as entecavir for the treatment of hepatitis B. In addition, the company is involved in the customized processing, and research and development business. Zhejiang Ausun Pharmaceutical Co., Ltd. was founded in 2010 is headquartered in Linhai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Linhai",
        "zipcode": "317016",
        "website": "http://www.ausunpharm.com",
        "market_cap": 8539654144
    },
    "603233.SS": {
        "short_name": "DASHENLIN PHARMACEUTICAL GROUP ",
        "long_name": "DaShenLin Pharmaceutical Group Co., Ltd.",
        "summary": "DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. The company was founded in 1999 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.dslyy.com",
        "market_cap": 35282325504
    },
    "603259.SS": {
        "short_name": "WUXI APPTEC CO LTD",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200131",
        "website": "http://www.wuxiapptec.com",
        "market_cap": 356218732544
    },
    "603301.SS": {
        "short_name": "ZHENDE MEDICAL CO LTD",
        "long_name": "Zhende Medical Co., Ltd.",
        "summary": "Zhende Medical Co., Ltd. engages in the research and development, production, and sale of medical products in China and internationally. It offers medical dressing products, pressure treatment and fixation products, wound care products, surgical infection management products, incontinence care products, industrial automation equipment, etc. The company is headquartered in Shaoxing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shaoxing",
        "zipcode": "312035",
        "website": "http://www.zhende.com/",
        "market_cap": 10905839616
    },
    "603367.SS": {
        "short_name": "CISEN PHARMACEUTICAL CO LTD",
        "long_name": "Cisen Pharmaceutical Co., Ltd.",
        "summary": "Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells chemical drug preparations and health care products in China and internationally. The company's chemical drug preparations include liver disease drugs, antitumor and auxiliary drugs, nutrition preparations, contrast agents, antibiotics, digestive system agents, polypropylene ampoules, and external preparations, as well as sedation anesthesia, cardiovascular, cough and asthma, immunomodulator, infusion, and therapeutic infusion products. It also engages in the formulation, development, manufacturing, and marketing of generic pharmaceutical products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd. and changed its name to Cisen Pharmaceutical Co., Ltd. in 2011. Cisen Pharmaceutical Co., Ltd. is based in Jining, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jining",
        "zipcode": "272073",
        "website": "http://www.lkcisen.com",
        "market_cap": 5675979776
    },
    "603368.SS": {
        "short_name": "GUANGXI LIUZHOU PHARMACEUTICAL ",
        "long_name": "Guangxi Liuzhou Pharmaceutical Co., Ltd.",
        "summary": "Guangxi Liuzhou Pharmaceutical Co., Ltd. engages in the distribution and retail of pharmaceutical products in China. The company was founded in 1981 and is based in Liuzhou, China. Guangxi Liuzhou Pharmaceutical Co., Ltd. is a subsidiary of Liuzhou Liangmianzhen Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Liuzhou",
        "zipcode": "545001",
        "website": "http://www.lzyy.cn",
        "market_cap": 7118360576
    },
    "603387.SS": {
        "short_name": "GETEIN BIOTECH INC",
        "long_name": "Getein Biotech, Inc",
        "summary": "Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "211505",
        "website": "http://www.bio-gp.com.cn",
        "market_cap": 8073174016
    },
    "603392.SS": {
        "short_name": "BEIJING WANTAI BIOLOGICAL PHARM",
        "long_name": "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",
        "summary": "Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.ystwt.com",
        "market_cap": 105147998208
    },
    "603439.SS": {
        "short_name": "GUIZHOU SANLI PHARMACEUTICAL CO",
        "long_name": "GuiZhou SanLi Pharmaceutical Co., Ltd.",
        "summary": "GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guiyang",
        "zipcode": "561100",
        "website": "http://www.gz-sanli.com",
        "market_cap": 5906168832
    },
    "603456.SS": {
        "short_name": "ZHEJIANG JIUZHOU PHARMACEUTICAL",
        "long_name": "Zhejiang Jiuzhou Pharmaceutical Co., Ltd",
        "summary": "Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, and cardiovascular drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is based in Taizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "318000",
        "website": "http://www.jiuzhoupharma.com",
        "market_cap": 35825287168
    },
    "603520.SS": {
        "short_name": "ZHEJIANG STARRY PHARMACEUTICAL ",
        "long_name": "Zhejiang Starry Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of active ingredient and intermediate X-CT non-ionic contrast agents, and fluoroquinolones in China and internationally. Its contrast medium products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, gadobenate dimeglumine, iodixanol, gadopentetate dimeglumine, and gadoterate meglumine; and fluoroquinolones products comprise levofloxacin hemihydrate, levofloxacin HCL, levofloxacin acid ester, levofloxacin acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xianju",
        "zipcode": "317300",
        "website": "http://www.starrypharm.com",
        "market_cap": 18737682432
    },
    "603538.SS": {
        "short_name": "NINGBO MENOVO PHARMACEUTICAL CO",
        "long_name": "Ningbo Menovo Pharmaceutical Co., Ltd.",
        "summary": "Ningbo Menovo Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products. It offers APIs, intermediates, and formulations for the treatment of cardiovascular, central nervous, respiratory, antitumor, anti-infection, digestive, geriatric, and antiviral diseases. The company was founded in 2004 and is headquartered in Ningbo, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Ningbo",
        "zipcode": "315040",
        "website": "http://www.menovopharm.com",
        "market_cap": 6626182144
    },
    "603566.SS": {
        "short_name": "PULIKE BIOLOGICAL",
        "long_name": "Pulike Biological Engineering, Inc.",
        "summary": "Pulike Biological Engineering, Inc. engages in the research and development, production, and operation of veterinary biological products and drugs. It offers vaccines and antibodies for poultry; and poultry and pig medicines, as well as other medicines. The company is headquartered in Luoyang City, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Luoyang City",
        "zipcode": "471000",
        "website": "http://en.pulike.com.cn",
        "market_cap": 8159568384
    },
    "603567.SS": {
        "short_name": "HEILONGJIANG ZBD PHARMACEUTICAL",
        "long_name": "Heilongjiang ZBD Pharmaceutical Co., Ltd.",
        "summary": "Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Hulin",
        "zipcode": null,
        "website": "http://www.zbdzy.com",
        "market_cap": 15165998080
    },
    "603590.SS": {
        "short_name": "BEIJING KONRUNS PHARMACEUTICAL ",
        "long_name": "Beijing Konruns Pharmaceutical Co.,Ltd.",
        "summary": "Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs. The company offers Haemocoagulase Agkistrodon used in auxiliary stopping of capillary hemorrhage on superficial wound in surgical operation; GuShuKang Keli and GuShuKang Jiaonang products for osteoporosis; Fangshen Zhiyang Keli for acute hives of wind-heat syndrome; Siyu Yangxue Yishen to alleviate waist/knee soreness, listlessness, palpitation, and dyspnea in climacteric women; Qingxuan Zhitan Wan for symptoms caused by liver-yang hyperactivity and liver-fire flaming; Xiaoaiping Pian for esophagus, stomach, and lung cancer; and Guchi Xiaotong Jiaonang for hyperosteogeny rheumarthritis, and rheumatalgia. It also provides Liganlong Keli for acute/chronic, persistent, and chronic active hepatitis; Naoluotong Jiaonang for various cerebrovascular diseases and symptoms caused by qi deficiency and blood stasis; Compound Bismuth Aluminate Tablet for chronic gastritis, and the symptoms caused by hyperacidity; Shenshi Tong Keli for stones in kidney, renal pelvis, urinary bladder, and ureter; Naoxueshuan Pian to prevent and treat the stroke; and Kanggan Jiedu Keli for wind-heat cold. In addition, the company offers calcium carbonate capsules; Fosfomycin Calcium Capsule to lower urinary tract infection and intestinal infection; Yansheqing Keli for respiratory tract inflammation, bronchitis, pneumonia, acute tonsillitis, urinary system infection, and biliary tract infection; Sanqi Zhixue Pian to disperse blood stasis, stop bleeding, subside swelling, and relieve pain; Da Feng Wan for waist/leg soreness, limb numbness, and tendon/bone soreness; Yankening Pian to clear away heat, purge intense fire, diminish inflammation and relieve dysentery; Kudancao Jiaonang to eliminate dampness, and purge fire in liver and gallbladder; and Tongmai Pian to invigorate blood circulation and dredge channels. The company was founded in 1999 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100085",
        "website": "http://www.konruns.cn",
        "market_cap": 6024000000
    },
    "603658.SS": {
        "short_name": "AUTOBIO DIAGNOSTICS CO LTD",
        "long_name": "Autobio Diagnostics Co., Ltd.",
        "summary": "Autobio Diagnostics Co., Ltd. engages in the research and development, production, and distribution of clinical diagnostic products in China and internationally. It develops immunoassay, biochemistry, microbiology, and IVD reagents; and instruments, such as automation and semi-automation systems, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A2000 Plus, an automatic Chemiluminescence immunoassay analyzer; automatic microplate chemiluminescent enzyme immunoassay; and LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Its microbiology products comprise automated mass spectrometry microbial identification systems, automated blood culture systems; and blood culture bottles, AUTOMIC strips, and mycoplasma IES. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is based in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Auto Industrial Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhengzhou",
        "zipcode": "450016",
        "website": "http://www.autobio.com.cn",
        "market_cap": 35131265024
    },
    "603669.SS": {
        "short_name": "LIONCO PHARMACEUTICAL GROUP CO",
        "long_name": "Lionco Pharmaceutical Group Co., Ltd.",
        "summary": "Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular and cerebrovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shannan",
        "zipcode": "856000",
        "website": "http://www.lingkang.com.cn",
        "market_cap": 5850207744
    },
    "603676.SS": {
        "short_name": "TIBET WEIXINKANG MEDICINE CO LT",
        "long_name": "Tibet Weixinkang Medicine Co., Ltd.",
        "summary": "Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is headquartered in Lhasa, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Lhasa",
        "zipcode": null,
        "website": "http://www.wxkpharma.com",
        "market_cap": 3472829952
    },
    "603707.SS": {
        "short_name": "NANJING KING-FRIEND BIOCHEMICAL",
        "long_name": "Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd",
        "summary": "Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210061",
        "website": "http://www.nkf-pharma.com",
        "market_cap": 39916699648
    },
    "603716.SS": {
        "short_name": "THALYS MEDICAL TECHNOLOGY GROUP",
        "long_name": "Thalys Medical Technology Group Inc.",
        "summary": "Thalys Medical Technology Group Inc. engages in the medical intensive business and operation services in China. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430040",
        "website": "http://www.thalys.net.cn",
        "market_cap": 2956503808
    },
    "603718.SS": {
        "short_name": "SHANGHAI HILE BIO-",
        "long_name": "Shanghai Hile Bio-Technology Co., Ltd.",
        "summary": "Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers porcine parvovirus oil emulsion inactivated vaccines, Pseudorabies live vaccines, Streptococcus suis disease inactivated vaccines, Trivalent live vaccines, swine blast vaccines, porcine reproductive and respiratory syndrome vaccines, Piglet Escherichia coli K88/K99 Bivalent gene engineering inactivated vaccines, swine atrophic rhinitis inactivated vaccines, pig infectious gastroenteritis and porcine epidemic diarrhea inactivated vaccines, porcine circovirus type 2 inactivated vaccines, and porcine encephalitis live vaccines. It also provides newcastle disease low virulent live vaccines; newcastle disease, infectious bronchitis, and Avian Influenza triple inactivated vaccines; newcastle disease, infectious bronchitis, and egg drop syndrome triple inactivated oil emulsion vaccines; avian infectious bronchitis live vaccines; newcastle disease and avian infectious bronchitis combined living vaccines; newcastle disease inactivated vaccines; newcastle disease low virulent live vaccines; chicken Marek's disease turkey herpes virus live vaccines; chicken pox live vaccines; duck plague live vaccines; chicken newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; newcastle disease and Avian Influenza inactivated vaccines; chicken infectious rhinitis inactivated vaccines; chicken infectious bursal disease live vaccines; and chicken infectious rhinitis and newcastle disease inactivated vaccines, as well as various other live and inactivated vaccines. The company was founded in 1981 and is based in Shanghai, China. Shanghai Hile Bio-Technology Co., Ltd. is a subsidiary of Shanghai Haoyuan Science And Technology Development Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201403",
        "website": "http://www.hile-bio.com",
        "market_cap": 9885400064
    },
    "603739.SS": {
        "short_name": "QINGDAO VLAND BIOTECH CO LTD",
        "long_name": "Qingdao Vland Biotech INC.",
        "summary": "Qingdao Vland Biotech INC. engages in the research and development of enzymes, probiotics, and animal vaccines and health products. It offers animal feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological products, such as live and inactivated poultry, and swine vaccines, as well as antibodies; poultry drugs comprising anti-parastic, antiviral, and nutritional drugs, as well as disinfectants; and traditional Chinese veterinary medicines for scale and avian breeding, livestock, and laying hens. It serves agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection, and other industries. The company was founded in 2005 and is headquartered in Qingdao, China. Qingdao Vland Biotech INC. is a subsidiary of Qingdao Kangdien Industrial Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qingdao",
        "zipcode": "266061",
        "website": "http://www.vlandgroup.com",
        "market_cap": 4406092288
    },
    "603858.SS": {
        "short_name": "SHANDONG BUCHANG PHARMACEUTICAL",
        "long_name": "Shandong Buchang Pharmaceuticals Co., Ltd.",
        "summary": "Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. is a subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Heze",
        "zipcode": "274000",
        "website": "http://www.buchang.com",
        "market_cap": 25708382208
    },
    "603880.SS": {
        "short_name": "JIANGSU NANFANG MEDICAL CO LTD",
        "long_name": "Jiangsu Nanfang Medical Co., Ltd.",
        "summary": "Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal products, medical proof fabrics, adhesive tapes, bandages, sports protection products, first-aid kits, and care products in China and internationally. It offers medical adhesive tapes, medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, and zinc oxide adhesive plasters, as well as customized products. The company is based in Changzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changzhou",
        "zipcode": "213149",
        "website": "http://www.nfmedical.com.cn",
        "market_cap": 1747396864
    },
    "603882.SS": {
        "short_name": "GUANGZHOU KINGMED DIAGNOSTICS G",
        "long_name": "Guangzhou Kingmed Diagnostics Group Co., Ltd.",
        "summary": "Guangzhou Kingmed Diagnostics Group Co., Ltd. operates as a third-party medical laboratory company in China. The company offers medical examination, clinical trial, food and hygiene testing, and scientific research services. As of January 3, 2019, it operated 37 testing laboratories with approximately 2,400 testing items to serve approximately 21,000 medical institutions. The company has a strategic partnership with Personal Genome Diagnostics Inc. to serve the clinical trial screening needs of pharmaceutical partners in the Asian market. The company was founded in 1994 and is headquartered in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510030",
        "website": "http://www.kingmed.com.cn",
        "market_cap": 66740891648
    },
    "603883.SS": {
        "short_name": "LAOBAIXING PHARMACY CHAIN JO ST",
        "long_name": "LBX Pharmacy Chain Joint Stock Company",
        "summary": "LBX Pharmacy Chain Joint Stock Company operates pharmacy store chain in China. The company operates stores in 21 provincial markets, including Hunan, Jiangsu, Gansu, Shaanxi, Guangxi, Anhui, Zhejiang, Inner Mongolia, Hubei, Tianjin, Henan, Shanghai, Shandong, Guangdong, Hebei, Beijing, Jiangxi, Ningxia, Sichuan, Fujian, and Guizhou. The company was formerly known as Laobaixing Pharmacy Chain Joint Stock Company. LBX Pharmacy Chain Joint Stock Company was founded in 2001 and is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": null,
        "website": "http://www.lbxdrugs.com",
        "market_cap": 22398513152
    },
    "603896.SS": {
        "short_name": "ZHEJIANG SHOUXIANGU PHARMACEUTI",
        "long_name": "Zhejiang Shouxiangu Pharmaceutical Co., Ltd.",
        "summary": "Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Jinhua",
        "zipcode": null,
        "website": "http://www.sxg1909.com",
        "market_cap": 5574708736
    },
    "603939.SS": {
        "short_name": "YIFENG PHARMACY CHAIN CO LTD",
        "long_name": "Yifeng Pharmacy Chain Co., Ltd.",
        "summary": "Yifeng Pharmacy Chain Co., Ltd. retails pharmaceutical products in China. The company primarily offers ENT, dermatology, gastroenterology, rheumatology, andrology, gynecology, pediatric, body slimming, and nutrition products. It operates approximately 680 pharmaceutical chain stores in Hunan, Hubei, Shanghai, Jiangsu, Zhejiang, Jiangxi, and other six provinces and cities. The company is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": null,
        "website": "http://www.yfdyf.com",
        "market_cap": 31729534976
    },
    "603987.SS": {
        "short_name": "SHANGHAI KINDLY ENTERPRISE DEVE",
        "long_name": "Shanghai Kindly Enterprise Development Group Co.,LTD.",
        "summary": "Shanghai Kindly Enterprise Development Group Co.,LTD. produces and sells disposable medical polymer devices worldwide. It offers syringes, infusion sets, transfusion sets, medical tubes, needles and cannulas, and medical bags. The company also provides medical package materials, including PPPE composite films, medical packing films, sterilization indicator strips and Bowie Dick test packs, sterilization indicator tapes, medical wrapping papers, paper bags, and sterilization reels; and intervention accessories, such as guide wire, Y-connectors, inflation device, mainfold kit, pressure bandages, angiography syringes, stopcocks, sterile seldinger needle, introducer sets and tool kits, pressure transducer, extension tube, seldinger needles, hemostasis balloons, extension lines with needle free valves, pressure monitoring tubing products, and spine tool kits, as well as guiding, micro, and angiography catheters. In addition, it offers self-sealing pouches, tyverk reels, mini-spikes, PE extension tubes, suction catheter kits, irrigation kits, heparin caps, and umbilical cord clamps. Further, the company provides accessories, such as umbilical cord clamps, safety box, and stopcocks; and medical kits includes suction catheter and irrigation kits, and puncture sets. The company was founded in 1987 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201803",
        "website": "http://www.kdlchina.cn",
        "market_cap": 11786544128
    },
    "603990.SS": {
        "short_name": "SUZHOU MEDICALSYSTEM TECHNOLOGY",
        "long_name": "Suzhou MedicalSystem Technology Co., Ltd.",
        "summary": "Suzhou MedicalSystem Technology Co., Ltd. provides solutions in clinical informatics and digital hospital field in China. It offers DoCare anesthesia clinical information system that focuses on serving the perioperative clinical work; and provides streamlined, informational, automatic, and intelligent integrated management platform for clinical business. The company also provides DoCare intensive auxiliary diagnosis clinical information system that mines and scientifically analyzes for ICU patients' treatment data with medical information, such as patients' treatment information, inspection information, nursing information, and doctor's advice data. In addition, it offers DoCare operative medical behavior management system that establishes the intelligent management system for the operation resources and personnel behavior; and DoCare emergency clinical information system for management of emergency clinical, including pre-hospital first aid, pre-examination and triage, emergency rescue, emergency under observation, emergency operating room, emergency ICU, and patient outcome. Further, the company provides DoCare pre-hospital first aid clinical information system that provides a unified service platform, which has digital information for emergency command center, emergency doctors, emergency nurses, visiting medical personnel, and patients. Additionally, it offers smart OT, ICU, and emergency solutions; and smart specialty solutions, such as laminar airflow room, clinical pathway, and mobile nursing information systems, as well as central sterile supply department management systems. The company was founded in 2005 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215000",
        "website": "http://www.medicalsystem.com.cn",
        "market_cap": 6194934784
    },
    "603998.SS": {
        "short_name": "HUNAN FANGSHENG PHARMACEUTICAL ",
        "long_name": "Hunan Fangsheng Pharmaceutical Co., Ltd.",
        "summary": "Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers cardio-cerebrovascular, pediatric, gynecological, orthopedics, traumatology, anti-infective, oncology, digestive system, urinary system, heat-clearing and detoxifying, and other drugs. It is also involved in the wholesale of pharmaceutical products and medical devices; provision of biotechnology related research, consulting, technical transfer, and other technology based services; and research and industrialization of individualized medicine laboratory technology. The company was founded in 2002 and is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": null,
        "website": "http://www.fangsheng.com.cn",
        "market_cap": 2752646400
    },
    "605116.SS": {
        "short_name": "AURISCO PHARMACEUTICAL CO LTD",
        "long_name": "Aurisco Pharmaceutical Co.,Ltd.",
        "summary": "Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers steroids, oncology, antiretroviral, and other APIs and intermediates. It also provides contract manufacturing services and related development works for chemicals, intermediates, and API's. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tiantai",
        "zipcode": "317200",
        "website": "http://www.aurisco.com",
        "market_cap": 5786429952
    },
    "605199.SS": {
        "short_name": "HAINAN HULUWA PHARMACEUTICAL GR",
        "long_name": "Hainan Huluwa Pharmaceutical Group Co., Ltd.",
        "summary": "Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570300",
        "website": "http://www.huluwayaoye.com",
        "market_cap": 11783209984
    },
    "605369.SS": {
        "short_name": "ZHEJIANG GONGDONG MEDICAL TECHN",
        "long_name": "Zhejiang Gongdong Medical Technology Co.,Ltd.",
        "summary": "Zhejiang Gongdong Medical Technology Co.,Ltd. develops, produces, and sells medical devices and medical testing supplies in China. Its products include lab consumables, vacuum blood collection systems, specimen collection systems, medical nursing wares, medicine package wares, nd mold customization products. Zhejiang Gongdong Medical Technology Co.,Ltd.was founded in 1985 and is based in Taizhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": null,
        "website": "http://www.chinagongdong.com",
        "market_cap": 11318719488
    },
    "6078.HK": {
        "short_name": "HYGEIA HEALTH",
        "long_name": "Hygeia Healthcare Holdings Co., Limited",
        "summary": "Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals, which offer a range of oncology healthcare and other healthcare services. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital management and supply chain services. As of December 31, 2020, it operated or managed a network of 10 oncology-focused hospitals in 7 cities in 6 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.hygeia-group.com.cn",
        "market_cap": 55310999552
    },
    "6118.HK": {
        "short_name": "AUSTAR",
        "long_name": "Austar Lifesciences Limited",
        "summary": "Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, in-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.austar.com.hk",
        "market_cap": 4408205312
    },
    "6127.HK": {
        "short_name": "JOINN",
        "long_name": "Joinn Laboratories (China) Co.,Ltd.",
        "summary": "Joinn Laboratories (China) Co., Ltd. provides preclinical and non-clinical services. It evaluates various drugs, including biologics, pharmaceutical chemicals, and plant medicines for indications, such as renal, metabolic, cardiology, hematology, COPD, ophthalmic, oncology, and immune-related diseases. The company's services include screening services, such as efficiency screening, bioavailability, ADME screening, and non-GLP toxicology studies; pre-clinical safety assessment comprising general toxicology, safety pharmacology, developmental and reproductive toxicology, genetic and ocular toxicology, clinical pathology, analytical and bioanalytical analysis, immunology, and biomarker assays; pharmacodynamics services; and services to evaluate and optimize the absorption, distribution, metabolism, and elimination (ADME), as well as pharmacokinetic properties of potential drugs from early discovery projects. Its services also comprise clinical trials; a range of safety assessment services for medical devices, chemicals, and agrochemicals; regulatory consulting services in the areas of pharmaceuticals, biologics, Chinese medicine, medical devices, veterinary medicines, and agrochemicals; and food animal evaluation services comprising candidate selection, efficacy, safety evaluation studies on animals' health products, animal remedies, and fodders. In addition, the company offers traditional animals, such as outbred rats, inbred strain mice, outbred mice, and immunodeficient mice. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies, as well as regulatory and other government agencies. It serves pharmaceutical, medical device, chemical, biotechnology, and agricultural development companies. The company operates in China, Europe, North America, Southeast Asia, and Australia. The company was founded in 1995 and is based in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.joinn-lab.com",
        "market_cap": 54709121024
    },
    "6160.HK": {
        "short_name": "BEIGENE",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.beigene.com",
        "market_cap": 256472580096
    },
    "6185.HK": {
        "short_name": "CANSINOBIO-B",
        "long_name": "CanSino Biologics Inc.",
        "summary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.cansinotech.com",
        "market_cap": 119083360256
    },
    "6600.HK": {
        "short_name": "SCICLONE PHARMA",
        "long_name": "SciClone Pharmaceuticals (Holdings) Limited",
        "summary": "SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, a thymalfasin for Injection. Its in-licensed products include Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome; and Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy. The company also sells promotion products on behalf of its business partners. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.sciclone.com",
        "market_cap": 9856287744
    },
    "6606.HK": {
        "short_name": "NH HEALTH-B",
        "long_name": "New Horizon Health Limited",
        "summary": "New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical transfers and consultation, technical, and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310052",
        "website": "http://ir.newhorizonbio.com",
        "market_cap": 36717203456
    },
    "6622.HK": {
        "short_name": "ZHAOKE OPHTH-B",
        "long_name": "Zhaoke Ophthalmology Limited",
        "summary": "Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.zkoph.com",
        "market_cap": 6721547264
    },
    "67N.F": {
        "short_name": "JHBP (CY) HLDGS DL-,00002",
        "long_name": "JHBP (CY) Holdings Limited",
        "summary": "JHBP (CY) Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer; GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors; GB242, an infliximab (Remicade) biosimilar; and GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate. JHBP (CY) Holdings Limited was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.genorbio.com",
        "market_cap": null
    },
    "6826.HK": {
        "short_name": "HAOHAI BIOTEC",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and recombinant human epidermal growth factor (rhEGF), as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.3healthcare.com",
        "market_cap": 30046056448
    },
    "6855.HK": {
        "short_name": "ASCENTAGE-B",
        "long_name": "Ascentage Pharma Group International",
        "summary": "Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product under development include HQP1351, a BCR-ABL/KIT inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for the treatment of patients with tyrosine kinase inhibitors resistant/refractory GIST. The company also engages in developing APG-2575, an orally administered Bcl-2 selective inhibitor for the treatment of hematologic malignancies with Bcl-2 overexpression, including leukemia, lymphoma, and multiple myeloma; APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of SCLC, lymphoma, and other solid tumors; and APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for the treatment of solid tumors or lymphoma. In addition, it is involved in the development of APG-1387, a small molecule inhibitor of apoptosis proteins for the treatment of advanced solid tumors and chronic HBV infection; AT-101 for the treatment of chronic lymphocytic leukemia; APG-2449 for non-small-cell lung carcinoma; and HQP8361 for the treatment of cancer. Ascentage Pharma Group International has a clinical collaboration with Acerta Pharma to evaluate the combination of Bcl-2 and BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; and MSD to evaluate APG-115. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215000",
        "website": "http://www.ascentagepharma.com",
        "market_cap": 11208529920
    },
    "688016.SS": {
        "short_name": "SHANGHAI MICROPORT ENDOVASCULAR",
        "long_name": "Shanghai MicroPort Endovascular MedTech Co., Ltd.",
        "summary": "Shanghai MicroPort Endovascular MedTech Co., Ltd. develops, manufactures, and sells technologies and products in the healthcare business. The company primarily offers solutions for aortic and peripheral diseases. Its products include TAA and AAA stent graft systems, balloon inflation catheters, and PTA balloon dilatation catheters. The company was founded in 2012 and is based in Shanghai, the People's Republic of China. Shanghai MicroPort Endovascular MedTech Co., Ltd. is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201318",
        "website": "http://www.endovastec.com",
        "market_cap": 25337729024
    },
    "688026.SS": {
        "short_name": "GUANGZHOU JET BIOFILTRATION CO ",
        "long_name": "Guangzhou Jet Bio-Filtration Co., Ltd.",
        "summary": "Guangzhou Jet Bio-Filtration Co., Ltd. researches, develops, manufactures, and sells laboratory consumable products. The company's principal products include laboratory consumables, such as pipettes, tissue culture products, centrifuge tubes, filtration products etc.; and analyzers, lab equipment, reagents, gloves, and other products. It provides its products to approximately 50 countries, including the United States, Japan, Canada, Germany, Australia, and South Korea. The company was founded in 2001 and is based in Guangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "511356",
        "website": "http://www.jetbiofil.com",
        "market_cap": 7259999744
    },
    "688050.SS": {
        "short_name": "EYEBRIGHT MEDICAL TECHNOLOGY (B",
        "long_name": "Eyebright Medical Technology (Beijing) Co., Ltd.",
        "summary": "Eye Bright Medical Technology Co., Ltd. develops a range of ophthalmic medical products. Its products include surgical implants and instruments, equipment, optometric lenses, eye drops, etc. for the treatment of ophthalmic diseases and vision problems, such as cataract, glaucoma, refractive errors, and other ophthalmic diseases. The company was founded in 2010 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.ebmedical.com",
        "market_cap": 30899302400
    },
    "688068.SS": {
        "short_name": "BEIJING HOTGEN BIOTECH CO LTD",
        "long_name": "Beijing Hotgen Biotech Co., Ltd.",
        "summary": "Beijing Hotgen Biotech Co., Ltd. develops, manufactures, and sells in-vitro diagnostic (IVD), point-of-care-testing (POCT) and biodefense products worldwide. Its IVD products include instruments and kits for aiding diagnosis in cardiovascular diseases, chronic liver diseases, tumor screening and risk stratification, kidney injury, rheumatoid arthritis, infection, infectious diseases, and risk assessment of preterm labor. The company's biodefense and food safety product line covers various bioterrorist agents, including Yersinia pestis, Anthrax, Brucella, Ricin, Abrin, etc.; and various food borne pathogenic bacteria, such as cholera, E. coli, salmonella, etc. Its biodefense products are used for military anti-bioterrorism campaign, customs inspection and quarantine, on-site inspection in centers for disease control, mobile bio-emergency inspection, on-site detection of food-borne pathogenic microorganisms, etc. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102600",
        "website": "http://www.hotgen.com.cn",
        "market_cap": 9925285888
    },
    "688085.SS": {
        "short_name": "SHANGHAI SANYOU MEDICAL CO LTD",
        "long_name": "Shanghai Sanyou Medical Co., Ltd.",
        "summary": "Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and z-minimally invasive products; and trauma implants, including shoulder and elbow system, hip and pelvis system, knee system, knee system, and palm and wrist systems. Shanghai Sanyou Medical Co., Ltd. is based in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.sanyoumed.com",
        "market_cap": 7484424704
    },
    "688139.SS": {
        "short_name": "QINGDAO HAIER BIOMEDICAL CO LTD",
        "long_name": "Qingdao Haier Biomedical Co., Ltd.",
        "summary": "Qingdao Haier Biomedical Co., Ltd. engages in the design, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples worldwide. The company offers preservation equipment, biological safety cabinets, liquid nitrogen containers, cryogenic supplies, and CO2 incubators, as well as WHO/PQS certificated equipment. It provides storage solutions for biological sample banks and medical supplies, as well as blood, vaccine, and reagent safety. The company was founded in 2005 and is based in Qingdao, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Qingdao",
        "zipcode": "266101",
        "website": "http://www.haierbiomedical.com",
        "market_cap": 30229643264
    },
    "688166.SS": {
        "short_name": "BRIGHTGENE BIO-MEDICAL TECHNOLO",
        "long_name": "BrightGene Bio-Medical Technology Co., Ltd.",
        "summary": "BrightGene Bio-Medical Technology Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of medicines, and generic APIs and FDFs in China. Its product pipeline includes immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis. The company also develops Eribulin, Trabectedin, Fondaparinux, Caspofungin, and non-biological molecules; macromolecules, such as Ferumoxytol and Ferric pyrophosphate citrate; and ADC cytotoxic payloads comprising Maytansinoids, Auristatins, and Calicheamicin. It offers cardiovascular, antibacterial, ADC, oncology, antifungal, iron supplement, anti-HBV, veterinary, and immuno products. The company was founded in 2001 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.bright-gene.com",
        "market_cap": 18429499392
    },
    "688180.SS": {
        "short_name": "SHANGHAI JUNSHI BIOSCIENCES CO ",
        "long_name": "Shanghai Junshi Biosciences Co., Ltd.",
        "summary": "Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients, as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.junshipharma.com",
        "market_cap": 72109056000
    },
    "688185.SS": {
        "short_name": "CANSINO BIOLOGICS INC",
        "long_name": "CanSino Biologics Inc.",
        "summary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.cansinotech.com",
        "market_cap": 127954886656
    },
    "688202.SS": {
        "short_name": "SHANGHAI MEDICILON INC",
        "long_name": "Shanghai Medicilon Inc.",
        "summary": "Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201299",
        "website": "http://www.medicilon.com.cn",
        "market_cap": 30888400896
    },
    "688222.SS": {
        "short_name": "HITGEN INC",
        "long_name": "HitGen Inc.",
        "summary": "HitGen Inc. operates a platform for early-stage drug discovery research focusing on DNA encoded chemical libraries (DELs). Its DELs include encoded syntheses for diverse, drug-likesmall molecule, and macrocycle compounds. The company has internal projects in research, with Phase I, PCC generation, and in lead generation stages that focus on oncology, CVD, inflammation/respiratory, metabolism, and ophthalmology therapeutic areas. HitGen Inc. has a drug discovery research collaboration with Gilead Sciences, Galapagos NV, Kymera Therapeutics, Inc., and Morphic Therapeutic to identify potential small molecule leads; a strategic partnership with Oncodesign Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme for the identification and progression of new chemical entities; and an agreement with Lipigon Pharmaceuticals AB to include a second novel target. The company was founded in 2012 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "610200",
        "website": "http://www.hitgen.com",
        "market_cap": 11371297792
    },
    "688266.SS": {
        "short_name": "SUZHOU ZELGEN BIOPHARMACEUTICAL",
        "long_name": "Suzhou Zelgen Biopharmaceuticals Co., Ltd.",
        "summary": "Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Kunshan",
        "zipcode": "215300",
        "website": "http://www.zelgen.com",
        "market_cap": 17899200512
    },
    "688277.SS": {
        "short_name": "TINAVI MEDICAL TECHNOLOGIES CO ",
        "long_name": "TINAVI Medical Technologies Co., Ltd.",
        "summary": "TINAVI Medical Technologies Co., Ltd. engages in the research and development, production, and clinical application of orthopedic robotic systems. It offers TiRobot, an orthopedic robotic system used in orthopedic surgeries for spine and trauma. The company was founded in 2010 and is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100192",
        "website": "http://www.tinavi.com",
        "market_cap": 15716719616
    },
    "688278.SS": {
        "short_name": "XIAMEN AMOYTOP BIOTECH CO LTD",
        "long_name": "Xiamen Amoytop Biotech Co., Ltd.",
        "summary": "Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Xiamen",
        "zipcode": "361022",
        "website": "http://www.amoytop.com",
        "market_cap": 14095621120
    },
    "688289.SS": {
        "short_name": "SANSURE BIOTECH INC",
        "long_name": "Sansure Biotech Inc.",
        "summary": "Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Changsha",
        "zipcode": "410205",
        "website": "http://www.sansure.com.cn",
        "market_cap": 39288000512
    },
    "688298.SS": {
        "short_name": "ZHEJIANG ORIENT GENE BIOTECH CO",
        "long_name": "Zhejiang Orient Gene Biotech Co., Ltd.",
        "summary": "Zhejiang Orient Gene Biotech Co., Ltd. researches and develops, produces, and sells colloidal gold tests, urinalysis strips, raw materials, instruments, and molecular diagnosis products primarily in China. Its products include genetic diagnosis products; colloidal gold rapid diagnostic tests for drugs of abuse, infectious diseases, fertility, cardiac and tumor markers, and autoimmunity; dry chemical strips; bio-liquid diagnostic kits; clinical test instruments; POCT time-resolved fluor immunoassay test kits; raw materials; etc. The company also exports its products to North and South America, Europe, South Asia, Southeast Asia, the Middle East, Africa, Russia, and Australia. Zhejiang Orient Gene Biotech Co., Ltd. was founded in 2005 and is based in Huzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Huzhou",
        "zipcode": "313300",
        "website": "http://www.orientgene.com",
        "market_cap": 22553999360
    },
    "688301.SS": {
        "short_name": "IRAY TECHNOLOGY COMPANY LTD",
        "long_name": "iRay Technology Company Limited",
        "summary": "iRay Technology Company Limited develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally. It offers wireless radiography, tethered radiography, mammography, dynamic/real-time, and linear detector array products, as well as related software. The company was founded in 2011 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201206",
        "website": "http://www.iraygroup.com",
        "market_cap": 18826881024
    },
    "688321.SS": {
        "short_name": "SHENZHEN CHIPSCREEN BIOSCIENCES",
        "long_name": "Shenzhen Chipscreen Biosciences Co., Ltd.",
        "summary": "Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.chipscreen.com",
        "market_cap": 15858799616
    },
    "688338.SS": {
        "short_name": "BEIJING SUCCEEDER TECHNOLOGY IN",
        "long_name": "Beijing Succeeder Technology Inc.",
        "summary": "Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. Its products include coagulation analyzers and reagents, blood rheology analyzers, ESR analyzers, and platelet aggregation analyzers. The company was founded in 2003 and is headquartered in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102200",
        "website": "http://www.succeeder.com.cn",
        "market_cap": 4461246464
    },
    "688366.SS": {
        "short_name": "SHANGHAI HAOHAI BIOLOGICAL TECH",
        "long_name": "Shanghai Haohai Biological Technology Co., Ltd.",
        "summary": "Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. The company offers ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion, and homostasis products. It also provides medical sodium hyaluronate, medical chitosan, medical collagen sponge, and recombinant human epidermal growth factor (rhEGF), as well as biological reagents and materials. In addition, the company engages in the manufacture and sale of contact lens and intraocular lens materials, machines, and accessories; and investment and trading businesses. Further, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.3healthcare.com",
        "market_cap": 24741326848
    },
    "688488.SS": {
        "short_name": "JIANGSU AIDEA PHARMACEUTICAL CO",
        "long_name": "Jiangsu Aidea Pharmaceutical Co., Ltd.",
        "summary": "Jiangsu Aidea Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. It offers folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules, as well as raw materials. The company was founded in 2009 and is based in Yangzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Yangzhou",
        "zipcode": null,
        "website": "http://www.aidea.com.cn",
        "market_cap": 8723400704
    },
    "688505.SS": {
        "short_name": "SHANGHAI FUDAN-ZHANGJIAN BIO-PH",
        "long_name": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.",
        "summary": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-MMAE, which is in clinical trial Phase I for tumors; Trop 2 antibody-conjugated drug that is in pre-clinical studies for triple negative breast cancer, bladder and gastric cancer, and other tumors; and HER2 antibody-drug conjugate, which is in pre-clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV; and aminolevulinic acid that is in Phase I clinical trials for acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs comprising Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for Hepatobiliary disease; and JAK1 inhibitor that is in Phase I clinical trial for rheumatoid arthritis. Additionally, it researches and develops pharmaceutical and medical devices; medical diagnostic products; provides related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; and production of freeze-dried powder injections and APIs, as well as invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.fd-zj.com",
        "market_cap": 18554970112
    },
    "688513.SS": {
        "short_name": "CHENGDU EASTON BIO PHARMACEUTIC",
        "long_name": "Chengdu Easton Biopharmaceuticals Co., Ltd.",
        "summary": "Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry , and urinary system therapeutic categories. The company was founded in 2009 and is based in Chengdu, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": "611731",
        "website": "http://www.eastonpharma.cn",
        "market_cap": 5485711360
    },
    "688520.SS": {
        "short_name": "SINOCELLTECH GROUP LTD",
        "long_name": "Sinocelltech Group Limited",
        "summary": "Sinocelltech Group Limited, a biotech company, focuses on the development of technologies for the development and manufacturing of recombinant proteins, monoclonal antibodies, and vaccines in China. The company is based in Beijing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.sinocelltech.com",
        "market_cap": 20112523264
    },
    "688526.SS": {
        "short_name": "WUHAN KEQIAN BIOLOGY CO LTD",
        "long_name": "Wuhan Keqian Biology Co.,Ltd",
        "summary": "Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for swine, poultry, and pets, as well as diagnostic reagents. The company was founded in 2001 and is based in Wuhan, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Wuhan",
        "zipcode": "430073",
        "website": "http://www.kqbio.com",
        "market_cap": 19948500992
    },
    "688555.SS": {
        "short_name": "ESSENCE INFORMATION TECHNOLOGY ",
        "long_name": "Essence Information Technology Co., Ltd.",
        "summary": "Essence Information Technology Co., Ltd. operates as an information technology medical and health industry chain solution provider. The company provides its services in the areas of smart medicine, healthcare, manufacturing, and health, as well as big data and solutions. It offers drug safety supervision, food safety regulatory, medical device safety supervision, special equipment safety supervision, food and drug traceability, market supervision integrated business management, and government public service platforms. Essence Information Technology Co., Ltd. was founded in 2013 and is based in Tianjin, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300457",
        "website": "http://www.sino-essence.com",
        "market_cap": 2983649024
    },
    "688566.SS": {
        "short_name": "JIANGSU JIBEIER PHARMACEUTICAL ",
        "long_name": "JiangsuJibeier Pharmaceutical Co., Ltd.",
        "summary": "Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research, development, production, and sale of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products cover various therapeutic areas, such as improving white blood cells, enhancing immunity, treating joint diseases, anti-hypertension, anti-eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach diseases, and other diseases. The company was founded in 2001 and is based in Zhenjiang, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Zhenjiang",
        "zipcode": "212000",
        "website": "http://www.jibeier.com.cn",
        "market_cap": 4187500800
    },
    "688580.SS": {
        "short_name": "NANJING VISHEE MEDICAL TECHNOLO",
        "long_name": "Nanjing Vishee Medical Technology Co., Ltd",
        "summary": "Nanjing Vishee Medical Technology Co., Ltd. develops and manufactures medical rehabilitation devices in China. It offers pelvic floor and postpartum, neurological, and mental rehabilitation solutions; and bio-stimulation feedback devices, magnetic stimulators, etc. The company's solutions cover markets, such as electrical and magnetic stimulation, electrophysiology, and other technical directions. It offers its products through dealers, sales network, and distributors to hospitals, and terminal medical and professional institutions. The company was founded in 2001 and is based in Nanjing, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "210012",
        "website": "http://www.vishee.com",
        "market_cap": 9577423872
    },
    "688607.SS": {
        "short_name": "CARERAY DIGITAL MEDICAL TECHNOL",
        "long_name": "CareRay Digital Medical Technology Co., Ltd.",
        "summary": "CareRay Digital Medical Technology Co., Ltd. develops and produces digital X-ray flat panel detectors. The company offers wireless, wired, dynamic and breast flat panel, and industrial flat panel detectors, as well as accessories and tablet cases. Its products are used in medical, pet, security, and industrial imaging diagnostic products. The company was founded in 2007 and is headquartered in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.careray.cn",
        "market_cap": 3867100672
    },
    "688656.SS": {
        "short_name": "HOB BIOTECH GROUP CORP LTD",
        "long_name": "HOB Biotech Group Corp.,Ltd",
        "summary": "HOB Biotech Group Corp.,Ltd. operates as a in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immuno assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. The company was founded in 2009 and is based in Suzhou, China.",
        "currency": "CNY",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.hobiotech.com",
        "market_cap": 5013134848
    },
    "6896.HK": {
        "short_name": "GOLDEN THROAT",
        "long_name": "Golden Throat Holdings Group Company Limited",
        "summary": "Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine to relive symptoms of sore, dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat lozenge series products that include Dule lozenges and sugar-free Dule lozenges in various flavors, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn; Yinxingye tablet that are designed to facilitate blood circulation, remove blood stasis, and dredge energy channels; and herbal vegetable beverages for soothing voice and relieving sore throats. The company also exports its products to the United States, Canada, Russia, Japan, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Liuzhou",
        "zipcode": null,
        "website": "http://www.goldenthroat.com",
        "market_cap": 1330743552
    },
    "6978.HK": {
        "short_name": "IMMUNOTECH-B",
        "long_name": "Immunotech Biopharm Ltd",
        "summary": "Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. Its products also include CAR-T cell series products for the treatment of hematologic cancer; and TCR-T cell series products for solid tumour treatment. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": null,
        "website": "http://www.eaal.net",
        "market_cap": 9046386688
    },
    "6996.HK": {
        "short_name": "ANTENGENE-B",
        "long_name": "Antengene Corporation Limited",
        "summary": "Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-010 (selinexor), a SINE compound targeting XPO1, a key nuclear export protein for the treatment of hematologic malignancies, such as multiple myeloma and DLBCL. The company's products in pipeline include ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of various advanced solid tumors and hematological malignancies; ATG-016 (eltanexor), a SINE compound; ATG-527 (verdinexor), which is in Phase I clinical trial primarily for oncology; ATG-019, an oral dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; and ATG-017, an oral selective ERK1/2 inhibitor for the treatment of various solid tumors and hematological malignancies. Its products in pre-clinical stage include ATG-101, a PD-L1/CD137 (4-1BB) bi-specific antibody for the treatment of hematological malignancies and solid tumors; ATG-018, a small molecule inhibitor targeting ataxia telangiectasia and Rad3 related (ATR) kinase for the treatment of hematological malignancies and solid tumors; ATG-022, a humanized IgG1 monoclonal antibody against human Claudin 18.2 (CLDN18.2) antigen for the treatment of solid tumors; and ATG-012, a KRAS G12C inhibitor against KRAS oncoprotein for the treatment of solid tumors. The company was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.antengene.com",
        "market_cap": 11342958592
    },
    "6998.HK": {
        "short_name": "JHBP-B",
        "long_name": "JHBP (CY) Holdings Limited",
        "summary": "JHBP (CY) Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer; GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors; GB242, an infliximab (Remicade) biosimilar; and GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate. JHBP (CY) Holdings Limited was founded in 2007 and is headquartered in Shanghai, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.genorbio.com",
        "market_cap": 7856480256
    },
    "6IB.F": {
        "short_name": "INNOVENT BIOLOGICS INC.",
        "long_name": "Innovent Biologics, Inc.",
        "summary": "Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for the treatment of non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for treatment of ocular fundus disease; IBI-303, an adalimumab biosimilar for the treatment of autoimmune diseases; and IBI-305, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and non-small cell lung cancer. In addition, it is involved in the development of IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung cancer, esophageal cancer, gastric cancer, and Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for the treatment of advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological tumor and solid tumor. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has a strategic collaboration with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; and a strategic alliance with Eli Lilly and Company for TYVYT sintilimab injection. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.innoventbio.com",
        "market_cap": 13317762048
    },
    "72X.F": {
        "short_name": "MICROPORT CARDIO.MEDTECH.",
        "long_name": "MicroPort CardioFlow Medtech Corporation",
        "summary": "MicroPort CardioFlow Medtech Corporation, a medical device company, focuses on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases in the People's Republic of China. Its products include Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, which targets aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China. MicroPort CardioFlow Medtech Corporation is a subsidiary of Shanghai MicroPort Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.cardioflowmedtech.com",
        "market_cap": 4311650304
    },
    "8049.HK": {
        "short_name": "JILIN CHANGLONG",
        "long_name": "Jilin Province Huinan Changlong Bio-pharmacy Company Limited",
        "summary": "Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, bulk drugs, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Tonghua, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Tonghua",
        "zipcode": "135100",
        "website": "http://www.jlchanglong.com",
        "market_cap": 689107520
    },
    "8247.HK": {
        "short_name": "BIOSINO BIO-TEC",
        "long_name": "Biosino Bio-Technology and Science Incorporation",
        "summary": "Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products primarily in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, quality control products, and washing solution detergents; flow cytometers and bio chemical analyzers; time-resolved fluoroimmunoassay analyzers; Elisa kits; and rapid tests. The company also provides medical and medical inspection services; produces medical instruments; and distributes immunodiagnostic products, biological reagents, and instruments. Biosino Bio-Technology and Science Incorporation was founded in 1988 and is based in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102200",
        "website": "http://www.sinobio.com.cn",
        "market_cap": 191013264
    },
    "8329.HK": {
        "short_name": "NEP INTERLONG",
        "long_name": "Shenzhen Neptunus Interlong Bio-technique Company Limited",
        "summary": "Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products and in vitro diagnostic reagents. In addition, the company manufactures herbal medicines, generic drugs, and transfusion products, as well as medical devices. It serves approximately 500 medical organizations. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518000",
        "website": "http://www.interlong.com",
        "market_cap": 436279968
    },
    "900904.SS": {
        "short_name": "SHANGHAI SHENQI PHARM INVEST MA",
        "long_name": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd.",
        "summary": "Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceutical products primarily in China. It specializes in offering anti-tumor, cardio-cerebral vascular, and antifungal drugs, as well as cold and cough drugs under the miraculous brand, and medications for children under the Magic Doll name. The company also provides cantharidin sodium vitamin B6 injection under the Ai Yishu name for the treatment of cancer; Chinese medicines and chemical medicines; respiratory and digestive system medications; ginseng polysaccharide and cantharidin injections; and pediatric phlegm cough particles. In addition, it offers ethnic medicines; raw material medicines; drugs for rheumatic orthopedics, kidney, diarrhea, and gynecological menstruation; drugs under the Anshen Bunao name; sodium candida sulfate injections; Jie Yin Ling lotions; compound coral ginger solutions; and coral decoctions. Further, the company provides urea miconazole ointment complex products; cephalosporins; Yinqi Xinmai dripping pills; Yindan Xintai and Danxin Taidi pills; Metronidazole B6 tablets; Yuan Ye Zhike syrups; anti-particles; compound Shangfuning cream; and pediatric pharyngeal flat particles and clear toxic syrups. Additionally, it offers Keping, Paidui Jiangzhi, Zhizhike, Jinwugutong, Jingwu, and Tianma capsules; and Zhifan Zhike, Phenol yellow, Ganfu, and pediatric aminophenol alkylamine granules, as well as medications for injury, etc. The company also provides products in various other forms, such as sprays, films, tinctures, etc. It also operates under the magic, Guizhou, God, Speed Stop, and Qiang Lulu brand names. The company is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "SHH",
        "market": "cn_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200003",
        "website": "http://www.gzsq.com",
        "market_cap": 2956347136
    },
    "978.F": {
        "short_name": "ADAGENE INC. SP.ADR",
        "long_name": "Adagene Inc.",
        "summary": "Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "25125",
        "website": "http://www.adagene.com",
        "market_cap": 494160224
    },
    "9906.HK": {
        "short_name": "HONLIV HEALTH",
        "long_name": "Honliv Healthcare Management Group Company Limited",
        "summary": "Honliv Healthcare Management Group Company Limited operates private general hospitals in China. Its facilities include general healthcare services, such as obstetrics and gynecology, cardiovascular, orthopedics, nephrology and rheumatology, pediatrics, neurology, neonatal, gastroenterology, oncology, neurosurgery, endocrinology, gastrointestinal and hepatobiliary surgery, respiratory, emergency treatment, thyroid and breast surgery, ICU, thoracic surgery, otorhinolaryngology, cardiac surgery, hematology, infectious disease, urology, dermatology, rehabilitation, ophthalmology, pain treatment, proctology, stomatology, traditional Chinese medicine treatment, and plastic surgery services; anesthesiology, clinical laboratory and medical imaging services; and pharmaceuticals sales at hospital. The company also offers medical examination, disease screening, and other services to governmental and corporate customers in Changyuan County; and hospital management services. As of June 15, 2020, it owned one private general hospital and managed one private general hospital with 1,500 beds in operation located in Henan Province. The company was founded in 2004 and is headquartered in Changyuan, China. Honliv Healthcare Management Group Company Limited is a subsidiary of Sunny Rock Capital Limited.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Changyuan",
        "zipcode": null,
        "website": "http://www.honlivhp.com",
        "market_cap": 1188000000
    },
    "9926.HK": {
        "short_name": "AKESO-B",
        "long_name": "Akeso, Inc.",
        "summary": "Akeso, Inc., a clinical-stage biopharmaceutical company, engages in discovery, development and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for tumor infiltrating lymphocytes, which is in Phase Ia/Ib trial in Australia, and five Phase Ib/II and Phase II trials in China; Penpulimab AK105, a monoclonal antibody that is in Phase III clinical trials for squamous and non-squamous NSCLC, as well as Phase II clinical trial for relapsed/refractory classical hodgkin's lymphoma; and AK112, a PD-1/VEGF bi-specific antibody that is in a Phase I clinical study for the treatment of solid tumors. It is also developing AK101, a monoclonal antibody, which is in Phase IIb clinical trial to treat severe psoriasis patients; AK111, a monoclonal antibody for autoimmune disease target IL-17; and Ebronucimab (AK102) for the treatment of cardiovascular diseases. The company has collaboration agreements with Merck; Sino Biopharm; Dawnrays Pharma; and Zhongshan Health Technology Industrial Base Development Co., Ltd. and Torch Development Zone Linhai Industry Park Development Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Zhongshan",
        "zipcode": "528437",
        "website": "http://www.akesobio.com",
        "market_cap": 53231267840
    },
    "9939.HK": {
        "short_name": "KINTOR PHARMA-B",
        "long_name": "Kintor Pharmaceutical Limited",
        "summary": "Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer, as well as for the treatment of COVID-19; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; GT1708F for the treatment of leukaemia and basal-cell carcinoma; and GT20029 for the treatment of androgenetic alopecia and acne vulgaris. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.kintor.com.cn",
        "market_cap": 21664724992
    },
    "9966.HK": {
        "short_name": "ALPHAMAB-B",
        "long_name": "Alphamab Oncology",
        "summary": "Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215024",
        "website": "http://www.alphamabonc.com",
        "market_cap": 21176369152
    },
    "9969.HK": {
        "short_name": "INNOCARE-B",
        "long_name": "InnoCare Pharma Limited",
        "summary": "InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.innocarepharma.com",
        "market_cap": 38091616256
    },
    "9989.HK": {
        "short_name": "HEPALINK",
        "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
        "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.hepalink.com",
        "market_cap": 27014021120
    },
    "9995.HK": {
        "short_name": "REMEGEN-B",
        "long_name": "RemeGen Co., Ltd.",
        "summary": "RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in the People's Republic of China and internationally. The company's products in various stages of development include Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sj\u00c3\u00b6gren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. It is also developing RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; and RC88, which is in Phase 1 clinical trials for use in the treatment of diabetic macular edema, as well as pre-clinical products, such as RC108, RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Yantai",
        "zipcode": null,
        "website": "http://www.remegen.com",
        "market_cap": 60249948160
    },
    "9996.HK": {
        "short_name": "PEIJIA-B",
        "long_name": "Peijia Medical Limited",
        "summary": "Peijia Medical Limited engages in the research, development, production, and sales of interventional procedural medical devices for the treatment of structural heart and neurovascular diseases. Its product candidates include transcatheter aortic valve replacement (TAVR) products, such as TaurusOne, a transcatheter aortic valve replacement system, including prosthetic aortic valve, delivery catheter system, and LS; TaurusElite, a second-generation TAVR device; and TaurusNXT, a third-generation TAVR device. The company is also developing transcatheter mitral valve replacement devices for the treatment of mitral regurgitation; and transcatheter tricuspid valve replacement devices for the treatment of tricuspid regurgitation. In addition, it is developing lithotripsy and balloon aortic valvuloplasty catheters, introducer sheaths, guidewires, and mitral repair devices. Further, the company is developing neurointerventional procedural products, such as stent retrievers; balloon guide and dilatation, distal access, intermediate, and aspiration catheters; and balloon microcatheter, heat-fusion detachable coils, intracranial stents, and detachable coils. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, the People's Republic of China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215028",
        "website": "http://www.peijiamedical.com",
        "market_cap": 21334976512
    },
    "9997.HK": {
        "short_name": "KANGJI MEDICAL",
        "long_name": "Kangji Medical Holdings Limited",
        "summary": "Kangji Medical Holdings Limited, through its subsidiaries, engages in the research, development, manufacture, and sale of minimally invasive surgical instruments and accessories in China. It offers disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, and other types of disposable hand-held instruments; and reusable trocars, reusable forceps, and other reusable products, including veress needles, monopolar grasping forceps, and myomectomy surgical instrument sets. The company's products are used in obstetrics and gynecology, general surgery, urology, and thoracic surgery specialties. It primarily sells products to a network of distributors. The company was founded in 2004 and is headquartered in Hangzhou, China.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.kangjimedical.com",
        "market_cap": 16178553856
    },
    "ADAG": {
        "short_name": "Adagene Inc.",
        "long_name": "Adagene Inc.",
        "summary": "Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "25125",
        "website": "http://www.adagene.com",
        "market_cap": 597500736
    },
    "AIDA": {
        "short_name": "AIDA PHARMA INC",
        "long_name": "Aida Pharmaceuticals, Inc.",
        "summary": "Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310016",
        "website": null,
        "market_cap": 13615200
    },
    "AIH": {
        "short_name": "Aesthetic Medical International",
        "long_name": "Aesthetic Medical International Holdings Group Limited",
        "summary": "Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 25 treatment centers in China, Hong Kong, and Singapore. The company was founded in 1997 and is headquartered in Shenzhen, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518052",
        "website": "http://ir.aihgroup.net",
        "market_cap": 148194816
    },
    "ANPC": {
        "short_name": "AnPac Bio-Medical Science Co., ",
        "long_name": "AnPac Bio-Medical Science Co., Ltd.",
        "summary": "Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Lishui",
        "zipcode": "323006",
        "website": "http://www.anpacbio.com",
        "market_cap": 64408048
    },
    "AOBI": {
        "short_name": "AMERICAN ORIENTAL BIOENGINEERIN",
        "long_name": "American Oriental Bioengineering, Inc.",
        "summary": "American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offers over-the-counter pharmaceutical products comprising Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS) and other PMS and menopause-related symptoms; and Boke Nasal Spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. In addition, the company provides various nutraceutical products, such as soybean peptide based drinks, tablets, powder, and instant coffee. Further, it is involved in the wholesale and retail of pharmaceutical and nutraceutical products. The company sells its products directly and through distributors to hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical stores, and other retail outlets in the People's Republic of China. American Oriental Bioengineering, Inc. is headquartered in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": null,
        "market_cap": 145410
    },
    "AOXG": {
        "short_name": "AOXING PHARMACEUTICAL CO INC",
        "long_name": "Aoxing Pharmaceutical Company, Inc.",
        "summary": "Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": null,
        "website": "http://axzyen.icm.cn",
        "market_cap": 859639
    },
    "ASCLF": {
        "short_name": "ASCLETIS PHARMA INC",
        "long_name": "Ascletis Pharma Inc.",
        "summary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-\u00c3\u009f agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.ascletis.com",
        "market_cap": 66149500
    },
    "BFK.SI": {
        "short_name": "Pharmesis Intl",
        "long_name": "Pharmesis International Ltd.",
        "summary": "Pharmesis International Ltd., an investment holding company, researches, develops, produces, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the brand name of Kinna, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice, and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. Further, the company engages in the wholesale of chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. Pharmesis International Ltd. was founded in 1996 and is headquartered in the Chengdu, People's Republic of China.",
        "currency": "SGD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SES",
        "market": "sg_market",
        "country": "China",
        "state": null,
        "city": "Chengdu",
        "zipcode": null,
        "website": "http://www.pharmesis.com",
        "market_cap": 5060000
    },
    "BGNE": {
        "short_name": "BeiGene, Ltd.",
        "long_name": "BeiGene, Ltd.",
        "summary": "BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.beigene.com",
        "market_cap": 29424246784
    },
    "BIMI": {
        "short_name": "BOQI International Medical Inc.",
        "long_name": "BOQI International Medical, Inc.",
        "summary": "BOQI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. It offers prescription and over-the-counter drugs, nutritional supplements, health foods, and sundry products, as well as traditional Chinese medicines, personal and family care products, and miscellaneous items under the Lijiantang Pharmacy brand name. The company also provides IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as NF Energy Saving Corporation and changed its name to BOQI International Medical Inc. in December 2019. BOQI International Medical Inc. was incorporated in 2000 and is based in Dalian, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Dalian",
        "zipcode": "110015",
        "website": "http://www.usbimi.com",
        "market_cap": 27580156
    },
    "BNIGF": {
        "short_name": "BERONI GROUP LTD",
        "long_name": "Beroni Group Limited",
        "summary": "Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifiers, water filters, cosmetics, and health care products and supplements in China and Japan. It operates through Nicobloc, Fogibloc Air Purifier, Olansi Water Filter, MRET Water Activator, Health Supplements, Cosmetic products, and Cell Therapies segments. The company's products include NicoBloc, a smoking cessation/harm reduction product; Fogibloc, an air purifier system; and lung cleansing health supplements. It also offers cosmetic products, such as V show rejuvenation liquids, hyaluronic acid moisturizing silk masks, and avocado poly-peptide intensive treatment silk masks. In addition, the company provides fruit and vegetable detoxification machines, and multifunctional dust mite controllers. Further, it offers medical drugs, health foods, supplements, cosmetic products, and household goods under Vitatreal brand and third party brands through its wholesale network to chemists, clinics, dentists, supermarkets, and other retail outlets, as well as its Website. The company has a strategic cooperation agreement with Tianjin University in China to develop a medical solution for the coronavirus. The company was founded in 2014 and is based in Tianjin, the People's Republic of China. Beroni Group Limited is a subsidiary of Beroni Technology Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300380",
        "website": "http://www.beronigroup.com",
        "market_cap": 162802960
    },
    "BNR": {
        "short_name": "Burning Rock Biotech Limited",
        "long_name": "Burning Rock Biotech Limited",
        "summary": "Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510005",
        "website": "http://www.brbiotech.com",
        "market_cap": 2839523584
    },
    "BSPM": {
        "short_name": "Biostar Pharmaceuticals, Inc.",
        "long_name": "Biostar Pharmaceuticals, Inc.",
        "summary": "Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Xianyang",
        "zipcode": "712000",
        "website": "http://biostarpharmaceuticals.com",
        "market_cap": 316462
    },
    "C1P.F": {
        "short_name": "CONSUN PHARMAC.GR.HD -,10",
        "long_name": "Consun Pharmaceutical Group Limited",
        "summary": "Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": null,
        "website": "http://www.chinaconsun.com",
        "market_cap": 489068544
    },
    "C1S.F": {
        "short_name": "CHINA SHINEWAY PHAR.HD-10",
        "long_name": "China Shineway Pharmaceutical Group Limited",
        "summary": "China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections in various therapeutic areas, including cardio-cerebrovascular, antiviral, orthopedics, pediatrics, gynecology, neurology, gastroenterology, ophthalmology, oncology, and immunology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": "051430",
        "website": "http://www.shineway.com",
        "market_cap": 705749504
    },
    "C2CA.F": {
        "short_name": "CONCORD MED.ADR/3DL-,0001",
        "long_name": "Concord Medical Services Holdings Limited",
        "summary": "Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in Network and Hospital segments. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. It also offers other treatments and diagnostic services comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and chemotherapy; ultrasound therapy for the treatment of cancer; stereotactic radiofrequency ablation for the treatment of Parkinson's disease; and refraction and tonometry for the diagnosis of ophthalmic conditions. In addition, the company provides clinical support services, including developing treatment protocols for doctors; and organizing joint diagnosis between doctors in its network and clinical research. Further, it offers radiotherapy and diagnostic equipment leasing and management services to hospitals, as well as tele-consulting services; and sells medical equipment. Additionally, the company establishes the Beijing Proton Medical Center that provides radiotherapy treatment options to cancer patients; and other specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of June 30, 2019, it operated a network of 30 centers based in 20 hospitals in 20 cities across 13 provinces and administrative regions in China. Concord Medical Services Holdings Limited was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100013",
        "website": "http://www.concordmedical.com",
        "market_cap": 119986304
    },
    "CASBF": {
        "short_name": "CANSINO BIOLOGICS INC",
        "long_name": "CanSino Biologics Inc.",
        "summary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.cansinotech.com",
        "market_cap": 15500641280
    },
    "CBPI": {
        "short_name": "CHINA BOTANIC PHARMACEUTICAL",
        "long_name": "China Botanic Pharmaceutical Inc.",
        "summary": "China Botanic Pharmaceutical Inc. researches, develops, manufactures, and distributes of botanical products, bio-pharmaceutical products, and traditional Chinese medicines in the People's Republic of China. It offers botanical anti-depression and nerve-regulation products, including Acanthopanax, a Siberian ginseng that regulates the nervous system, delays aging process, strengthens the body, and treats neurasthenia, insomnia, cerebrovascular and cardiovascular diseases, and fatigue; Tianma tablets and compound Yangjiao tablets, which are botanic drugs for treating headaches and regulate nerves; and compound Schisandra tablets, a botanic drug used to regulate central nervous system, generate body fluids and alleviate thirst, nourish the kidneys, and cure insomnia and palpitations, as well as to cure neurasthenia. The company's biopharmaceutical products consist of Ginseng and Venison Extract, which comprises nutrients that nourish the blood and kidneys, and restore body's energy; and Badger oil expels that treats water and fire burns, scalds, and skin pain. Its botanical antibiotics and traditional over the counter Chinese medicines include Banlangen antiviral and broad-spectrum antibiotic granules; compound Honeysuckle antiviral, antibacterial, and anti-inflammatory granules; Shengmai granules, which regulate blood flow, strengthen heart beat, and improve the immune system and blood quality; and Qing Re Jie Du Oral Liquid that treats flu, upper respiratory infections, and sore throats. The company distributes its products through a network of approximately 3,000 distributors and approximately 70 sales centers. The company was formerly known as Renhuang Pharmaceuticals, Inc. and changed its name to China Botanic Pharmaceutical Inc. in November 2010. China Botanic Pharmaceutical Inc. was founded in 1996 and is headquartered in Harbin, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150090",
        "website": null,
        "market_cap": 207647
    },
    "CCM": {
        "short_name": "Concord Medical Services Holdin",
        "long_name": "Concord Medical Services Holdings Limited",
        "summary": "Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in Network and Hospital segments. The company's services comprise linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. It also offers other treatments and diagnostic services comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and chemotherapy; ultrasound therapy for the treatment of cancer; stereotactic radiofrequency ablation for the treatment of Parkinson's disease; and refraction and tonometry for the diagnosis of ophthalmic conditions. In addition, the company provides clinical support services, including developing treatment protocols for doctors; and organizing joint diagnosis between doctors in its network and clinical research. Further, it offers radiotherapy and diagnostic equipment leasing and management services to hospitals, as well as tele-consulting services; and sells medical equipment. Additionally, the company establishes the Beijing Proton Medical Center that provides radiotherapy treatment options to cancer patients; and other specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of June 30, 2019, it operated a network of 30 centers based in 20 hospitals in 20 cities across 13 provinces and administrative regions in China. Concord Medical Services Holdings Limited was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100013",
        "website": "http://www.concordmedical.com",
        "market_cap": 147234240
    },
    "CHME": {
        "short_name": "CHINA MEDICINE CORP",
        "long_name": "China Medicine Corporation",
        "summary": "China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510006",
        "website": "http://www.cmc621.com/cmc/index.php",
        "market_cap": 2464425
    },
    "CHYL": {
        "short_name": "CHINA SR LIVING IND INTL HLDG C",
        "long_name": "China Senior Living Industry International Holding Corporation",
        "summary": "China Senior Living Industry International Holding Corporation operates senior living facilities in Xianyang, the People's Republic of China. It provides healthcare, medical staff, meal preparation, and general care services for the elderly. The company was formerly known as China Forestry, Inc. and changed its name to China Senior Living Industry International Holding Corporation in September 2015. China Senior Living Industry International Holding Corporation was incorporated in 1986 and is based in Xianyang, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Xianyang",
        "zipcode": "712000",
        "website": null,
        "market_cap": 1411209
    },
    "CJH.F": {
        "short_name": "CANSINO BIOLOGICS H  YC 1",
        "long_name": "CanSino Biologics Inc.",
        "summary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.cansinotech.com",
        "market_cap": 11158929408
    },
    "CJH.SG": {
        "short_name": "CanSino Biologics Inc. Register",
        "long_name": "CanSino Biologics Inc.",
        "summary": "CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": null,
        "website": "http://www.cansinotech.com",
        "market_cap": 10763927552
    },
    "CJJD": {
        "short_name": "China Jo-Jo Drugstores, Inc.",
        "long_name": "China Jo-Jo Drugstores, Inc.",
        "summary": "China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates dada360.com, an online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms, such as Tmall, JD.com, and Amazon.com. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2020, it had 118 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 10 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": "310008",
        "website": "http://www.jiuzhou-drugstore.com",
        "market_cap": 41338460
    },
    "CNBI": {
        "short_name": "CHINA BCT PHARMACY GROUP INC",
        "long_name": "China BCT Pharmacy Group, Inc.",
        "summary": "China BCT Pharmacy Group, Inc., through its subsidiaries, operates as an integrated pharmaceutical company in the People's Republic of China. It operates through three segments: Pharmaceutical Distribution, Retail Pharmacy, and Manufacturing Pharmacy. The Pharmaceutical Distribution segment purchases pharmaceutical products from suppliers and distributes them to hospitals, retail drug stores, other pharmaceutical wholesalers, clinics, medical centers, and individuals. It offers approximately 8,000 pharmaceutical and healthcare products, including branded and generic prescription medicines, over-the counter medicines, and Western and Chinese medicines, as well as personal care products and medical supplies, Chinese herbs, and medical instruments. The Retail Pharmacy segment operates a retail pharmacy network of 196 directly owned stores, primarily in Guangxi province under the Baicaotang name. The retail stores provide professional pharmaceutical services, and supply various medicines, such as prescription medicines, over-the-counter medicines, Chinese herbal medicine, roughly processed Chinese herbal medicine, family planning products, and other pharmaceutical and healthcare products. The Manufacturing Pharmacy segment manufactures and sells generic and clinic drugs, such as traditional anti-inflammatory and antibacterial drugs, cancer treatment drugs, cardio-vascular disease drugs, and hepatitis drugs under the Asio name. Its products comprise Levodopa, Tabellae Sarcandrae, Rotandine Sulfate, Corydalis Saxicola Bunting, and Ethacridine Lactate injection. The company was formerly known as China Baicaotang Medicine Limited and changed its name to China BCT Pharmacy Group, Inc. in March 2010. China BCT Pharmacy Group, Inc. is headquartered in Liuzhou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Liuzhou",
        "zipcode": "545007",
        "website": null,
        "market_cap": 1743044
    },
    "CNTB": {
        "short_name": "Connect Biopharma Holdings Limi",
        "long_name": "Connect Biopharma Holdings Limited",
        "summary": "Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Taicang",
        "zipcode": "215400",
        "website": "http://www.connectbiopharm.com",
        "market_cap": 1035075584
    },
    "CPHI": {
        "short_name": "China Pharma Holdings, Inc.",
        "long_name": "China Pharma Holdings, Inc.",
        "summary": "China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "ASE",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570216",
        "website": "http://www.chinapharmaholdings.com",
        "market_cap": 32264654
    },
    "CSPHF": {
        "short_name": "CSTONE PHARMACEUTICALS",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.cstonepharma.com",
        "market_cap": 2567897600
    },
    "CVG.F": {
        "short_name": "CSPC PHARMACEUT.GR.",
        "long_name": "CSPC Pharmaceutical Group Limited",
        "summary": "CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson's disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events. It also offers Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; Gaoshunsong for arthritis, rheumatoid, and various pain; Debixin for various ulcer; and Qimaite for acute and chronic pains. In addition, the company provides antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and researches and develops various products with focus on the therapeutic areas of oncology, autoimmunity, psychiatry and neurology, digestion and metabolism, cardio-cerebrovascular system, and anti-infection. Further, it offers healthcare services and sells pharmaceutical equipment. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shijiazhuang",
        "zipcode": "050035",
        "website": "http://www.cspc.com.hk",
        "market_cap": 15683194880
    },
    "EB52.SG": {
        "short_name": "Essex Bio-Technology Ltd. Regis",
        "long_name": "Essex Bio-Technology Limited",
        "summary": "Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, Xalatan eye drops, and Xalacom eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties; and eye health care products, including Beifu shuhui capsules to treat fundus ocular diseases, asthenopia, and visual impairments. Further, the company offers T-Bactum, an anti-microbial oral care product; Carisolv dental caries removal gel; and Yi Xue An Granules. Essex Bio-Technology Limited has license agreements with Mitotech S.A. and Mitotech LLC. Essex Bio-Technology Limited was founded in 1990 and is headquartered in Zhuhai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": null,
        "website": "http://www.essexbio.com",
        "market_cap": 431941728
    },
    "EVGRF": {
        "short_name": "CHINA EVERGRANDE NEW ENERGY VEH",
        "long_name": "China Evergrande New Energy Vehicle Group Limited",
        "summary": "China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510620",
        "website": "http://health.evergrande.com",
        "market_cap": 48278999040
    },
    "G51.F": {
        "short_name": "GENSCRIPT BIOT. DL-,001",
        "long_name": "Genscript Biotech Corporation",
        "summary": "Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies and gene/cell therapy products. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. The company was founded in 2002 and is headquartered in Nanjing, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Nanjing",
        "zipcode": "211122",
        "website": "http://www.genscript.com",
        "market_cap": 6830189056
    },
    "GBLP": {
        "short_name": "GLOBAL PHARMATECH INC",
        "long_name": "Global Pharmatech, Inc.",
        "summary": "Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Changchun",
        "zipcode": "130 012",
        "website": null,
        "market_cap": 5656060
    },
    "GENX": {
        "short_name": "GENEX PHARMACEUTICALS INC",
        "long_name": "Genex Pharmaceutical, Inc.",
        "summary": "Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People's Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers. Genex Pharmaceutical is headquartered in Tianjin City, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Tianjin City",
        "zipcode": "300074",
        "website": null,
        "market_cap": 119641
    },
    "GPHG": {
        "short_name": "GLOBAL PHARM HLDGS GROUP INC",
        "long_name": "Global Pharm Holdings Group, Inc.",
        "summary": "Global Pharm Holdings Group, Inc., through its subsidiaries, engages in the distribution of pharmaceuticals-related products, Chinese herb cultivation, and preparation of raw materials for medicine in China. It distributes prescription and non-prescription drugs in the form of injections, tablets, pastes, granules, and capsules for various diseases. The company is also involved in the cultivation, processing, and sale of Chinese herbs, such as wild ginseng, chrysanthemum, salvia, angelica, wind, schisandra, rana, etc. In addition, it sells biochemical drugs, cosmetics, pre-packaged food, and medical devices. The company markets its products directly to hospitals, clinics, pharmacies and drugstores, and other healthcare institutions. Global Pharm Holdings Group, Inc. is based in Shenzhen, China. As of December 31, 2018, Global Pharm Holdings Group, Inc. operates as a subsidiary of Fortune Insight Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518026",
        "website": "http://www.globalpharmholdings.com",
        "market_cap": 4026588
    },
    "GRCL": {
        "short_name": "Gracell Biotechnologies Inc.",
        "long_name": "Gracell Biotechnologies Inc.",
        "summary": "Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.gracellbio.com",
        "market_cap": 772951808
    },
    "GTH": {
        "short_name": "Genetron Holdings Limited",
        "long_name": "Genetron Holdings Limited",
        "summary": "Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102206",
        "website": "http://www.genetronhealth.com",
        "market_cap": 1804095360
    },
    "GU5.F": {
        "short_name": "GUANG.BAIY.PHAR.HO.H YC 1",
        "long_name": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited",
        "summary": "Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the People's Republic of China and internationally. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, ganoderma spore oil capsules, lozenges, tortoise herb jelly, etc. In addition, it invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2020, the company had 141 retail chain pharmacy outlets, which included 27 Cai Zhi Lin pharmacy outlets, 33 Jian Min pharmacy outlets, 36 GPC Prescription Pharmacy outlets, and 24 Hainan Guangyao Chenfei Pharmaceutical Chain outlets, as well as 21 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Guangzhou",
        "zipcode": "510130",
        "website": "http://www.gybys.com.cn",
        "market_cap": 5836006912
    },
    "HAPP": {
        "short_name": "Happiness Biotech Group Limited",
        "long_name": "Happiness Biotech Group Limited",
        "summary": "Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powder, cordyceps mycelia, ejiao solution, American ginseng, and other products. It also offers a range of ganoderma lucidum products, such as essence oil, cleansing milk, shampoo, shower gel, and nourishing cream products under the Cai Zhi Ning brand, as well as edible fungi. In addition, the company provides disinfectants, non-medical face masks, and COVID-19 anti-body testing kits. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Nanping",
        "zipcode": "353200",
        "website": "http://www.happ.org.cn",
        "market_cap": 45325000
    },
    "HTDS": {
        "short_name": "HARD TO TREAT DISEASES INC",
        "long_name": "Hard to Treat Diseases Inc.",
        "summary": "Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518040",
        "website": "http://www.mellowhope.com",
        "market_cap": 5482
    },
    "HUMDF": {
        "short_name": "HUA MEDICINE",
        "long_name": "Hua Medicine (Shanghai) Ltd.",
        "summary": "Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes. The company also offers Dorzagliatin in combination with Metformin that is in Phase I clinical trial. In addition, it provides Dorzagliatin in combination with Sitagliptin, Empagli, Pioglitazone, and Insulin for the treatment of Type 2 diabetes that is in pre-clinical stage. Further, the company is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia or PD-LID. The company was incorporated in 2011 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.huamedicine.com",
        "market_cap": 598135296
    },
    "HYBT": {
        "short_name": "HEYU BIOLOGICAL TECHNOLOGY CORP",
        "long_name": "Heyu Biological Technology Corporation",
        "summary": "Heyu Biological Technology Corporation does not have significant operations. Previously, the company was engaged in the provision of application services; and development of business software technologies and services for business merchants and organizations. The company was formerly known as Pacific WebWorks, Inc. and changed its name to Heyu Biological Technology Corporation in June 2018. Heyu Biological Technology Corporation was incorporated in 1987 and is based in Xiamen, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Xiamen",
        "zipcode": "361022",
        "website": "http://heyubt.com",
        "market_cap": 19616930
    },
    "IMAB": {
        "short_name": "I-MAB",
        "long_name": "I-Mab",
        "summary": "I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.i-mabbiopharma.com",
        "market_cap": 4201679360
    },
    "JDHIF": {
        "short_name": "JD HEALTH INTERNATIONAL INC",
        "long_name": "JD Health International Inc.",
        "summary": "JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health and wellness products through direct selling and online retail pharmacy network. The company also provides online healthcare services, such as online consultation, prescription renewal, chronic disease management, family doctor, and consumer healthcare services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, its platform allows users to book appointments and pay for services, such as general physical exams, aesthetic medicines, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "101111",
        "website": "http://ir.jdhealth.com",
        "market_cap": 49323900928
    },
    "JFIL": {
        "short_name": "JUBILANT FLAME INTERNATIONAL LT",
        "long_name": "Jubilant Flame International, Ltd.",
        "summary": "Jubilant Flame International, Ltd. provides technical support services for the development of nutrition food products in the United States. Its nutritional oriented food includes sea-buckthourn and organic spouting powder. The company was formerly known as Jiu Feng Investment Hong Kong Ltd. and changed its name to Jubilant Flame International, Ltd. in May 2015. Jubilant Flame International, Ltd. was founded in 2009 and is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201103",
        "website": "http://www.acropass-shop.com",
        "market_cap": 1142892
    },
    "JP00.F": {
        "short_name": "UNIVERN HEALTH INTL",
        "long_name": "Universal Health International Group Holding Limited",
        "summary": "Universal Health International Group Holding Limited, an investment holding company, engages in the distribution and retail of drugs, healthcare products, and other pharmaceutical products in the northeastern region of the People's Republic of China. The company also provides storage services. It serves pharmaceutical retailers, hospitals, clinics, and distributors. The company was formerly known as Jintian Pharmaceutical Group Limited and changed its name to Universal Health International Group Holding Limited in July 2015. Universal Health International Group Holding Limited was founded in 1998 and is headquartered in Shenyang, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shenyang",
        "zipcode": null,
        "website": "http://www.uhighl.com",
        "market_cap": 8155614
    },
    "JRSS": {
        "short_name": "JRSIS HEALTH CARE CORP",
        "long_name": "JRSIS Health Care Corporation",
        "summary": "JRSIS Health Care Corporation provides a range of medical services in Harbin in the Heilongjiang Province of the People's Republic of China. The company offers services in the areas of pediatrics, dermatology, ears, nose, throat, traditional Chinese medicine, ophthalmology, internal medicine dentistry, general surgery, rehabilitation science, gynecology, general medical services, etc. It provides its services through Jiarun Hospital, which consists of 950 beds. The company was formerly known as China Runteng Medical Group Co., Ltd and changed its name to JRSIS Health Care Corporation in November 2013. JRSIS Health Care Corporation was founded in 2006 and is based in Harbin, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Harbin",
        "zipcode": "150025",
        "website": "http://www.jhcc.cn",
        "market_cap": 6568668
    },
    "KJFI": {
        "short_name": "COMJOYFUL INTERNATIONAL CO",
        "long_name": "Comjoyful International Company",
        "summary": "Comjoyful International Company operates and manages healthcare clubs in China. Its clubs provide traditional physiotherapy services and other relaxing treatments, such as foot massage, body massage, spa, moxibustion, and other relaxing treatments that are based on the Chinese traditional reflexology system. The company also provides beverages, including beer, tea, and juice, as well as fruits, nuts, and dumplings. It operates three healthcare clubs, which are located in Wuxi, Nanjing, and Jintan. The company was formerly known as Camelot Corporation and changed its name to Comjoyful International Company in January 2013. Comjoyful International Company was incorporated in 1975 and is based in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100600",
        "website": null,
        "market_cap": 58616
    },
    "KNTPF": {
        "short_name": "KINTOR PHARMACEUTICAL LTD",
        "long_name": "Kintor Pharmaceutical Limited",
        "summary": "Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. The company's lead drug candidates include Proxalutamide, a small molecule second generation AR antagonist that is in various clinical trials for metastatic castration-resistant prostate cancer and breast cancer; and Pyrilutamide, which is in various clinical trials for androgenetic alopecia and acne vulgaris. It also develops ALK-1 for the treatment of metastatic hepatocellular carcinoma and liver cancer; Detorsertib, a second-generation mTOR inhibitor for the treatment of metastatic solid tumours; and GT1708F, for the treatment of leukaemia and basal-cell carcinoma. The company was founded in 2009 and is headquartered in Suzhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Suzhou",
        "zipcode": "215123",
        "website": "http://www.kintor.com.cn",
        "market_cap": 8097236992
    },
    "LLIT": {
        "short_name": "Lianluo Smart Limited",
        "long_name": "Lianluo Smart Limited",
        "summary": "Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NCM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102200",
        "website": "http://www.lianluosmart.com",
        "market_cap": 55342096
    },
    "LP6.F": {
        "short_name": "LIVZON PHARMAC. GRP H YC1",
        "long_name": "Livzon Pharmaceutical Group Inc.",
        "summary": "Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical products in the People's Republic of China. Its products include Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, vertigo, and for the patients of lung cancer and stomach cancer. The company also offers active pharmaceutical ingredients (APIs) and intermediates, such as diagnostic kit for IgM/IgG antibody to coronavirus; and diagnostic reagents and equipment, including diagnostic kit for human immunodeficiency virus antibody, diagnostic kit for anti-nuclear antibody panel, and diagnostic kit for tuberculosis specific infected T cells. In addition, it provides biologic products, traditional Chinese drug medicine, biochemical drugs, microbiological preparations, antibiotics, and pharmaceutical raw materials. The company also exports its products. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Zhuhai",
        "zipcode": "519090",
        "website": "http://www.livzon.com.cn",
        "market_cap": 5214516224
    },
    "LUP.F": {
        "short_name": "LUYE PHARMA GROUP DL-,02",
        "long_name": "Luye Pharma Group Ltd.",
        "summary": "Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Rykindo, an injection for the treatment of acute and chronic schizophrenia; Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; Fengshiye for patients who have pains in bones, joints, and limbs; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; and glucosamine hydrochloride tablets for osteoarthritis. Additionally, it distributes and sells pharmaceutical drugs; and manufactures and sells of biopharmaceutical products. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Yantai",
        "zipcode": "264003",
        "website": "http://www.luye.cn",
        "market_cap": 2063813888
    },
    "MCRPF": {
        "short_name": "MICROPORT SCIENTIFIC CORPORATIO",
        "long_name": "MicroPort Scientific Corporation",
        "summary": "MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment provides coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment offers reconstructive joints, spine and trauma, and other professional implants and equipment. The company's Cardiac Rhythm Management Business segment develops, manufactures, and markets defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment provides products and services for neurovascular diseases, such as cerebral aneurysms, intracranial atherosclerotic diseases, carotid artery diseases, and other neurovasculature related diseases. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. The company's Heart Valve Business segment engages in the research and development, manufacture, and sale of VitaFlow Transcatheter aortic valve and delivery system for the treatment of valvular heart diseases. Its Surgical Robot Business segment provides research and technology integration in the fields of robot, intelligent control, and information to provide medical products. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.microport.com",
        "market_cap": 15028847616
    },
    "MDCE": {
        "short_name": "MEDICAL CARE TECHNOLOGIES INC",
        "long_name": "Medical Care Technologies Inc.",
        "summary": "Medical Care Technologies Inc., a development stage company, engages in opening and operating children's integrated health and wellness centers in China. The company sells and distributes pharmaceutical and nutraceutical products, and other merchandise, including over-the-counter medicines, herbal products, personal care products, and family care products. It serves retail pharmacies, pharmaceutical companies, hospitals, physicians' office practices, and consumers; and industrial and food microbiology laboratories. The company offers its products through its pediatric health and wellness centers, Website, and retail pharmacies, as well as through sales and distribution channels, and directly to end-users through independent sales representatives. Medical Care Technologies Inc. was founded in 2007 and is headquartered in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "10009",
        "website": "http://www.medicaretechinc.com",
        "market_cap": 382
    },
    "MSK.F": {
        "short_name": "MICRP.SCIEN.REGS HD-00001",
        "long_name": "MicroPort Scientific Corporation",
        "summary": "MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment provides coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment offers reconstructive joints, spine and trauma, and other professional implants and equipment. The company's Cardiac Rhythm Management Business segment develops, manufactures, and markets defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment provides products and services for neurovascular diseases, such as cerebral aneurysms, intracranial atherosclerotic diseases, carotid artery diseases, and other neurovasculature related diseases. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. The company's Heart Valve Business segment engages in the research and development, manufacture, and sale of VitaFlow Transcatheter aortic valve and delivery system for the treatment of valvular heart diseases. Its Surgical Robot Business segment provides research and technology integration in the fields of robot, intelligent control, and information to provide medical products. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.microport.com",
        "market_cap": 13419262976
    },
    "NFH": {
        "short_name": "New Frontier Health Corporation",
        "long_name": "New Frontier Health Corporation",
        "summary": "New Frontier Health Corporation provides healthcare services. It operates a network of hospital inpatient departments and integrated outpatient clinics, including satellite feeder clinics. The company's facilities include 24/7 emergency rooms, intensive care units, neonatal intensive care units, operating rooms, clinical laboratories, radiology, and blood banking services. It operates five hospitals and eight clinics in northern China; two hospitals and four clinics in eastern China; and two hospitals and two clinics in southern China. The company is based in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100015",
        "website": "http://www.nfh.com.cn",
        "market_cap": 1455436032
    },
    "PANHF": {
        "short_name": "PING AN HEALTHCARE & TECHNO CO ",
        "long_name": "Ping An Healthcare and Technology Company Limited",
        "summary": "Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in the People's Republic of China. It offers online medical services, such as online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; and consumer healthcare services, including various standardized service packages that integrate services at healthcare institutions. The company also provides healthcare products comprising medicines, health supplements, and medical devices; wellness products comprising fitness equipment and accessories, and personal care products; and other products. In addition, it offers health management and wellness interaction services, such as wellness programs, tools and activities, and personalized content. Further, the company provides medicine marketing services; technology services; application development and operation services; and hospital and clinic services, as well as operates an insurance agency. Ping An Healthcare and Technology Company Limited was incorporated in 2014 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.pagd.net",
        "market_cap": 13687916544
    },
    "PH4.F": {
        "short_name": "CSTONE PHARMAC.  DL-,0001",
        "long_name": "CStone Pharmaceuticals",
        "summary": "CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage clinical products include CS1001, a monoclonal antibody against programmed death ligand 1; CS1003, a monoclonal antibody against programmed death receptor; ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; and Pralsetinib for the treatment of medullary thyroid cancer and other advanced solid tumors. Its products also comprise CS1002, CS3002, CS3003, CS3005, and CS3006 for solid tumors; Fisogatinib that is used for the treatment of hepatocellular carcinoma; and CS3004, CS1009, and CS2004 for other indications. CStone Pharmaceuticals has a licensing agreement with Numab Therapeutics AG for the development and commercialization of NM21-1480, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; a clinical collaboration with Bayer HealthCare LLC to evaluate CS1001 in combination with Bayer's oral multi-kinase inhibitor Stivarga, as a treatment for various types of cancer, including gastric cancer; and a strategic partnership with Burning Rock Biotech Limited to co-develop and commercialize companion diagnostics for pralsetinib, an investigational treatment for the detection of RET alterations in cancer patients. The company was founded in 2015 in Cayman Islands, and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.cstonepharma.com",
        "market_cap": 1910894080
    },
    "PWE.F": {
        "short_name": "PW MEDTECH GROUP DL-,0001",
        "long_name": "PW Medtech Group Limited",
        "summary": "PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People's Republic of China. It manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets, light resistant infusion sets, and intravenous cannula products, as well as human plasma-based biopharmaceutical products. The company was formerly known as Pyholding Limited. PW Medtech Group Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "101204",
        "website": "http://www.pwmedtech.com",
        "market_cap": 147662800
    },
    "QDMI": {
        "short_name": "QDM INTL INC",
        "long_name": "QDM International Inc.",
        "summary": "QDM International Inc. operates as an insurance brokerage company primarily in Hong Kong. It sells a range of insurance products consisting of life and medical insurance, such as individual life insurance; and general insurance, such as automobile insurance, commercial property insurance, liability insurance, and homeowner insurance. The company was incorporated in 2020 and is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200051",
        "website": null,
        "market_cap": 681972
    },
    "QLI": {
        "short_name": "Qilian International Holding Gr",
        "long_name": "Qilian International Holding Group Limited",
        "summary": "Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivative (TCMD) products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings comprising Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Jiuquan",
        "zipcode": "735000",
        "website": "http://www.qlsyy.net",
        "market_cap": 165343744
    },
    "S1R.F": {
        "short_name": "SHANGHAI PHARM.HLDG H YC1",
        "long_name": "Shanghai Pharmaceuticals Holding Co., Ltd",
        "summary": "Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug retail business; and provision of consulting services, as well as in the assets management operations, etc. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200020",
        "website": "http://www.sphchina.com",
        "market_cap": 6927394816
    },
    "SFOSF": {
        "short_name": "SHANGHAI FOSUN PHARMACEUTICAL G",
        "long_name": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd.",
        "summary": "Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200233",
        "website": "http://www.fosunpharma.com",
        "market_cap": 22632415232
    },
    "SHEZF": {
        "short_name": "SHENZHEN HEPALINK PHARMACEUTICA",
        "long_name": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.",
        "summary": "Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through three segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), and CDMO. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, including pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; and trading of medical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shenzhen",
        "zipcode": "518057",
        "website": "http://www.hepalink.com",
        "market_cap": 3427335168
    },
    "SHPMF": {
        "short_name": "SHANGHAI PHARMACEUTICALS HOLDIN",
        "long_name": "Shanghai Pharmaceuticals Holding Co., Ltd",
        "summary": "Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug retail business; and provision of consulting services, as well as in the assets management operations, etc. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200020",
        "website": "http://www.sphchina.com",
        "market_cap": 8262042112
    },
    "SHPMY": {
        "short_name": "SHANGHAI PHARMACEUTICALS HOLDIN",
        "long_name": "Shanghai Pharmaceuticals Holding Co., Ltd",
        "summary": "Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestion and immune system, cardiovascular, anti-infection, nervous system and mental disorder, and oncology. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug retail business; and provision of consulting services, as well as in the assets management operations, etc. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 16 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200020",
        "website": "http://www.sphchina.com",
        "market_cap": 8651726848
    },
    "SHTDF": {
        "short_name": "SINOPHARM GROUP CO. LTD.",
        "long_name": "Sinopharm Group Co., Ltd.",
        "summary": "Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200023",
        "website": "http://www.sinopharmgroup.com.cn",
        "market_cap": 10500503552
    },
    "SHTDY": {
        "short_name": "SINOPHARM GROUP CO. LTD.",
        "long_name": "Sinopharm Group Co., Ltd.",
        "summary": "Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200023",
        "website": "http://www.sinopharmgroup.com.cn",
        "market_cap": 9507845120
    },
    "SHWGF": {
        "short_name": "SHANDONG WEIGAO GROUP MEDICAL",
        "long_name": "Shandong Weigao Group Medical Polymer Company Limited",
        "summary": "Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. The company also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, it engages in the production and sale of orthopedic products; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemo-dialysis equipment; and type I, type II, and type III medical devices. Further, the company is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; and provision of asset management and enterprise consulting services, as well as logistics and storage services. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. The company also export its products. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Weihai",
        "zipcode": "264210",
        "website": "http://www.weigaogroup.com",
        "market_cap": 11310015488
    },
    "SHWGY": {
        "short_name": "SHANDONG WEIGAO GROUP MEDICAL",
        "long_name": "Shandong Weigao Group Medical Polymer Company Limited",
        "summary": "Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. The company also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, it engages in the production and sale of orthopedic products; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemo-dialysis equipment; and type I, type II, and type III medical devices. Further, the company is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; and provision of asset management and enterprise consulting services, as well as logistics and storage services. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. The company also export its products. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Weihai",
        "zipcode": "264210",
        "website": "http://www.weigaogroup.com",
        "market_cap": 10481811456
    },
    "SXTC": {
        "short_name": "China SXT Pharmaceuticals, Inc.",
        "long_name": "China SXT Pharmaceuticals, Inc.",
        "summary": "China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of May 2, 2020, it served 116 pharmaceutical companies, 56 pharmacies, and 76 hospitals. The company was founded in 2005 and is based in Taizhou, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Taizhou",
        "zipcode": "225300",
        "website": "http://www.sxtchina.com",
        "market_cap": 22020570
    },
    "SY": {
        "short_name": "So-Young International Inc. - A",
        "long_name": "So-Young International Inc.",
        "summary": "So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in the People's Republic of China and internationally. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment. As of December 31, 2020, it had approximately 6,900 medical aesthetic service providers and 4,200 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in the People's Republic of China and internationally. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment. As of December 31, 2020, it had approximately 6,900 medical aesthetic service providers and 4,200 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100102",
        "website": "http://www.soyoung.com",
        "market_cap": 983728384
    },
    "SYUP": {
        "short_name": "ANBC INC",
        "long_name": "ANBC, INC.",
        "summary": "Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery. It offers its products to distributors on a wholesale basis. The company is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201702",
        "website": null,
        "market_cap": 1731404
    },
    "T14.SI": {
        "short_name": "Tianjin ZX USD",
        "long_name": "Tianjin Zhong Xin Pharmaceutical Group Corporation Limited",
        "summary": "Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, together with its subsidiaries, manufactures and sells Chinese herbal medicines, proprietary Chinese medicines, chemical raw materials and preparations, and nutritional and health products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals, as well as offers pharmaceutical consultancy services. In addition, it provides logistics, stocks, equipment installation, and medicine processing services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products and biological products under other brands from distributors and sells these to other wholesalers. Tianjin Zhong Xin Pharmaceutical Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "SES",
        "market": "sg_market",
        "country": "China",
        "state": null,
        "city": "Tianjin",
        "zipcode": "300193",
        "website": "http://www.zhongxinp.com",
        "market_cap": 2537137664
    },
    "TGRNF": {
        "short_name": "TONG REN TANG TECHNOLOGIES CO",
        "long_name": "Tong Ren Tang Technologies Co. Ltd.",
        "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100079",
        "website": "http://www.tongrentangkj.com",
        "market_cap": 1088403840
    },
    "TNG.F": {
        "short_name": "TONG REN TANG TECHS NEW H",
        "long_name": "Tong Ren Tang Technologies Co. Ltd.",
        "summary": "Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicines in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, foot care products, and healthcare products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, and cosmetics; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food products. The company was founded in 1669 and is based in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100079",
        "website": "http://www.tongrentangkj.com",
        "market_cap": 942327040
    },
    "TNPH": {
        "short_name": "TIAN'AN PHARMACEUTICAL COMPANY ",
        "long_name": "Tian'an Pharmaceutical Co., Ltd.",
        "summary": "Tian'an Pharmaceutical Co., Ltd. develops, manufactures, and sells traditional Chinese herbal medicines, including pallets, hard capsules, and soft ointments for the treatment and prevention of diseases in China. It also engages in the research and development of biology goods and health care products. The company's pharmaceutical and nutraceutical products include Compound Ginseng capsule, a Chinese medicine preparation that is used to cure and treat prostate gland proliferation; Nizhuanle Yin granule, a Chinese medicine preparation that treats the decomposition or inflammation of the stomach's mucous membrane; and Tianan soft capsule, which is used to adjust high amounts of fat in the blood stream, improve blood vessel ventilation, and soften blood vessels. Its products also include Tianan Pain Relief Capsule, a Chinese medicine preparation, which is under development to cure pain in joints, headache, pain from muscle injury, cancer, and gynecological disorders, as well as general pain. Tian' An Pharmaceutical sells its products to independent distributors, who sell products to pharmacies and drugstores, and hospitals. The company was founded in 2003 and is based in Xi'an, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Xi'an",
        "zipcode": null,
        "website": null,
        "market_cap": 996246
    },
    "TYHT": {
        "short_name": "Shineco, Inc.",
        "long_name": "Shineco, Inc.",
        "summary": "Shineco, Inc., through its subsidiaries, produces, distributes, and sells health and well-being focused plant-based products in China. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers. The company also plants, processes, and distributes green and organic vegetables and fruits; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality. In addition, it offers logistics services for agricultural products. Further, the company develops, manufactures, and distributes specialized fabrics, textiles, health supplements, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum. The company sells its Chinese medicinal products and western medicines through wholesale customers; and its 13 Ankang retail pharmacies operating under the Sunsimiao Pharmacies name, as well as 66 pharmacies operated by third parties. Shineco, Inc. sells its decoction pieces on the Anhui Bozhou Chinese medicine transaction market to medical materials companies and Chinese patent medicine factories. The company sells its Luobuma textile products online through third party e-commerce websites, as well as through distributors under the Tenethealth brand; and yew trees and agricultural products primarily through its sales personnel, and group and institutional sales. The company was formerly known as Beijing Tenet Jove Technological Development Co., Ltd. and changed its name to Shineco, Inc. in June 2005. Shineco, Inc. was founded in 1997 and is based in Beijing, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "100176",
        "website": "http://www.tianyiluobuma.com",
        "market_cap": 62424644
    },
    "UK2.F": {
        "short_name": "SHANDONG WEIGAO H  YC-,10",
        "long_name": "Shandong Weigao Group Medical Polymer Company Limited",
        "summary": "Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. The company also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, it engages in the production and sale of orthopedic products; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemo-dialysis equipment; and type I, type II, and type III medical devices. Further, the company is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; and provision of asset management and enterprise consulting services, as well as logistics and storage services. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. The company also export its products. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Weihai",
        "zipcode": "264210",
        "website": "http://www.weigaogroup.com",
        "market_cap": 8569427456
    },
    "UPC": {
        "short_name": "Universe Pharmaceuticals Inc",
        "long_name": "Universe Pharmaceuticals INC",
        "summary": "Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Ji'an",
        "zipcode": null,
        "website": "http://www.dzrzy.com",
        "market_cap": 62370000
    },
    "VB0.F": {
        "short_name": "VIVA BIOTECH HOLD",
        "long_name": "Viva Biotech Holdings",
        "summary": "Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company develops structure based drug discovery, fragment based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. The company's products include cell lines, crystal structures, GPCR proteins, antibodies, and proteins. It also offers EFS, gene-to-protein and gene-to-structure, viva engine for lead discovery, medicinal chemistry, in vitro pharmacology, and antibody discovery services. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.vivabiotech.com.cn",
        "market_cap": 2008706048
    },
    "VBIZF": {
        "short_name": "VIVA BIOTECH HOLDINGS",
        "long_name": "Viva Biotech Holdings",
        "summary": "Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company develops structure based drug discovery, fragment based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. The company's products include cell lines, crystal structures, GPCR proteins, antibodies, and proteins. It also offers EFS, gene-to-protein and gene-to-structure, viva engine for lead discovery, medicinal chemistry, in vitro pharmacology, and antibody discovery services. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.vivabiotech.com.cn",
        "market_cap": 1758290048
    },
    "VMTHF": {
        "short_name": "VENUS MEDTECH (HANGZHOU) INC",
        "long_name": "Venus Medtech (Hangzhou) Inc.",
        "summary": "Venus Medtech (Hangzhou) Inc. develops and sells transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of cerebral damage during TAVR and other structural heart procedures. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Hangzhou",
        "zipcode": null,
        "website": "http://www.venusmedtech.com",
        "market_cap": 3877932800
    },
    "VNL1.F": {
        "short_name": "CHINA HEALTH GRP  HD-,10",
        "long_name": "China Health Group Inc.",
        "summary": "China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People's Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drugs technologies. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Beijing",
        "zipcode": "102200",
        "website": "http://www.chgi.net",
        "market_cap": 43612800
    },
    "WFHG": {
        "short_name": "WORLD FINANCIAL HOLDING GROUP",
        "long_name": "World Financial Holding Group",
        "summary": "World Financial Holding Group operates as a professional listing coaching company in the China. It offers services in the areas of strategic investment, international merger, asset reorganization, private financing, capital operation, overseas stock issue and listing, initial public listing and reverse acquisition, management consulting, and other investment banking advisory services. The company also provides guidance process for listing of a company; coaching services for listing of companies in the United States; and backdoor listing services. World Financial Holding Group is based in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": null,
        "website": "http://www.worldfh.com",
        "market_cap": null
    },
    "WUXAY": {
        "short_name": "WUXI APPTEC CO LTD UNSPON ADS E",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200131",
        "website": "http://www.wuxiapptec.com",
        "market_cap": 59802599424
    },
    "WUXIF": {
        "short_name": "WUXI APPTEC CO LTD",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200131",
        "website": "http://www.wuxiapptec.com",
        "market_cap": 59653115904
    },
    "WX8.F": {
        "short_name": "WUXI APPTEC H 02359 YC1",
        "long_name": "WuXi AppTec Co., Ltd.",
        "summary": "WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through China-Based Laboratory Services, U.S.-Based Laboratory Services, Clinical Research and Other CRO Services, CDMO Services, and Others segments. It offers laboratory services, such as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, testing, drug metabolism and pharmacokinetics, toxicology, bioanalytical, and medical devices safety testing services, as well as manufacturing and testing for cell and gene therapies, and absorption, distribution, metabolism, and excretion services. The company also provides clinical research services, including clinical development and site management organization services; clinical development services comprising project planning, clinical operation, and monitoring and management of phase I-IV clinical trials, outcomes research, and medical device trials; embedded outsourcing; and clinical informatics services. In addition, it offers CDMO services; and administrative services, as well as sells raw and scrap materials. Further, the company engages in the laboratory-used biological assets cultivation business. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200131",
        "website": "http://www.wuxiapptec.com",
        "market_cap": 375746035712
    },
    "WXIBF": {
        "short_name": "WUXI BIOLOGICS (CAYMAN) INC",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Wuxi",
        "zipcode": "214092",
        "website": "http://www.wuxibiologics.com",
        "market_cap": 69245280256
    },
    "WXXWY": {
        "short_name": "WUXI BIOLOGICS (CAYMAN) INC",
        "long_name": "WuXi Biologics (Cayman) Inc.",
        "summary": "WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Wuxi",
        "zipcode": "214092",
        "website": "http://www.wuxibiologics.com",
        "market_cap": 57161441280
    },
    "X2S.F": {
        "short_name": "SINOPHARM GRP CO.LTD.YC 1",
        "long_name": "Sinopharm Group Co., Ltd.",
        "summary": "Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200023",
        "website": "http://www.sinopharmgroup.com.cn",
        "market_cap": 8975308800
    },
    "X2S1.F": {
        "short_name": "SINOPHARM GROUP 1/5/O.N.",
        "long_name": "Sinopharm Group Co., Ltd.",
        "summary": "Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2020, this segment had 8,977 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200023",
        "website": "http://www.sinopharmgroup.com.cn",
        "market_cap": 8470696448
    },
    "XIN.F": {
        "short_name": "SHANDONG XINHUA PHA.H YC1",
        "long_name": "Shandong Xinhua Pharmaceutical Company Limited",
        "summary": "Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical Bulk Drugs, Preparations, and Chemical Intermediates and Other products. It offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for central nervous system diseases; and other drugs under the brand of Xinhua. The company also provides prepared Chinese herbal medicine for decoction, traditional Chinese medicines, chemical raw materials, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates, powders for injection and tablets, and bulk pharmaceutical and intermediates; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; develops and sells real estate; and health products research and development activities. Additionally, the company engages in the certification and import and export business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as sales of mechanical, hardware, and electrical equipment. It also provides contract manufacturing services of APIs and pharmaceutical intermediates, as well as OTC and generic products; and internet data services, internet sales, and internet information services for pharmaceuticals and medical devices, etc. The company operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Zibo",
        "zipcode": "255086",
        "website": "http://www.xhzy.com",
        "market_cap": 548865472
    },
    "XQJ.F": {
        "short_name": "CHINA PHARMA HLDGS DL-001",
        "long_name": "China Pharma Holdings, Inc.",
        "summary": "China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "China",
        "state": null,
        "city": "Haikou",
        "zipcode": "570216",
        "website": "http://www.chinapharmaholdings.com",
        "market_cap": 23570644
    },
    "XYNO": {
        "short_name": "XYNOMIC PHARMACEUTICALS HLDGS I",
        "long_name": "Xynomic Pharmaceuticals Holdings, Inc.",
        "summary": "Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200031",
        "website": "http://xynomicpharma.com",
        "market_cap": 102727840
    },
    "YI": {
        "short_name": "111, Inc.",
        "long_name": "111, Inc.",
        "summary": "111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2019, it operated 12 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Shanghai, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "NGM",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201203",
        "website": "http://www.111.com.cn",
        "market_cap": 1026198144
    },
    "ZCMD": {
        "short_name": "Zhongchao Inc.",
        "long_name": "Zhongchao Inc.",
        "summary": "Zhongchao Inc. provides healthcare information, education, and training services in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company operates through its mdmooc.org online platform, as well as Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "200040",
        "website": "http://www.izcmd.com",
        "market_cap": 45627576
    },
    "ZLAB": {
        "short_name": "Zai Lab Limited",
        "long_name": "Zai Lab Limited",
        "summary": "Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00c3\u00afve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "China",
        "state": null,
        "city": "Shanghai",
        "zipcode": "201210",
        "website": "http://www.zailaboratory.com",
        "market_cap": 13570381824
    }
}